id	sid	tid	token	lemma	pos
ijpds-3318	1	1	kareenmulla	kareenmulla	PROPN
ijpds-3318	1	2	et	et	PROPN
ijpds-3318	1	3	al	al	PROPN
ijpds-3318	1	4	efficacy	efficacy	PROPN
ijpds-3318	1	5	,	,	PUNCT
ijpds-3318	1	6	safety	safety	NOUN
ijpds-3318	1	7	of	of	ADP
ijpds-3318	1	8	vildagliptin	vildagliptin	NOUN
ijpds-3318	1	9	-	-	PUNCT
ijpds-3318	1	10	metformin	metformin	NOUN
ijpds-3318	1	11	versus	versus	ADP
ijpds-3318	1	12	glimepiride	glimepiride	NOUN
ijpds-3318	1	13	-	-	PUNCT
ijpds-3318	1	14	metformin	metformin	NOUN
ijpds-3318	1	15	vol	vol	NOUN
ijpds-3318	1	16	1	1	NUM
ijpds-3318	2	1	|	|	NOUN
ijpds-3318	2	2	issue	issue	NOUN
ijpds-3318	2	3	2	2	NUM
ijpds-3318	3	1	|	|	ADV
ijpds-3318	3	2	jul	jul	PROPN
ijpds-3318	3	3	sep	sep	PROPN
ijpds-3318	3	4	2022	2022	NUM
ijpds-3318	3	5	indian	indian	PROPN
ijpds-3318	3	6	j	j	PROPN
ijpds-3318	3	7	pharm	pharm	PROPN
ijpds-3318	3	8	drug	drug	PROPN
ijpds-3318	3	9	studies	study	NOUN
ijpds-3318	3	10	|	|	ADV
ijpds-3318	3	11	63	63	NUM
ijpds-3318	3	12	original	original	ADJ
ijpds-3318	3	13	article	article	NOUN
ijpds-3318	3	14	a	a	DET
ijpds-3318	3	15	comparitive	comparitive	NOUN
ijpds-3318	3	16	study	study	NOUN
ijpds-3318	3	17	on	on	ADP
ijpds-3318	3	18	efficacy	efficacy	NOUN
ijpds-3318	3	19	and	and	CCONJ
ijpds-3318	3	20	safety	safety	NOUN
ijpds-3318	3	21	of	of	ADP
ijpds-3318	3	22	vildagliptin	vildagliptin	NOUN
ijpds-3318	3	23	-	-	PUNCT
ijpds-3318	3	24	metformin	metformin	NOUN
ijpds-3318	3	25	versus	versus	ADP
ijpds-3318	3	26	glimepiride	glimepiride	NOUN
ijpds-3318	3	27	metformin	metformin	NOUN
ijpds-3318	3	28	in	in	ADP
ijpds-3318	3	29	type	type	NOUN
ijpds-3318	3	30	2	2	NUM
ijpds-3318	3	31	diabetes	diabetes	NOUN
ijpds-3318	3	32	mellitus	mellitus	NOUN
ijpds-3318	3	33	patients	patient	NOUN
ijpds-3318	3	34	prathap	prathap	PROPN
ijpds-3318	3	35	bingi1	bingi1	PROPN
ijpds-3318	3	36	,	,	PUNCT
ijpds-3318	3	37	shaik	shaik	PROPN
ijpds-3318	3	38	kareemulla2	kareemulla2	PROPN
ijpds-3318	3	39	,	,	PUNCT
ijpds-3318	3	40	b.	b.	PROPN
ijpds-3318	3	41	himabindu3	himabindu3	PROPN
ijpds-3318	3	42	,	,	PUNCT
ijpds-3318	3	43	d.	d.	PROPN
ijpds-3318	3	44	sheklane	sheklane	PROPN
ijpds-3318	3	45	khan3	khan3	PROPN
ijpds-3318	3	46	,	,	PUNCT
ijpds-3318	3	47	g.	g.	PROPN
ijpds-3318	3	48	ramu3	ramu3	PROPN
ijpds-3318	3	49	,	,	PUNCT
ijpds-3318	3	50	s.	s.	PROPN
ijpds-3318	3	51	mahammed	mahammed	PROPN
ijpds-3318	3	52	rafi3	rafi3	PROPN
ijpds-3318	3	53	from	from	ADP
ijpds-3318	3	54	,	,	PUNCT
ijpds-3318	3	55	1assistant	1assistant	NUM
ijpds-3318	3	56	professor	professor	NOUN
ijpds-3318	3	57	(	(	PUNCT
ijpds-3318	3	58	ggh	ggh	NOUN
ijpds-3318	3	59	-	-	PUNCT
ijpds-3318	3	60	rims	rim	NOUN
ijpds-3318	3	61	)	)	PUNCT
ijpds-3318	3	62	,	,	PUNCT
ijpds-3318	3	63	kadapa	kadapa	PROPN
ijpds-3318	3	64	,	,	PUNCT
ijpds-3318	3	65	2associate	2associate	NUM
ijpds-3318	3	66	professor	professor	NOUN
ijpds-3318	3	67	,	,	PUNCT
ijpds-3318	3	68	3pharmd	3pharmd	NUM
ijpds-3318	3	69	intern	intern	NOUN
ijpds-3318	3	70	,	,	PUNCT
ijpds-3318	3	71	department	department	NOUN
ijpds-3318	3	72	of	of	ADP
ijpds-3318	3	73	pharmacy	pharmacy	NOUN
ijpds-3318	3	74	practice	practice	NOUN
ijpds-3318	3	75	,	,	PUNCT
ijpds-3318	3	76	p.	p.	PROPN
ijpds-3318	3	77	rami	rami	PROPN
ijpds-3318	3	78	reddy	reddy	PROPN
ijpds-3318	3	79	pharmacy	pharmacy	PROPN
ijpds-3318	3	80	college	college	PROPN
ijpds-3318	3	81	,	,	PUNCT
ijpds-3318	3	82	kadapa	kadapa	PROPN
ijpds-3318	3	83	andhra	andhra	PROPN
ijpds-3318	3	84	pradesh	pradesh	PROPN
ijpds-3318	3	85	.	.	PUNCT
ijpds-3318	4	1	correspondence	correspondence	NOUN
ijpds-3318	4	2	to	to	ADP
ijpds-3318	4	3	:	:	PUNCT
ijpds-3318	4	4	shaik	shaik	PROPN
ijpds-3318	4	5	kareemulla	kareemulla	PROPN
ijpds-3318	4	6	,	,	PUNCT
ijpds-3318	4	7	associate	associate	NOUN
ijpds-3318	4	8	professor	professor	NOUN
ijpds-3318	4	9	,	,	PUNCT
ijpds-3318	4	10	department	department	NOUN
ijpds-3318	4	11	of	of	ADP
ijpds-3318	4	12	pharmacy	pharmacy	NOUN
ijpds-3318	4	13	practice	practice	NOUN
ijpds-3318	4	14	,	,	PUNCT
ijpds-3318	5	1	p.	p.	PROPN
ijpds-3318	5	2	rami	rami	PROPN
ijpds-3318	5	3	reddy	reddy	PROPN
ijpds-3318	5	4	memorial	memorial	PROPN
ijpds-3318	5	5	college	college	PROPN
ijpds-3318	5	6	of	of	ADP
ijpds-3318	5	7	pharmacy	pharmacy	NOUN
ijpds-3318	5	8	(	(	PUNCT
ijpds-3318	5	9	prrmcp	prrmcp	NOUN
ijpds-3318	5	10	)	)	PUNCT
ijpds-3318	5	11	,	,	PUNCT
ijpds-3318	5	12	kadapa	kadapa	PROPN
ijpds-3318	5	13	,	,	PUNCT
ijpds-3318	5	14	andhra	andhra	PROPN
ijpds-3318	5	15	pradesh	pradesh	PROPN
ijpds-3318	5	16	,	,	PUNCT
ijpds-3318	5	17	email	email	NOUN
ijpds-3318	5	18	:	:	PUNCT
ijpds-3318	5	19	tanveerkareems@gmail.com	tanveerkareems@gmail.com	X
ijpds-3318	5	20	abstract	abstract	ADJ
ijpds-3318	5	21	background	background	NOUN
ijpds-3318	5	22	:	:	PUNCT
ijpds-3318	5	23	inadequate	inadequate	ADJ
ijpds-3318	5	24	control	control	NOUN
ijpds-3318	5	25	of	of	ADP
ijpds-3318	5	26	blood	blood	NOUN
ijpds-3318	5	27	glucose	glucose	NOUN
ijpds-3318	5	28	in	in	ADP
ijpds-3318	5	29	patients	patient	NOUN
ijpds-3318	5	30	leads	lead	VERB
ijpds-3318	5	31	to	to	ADP
ijpds-3318	5	32	micro	micro	ADJ
ijpds-3318	5	33	or	or	CCONJ
ijpds-3318	5	34	macrovascular	macrovascular	ADJ
ijpds-3318	5	35	complications	complication	NOUN
ijpds-3318	5	36	.	.	PUNCT
ijpds-3318	6	1	metformin	metformin	NOUN
ijpds-3318	6	2	is	be	AUX
ijpds-3318	6	3	an	an	DET
ijpds-3318	6	4	initial	initial	ADJ
ijpds-3318	6	5	drug	drug	NOUN
ijpds-3318	6	6	used	use	VERB
ijpds-3318	6	7	to	to	PART
ijpds-3318	6	8	treat	treat	VERB
ijpds-3318	6	9	diabetes	diabetes	NOUN
ijpds-3318	6	10	.	.	PUNCT
ijpds-3318	7	1	in	in	ADP
ijpds-3318	7	2	case	case	NOUN
ijpds-3318	7	3	of	of	ADP
ijpds-3318	7	4	inefficient	inefficient	ADJ
ijpds-3318	7	5	glucose	glucose	NOUN
ijpds-3318	7	6	control	control	NOUN
ijpds-3318	7	7	with	with	ADP
ijpds-3318	7	8	metformin	metformin	NOUN
ijpds-3318	7	9	,	,	PUNCT
ijpds-3318	7	10	add	add	VERB
ijpds-3318	7	11	-	-	PUNCT
ijpds-3318	7	12	on	on	ADP
ijpds-3318	7	13	therapy	therapy	NOUN
ijpds-3318	7	14	is	be	AUX
ijpds-3318	7	15	recommended	recommend	VERB
ijpds-3318	7	16	.	.	PUNCT
ijpds-3318	8	1	the	the	DET
ijpds-3318	8	2	motto	motto	NOUN
ijpds-3318	8	3	of	of	ADP
ijpds-3318	8	4	our	our	PRON
ijpds-3318	8	5	study	study	NOUN
ijpds-3318	8	6	is	be	AUX
ijpds-3318	8	7	to	to	PART
ijpds-3318	8	8	compare	compare	VERB
ijpds-3318	8	9	the	the	DET
ijpds-3318	8	10	efficacy	efficacy	NOUN
ijpds-3318	8	11	and	and	CCONJ
ijpds-3318	8	12	safety	safety	NOUN
ijpds-3318	8	13	of	of	ADP
ijpds-3318	8	14	vildagliptin	vildagliptin	NOUN
ijpds-3318	8	15	-	-	PUNCT
ijpds-3318	8	16	metformin	metformin	NOUN
ijpds-3318	8	17	with	with	ADP
ijpds-3318	8	18	glimepiride	glimepiride	NOUN
ijpds-3318	8	19	–	–	PUNCT
ijpds-3318	8	20	metformin	metformin	NOUN
ijpds-3318	8	21	in	in	ADP
ijpds-3318	8	22	type	type	NOUN
ijpds-3318	8	23	2	2	NUM
ijpds-3318	8	24	diabetes	diabetes	NOUN
ijpds-3318	8	25	.	.	PUNCT
ijpds-3318	9	1	aim	aim	NOUN
ijpds-3318	9	2	&	&	CCONJ
ijpds-3318	9	3	objectives	objective	NOUN
ijpds-3318	9	4	:	:	PUNCT
ijpds-3318	9	5	this	this	DET
ijpds-3318	9	6	study	study	NOUN
ijpds-3318	9	7	was	be	AUX
ijpds-3318	9	8	aimed	aim	VERB
ijpds-3318	9	9	to	to	PART
ijpds-3318	9	10	compare	compare	VERB
ijpds-3318	9	11	the	the	DET
ijpds-3318	9	12	efficacy	efficacy	NOUN
ijpds-3318	9	13	and	and	CCONJ
ijpds-3318	9	14	safety	safety	NOUN
ijpds-3318	9	15	of	of	ADP
ijpds-3318	9	16	vildagliptin	vildagliptin	NOUN
ijpds-3318	9	17	-	-	PUNCT
ijpds-3318	9	18	metformin	metformin	NOUN
ijpds-3318	9	19	with	with	ADP
ijpds-3318	9	20	glimepiride	glimepiride	NOUN
ijpds-3318	9	21	metformin	metformin	NOUN
ijpds-3318	9	22	for	for	ADP
ijpds-3318	9	23	patients	patient	NOUN
ijpds-3318	9	24	with	with	ADP
ijpds-3318	9	25	type	type	NOUN
ijpds-3318	9	26	2	2	NUM
ijpds-3318	9	27	diabetes	diabetes	NOUN
ijpds-3318	9	28	mellitus	mellitus	NOUN
ijpds-3318	9	29	at	at	ADP
ijpds-3318	9	30	government	government	PROPN
ijpds-3318	9	31	general	general	ADJ
ijpds-3318	9	32	hospital	hospital	NOUN
ijpds-3318	9	33	(	(	PUNCT
ijpds-3318	9	34	ggh	ggh	NOUN
ijpds-3318	9	35	-	-	PUNCT
ijpds-3318	9	36	rims	rim	NOUN
ijpds-3318	9	37	)	)	PUNCT
ijpds-3318	9	38	,	,	PUNCT
ijpds-3318	9	39	kadapa	kadapa	PROPN
ijpds-3318	9	40	.	.	PUNCT
ijpds-3318	10	1	objective	objective	NOUN
ijpds-3318	10	2	:	:	PUNCT
ijpds-3318	10	3	to	to	PART
ijpds-3318	10	4	assess	assess	VERB
ijpds-3318	10	5	the	the	DET
ijpds-3318	10	6	prognosis	prognosis	NOUN
ijpds-3318	10	7	report	report	NOUN
ijpds-3318	10	8	,	,	PUNCT
ijpds-3318	10	9	and	and	CCONJ
ijpds-3318	10	10	compare	compare	VERB
ijpds-3318	10	11	the	the	DET
ijpds-3318	10	12	effectiveness	effectiveness	NOUN
ijpds-3318	10	13	and	and	CCONJ
ijpds-3318	10	14	safety	safety	NOUN
ijpds-3318	10	15	profiles	profile	NOUN
ijpds-3318	10	16	of	of	ADP
ijpds-3318	10	17	group	group	NOUN
ijpds-3318	10	18	i	i	PRON
ijpds-3318	10	19	(	(	PUNCT
ijpds-3318	10	20	vildagliptinmetformin	vildagliptinmetformin	NOUN
ijpds-3318	10	21	)	)	PUNCT
ijpds-3318	10	22	patients	patient	NOUN
ijpds-3318	10	23	with	with	ADP
ijpds-3318	10	24	group	group	PROPN
ijpds-3318	10	25	ii	ii	PROPN
ijpds-3318	10	26	(	(	PUNCT
ijpds-3318	10	27	glimepiridemetformin	glimepiridemetformin	NOUN
ijpds-3318	10	28	)	)	PUNCT
ijpds-3318	10	29	patients	patient	NOUN
ijpds-3318	10	30	and	and	CCONJ
ijpds-3318	10	31	counsel	counsel	VERB
ijpds-3318	10	32	them	they	PRON
ijpds-3318	10	33	about	about	ADP
ijpds-3318	10	34	a	a	DET
ijpds-3318	10	35	multi	multi	ADJ
ijpds-3318	10	36	-	-	ADJ
ijpds-3318	10	37	disciplinary	disciplinary	ADJ
ijpds-3318	10	38	treatment	treatment	NOUN
ijpds-3318	10	39	approach	approach	NOUN
ijpds-3318	10	40	by	by	ADP
ijpds-3318	10	41	prov	prov	PROPN
ijpds-3318	10	42	iding	ide	VERB
ijpds-3318	10	43	patient	patient	ADJ
ijpds-3318	10	44	information	information	NOUN
ijpds-3318	10	45	leaflets	leaflet	NOUN
ijpds-3318	10	46	to	to	PART
ijpds-3318	10	47	exhibit	exhibit	VERB
ijpds-3318	10	48	a	a	DET
ijpds-3318	10	49	better	well	ADJ
ijpds-3318	10	50	life	life	NOUN
ijpds-3318	10	51	.	.	PUNCT
ijpds-3318	11	1	methodology	methodology	NOUN
ijpds-3318	11	2	:	:	PUNCT
ijpds-3318	11	3	a	a	DET
ijpds-3318	11	4	single	single	ADJ
ijpds-3318	11	5	-	-	PUNCT
ijpds-3318	11	6	center	center	NOUN
ijpds-3318	11	7	prospective	prospective	ADJ
ijpds-3318	11	8	observational	observational	ADJ
ijpds-3318	11	9	study	study	NOUN
ijpds-3318	11	10	was	be	AUX
ijpds-3318	11	11	conducted	conduct	VERB
ijpds-3318	11	12	for	for	ADP
ijpds-3318	11	13	6	6	NUM
ijpds-3318	11	14	months	month	NOUN
ijpds-3318	11	15	in	in	ADP
ijpds-3318	11	16	the	the	DET
ijpds-3318	11	17	general	general	ADJ
ijpds-3318	11	18	medicine	medicine	PROPN
ijpds-3318	11	19	department	department	PROPN
ijpds-3318	11	20	at	at	ADP
ijpds-3318	11	21	a	a	DET
ijpds-3318	11	22	government	government	NOUN
ijpds-3318	11	23	general	general	ADJ
ijpds-3318	11	24	hospital	hospital	NOUN
ijpds-3318	11	25	,	,	PUNCT
ijpds-3318	11	26	in	in	ADP
ijpds-3318	11	27	india	india	PROPN
ijpds-3318	11	28	.	.	PUNCT
ijpds-3318	12	1	a	a	DET
ijpds-3318	12	2	total	total	NOUN
ijpds-3318	12	3	of	of	ADP
ijpds-3318	12	4	100	100	NUM
ijpds-3318	12	5	patients	patient	NOUN
ijpds-3318	12	6	were	be	AUX
ijpds-3318	12	7	recruited	recruit	VERB
ijpds-3318	12	8	for	for	ADP
ijpds-3318	12	9	this	this	DET
ijpds-3318	12	10	study	study	NOUN
ijpds-3318	12	11	and	and	CCONJ
ijpds-3318	12	12	divided	divide	VERB
ijpds-3318	12	13	into	into	ADP
ijpds-3318	12	14	2	2	NUM
ijpds-3318	12	15	groups	group	NOUN
ijpds-3318	12	16	of	of	ADP
ijpds-3318	12	17	50	50	NUM
ijpds-3318	12	18	patients	patient	NOUN
ijpds-3318	12	19	each	each	PRON
ijpds-3318	12	20	.	.	PUNCT
ijpds-3318	13	1	vildagliptin	vildagliptin	NOUN
ijpds-3318	13	2	-	-	PUNCT
ijpds-3318	13	3	metformin	metformin	NOUN
ijpds-3318	13	4	group	group	NOUN
ijpds-3318	13	5	1	1	NUM
ijpds-3318	13	6	and	and	CCONJ
ijpds-3318	13	7	glimepiride	glimepiride	NOUN
ijpds-3318	13	8	-	-	PUNCT
ijpds-3318	13	9	metformin	metformin	NOUN
ijpds-3318	13	10	group	group	NOUN
ijpds-3318	13	11	2	2	NUM
ijpds-3318	13	12	.	.	PUNCT
ijpds-3318	13	13	results	result	NOUN
ijpds-3318	13	14	:	:	PUNCT
ijpds-3318	13	15	glycated	glycate	VERB
ijpds-3318	13	16	hemoglobin	hemoglobin	NOUN
ijpds-3318	13	17	(	(	PUNCT
ijpds-3318	13	18	hba1c	hba1c	PROPN
ijpds-3318	13	19	)	)	PUNCT
ijpds-3318	13	20	,	,	PUNCT
ijpds-3318	13	21	fasting	fast	VERB
ijpds-3318	13	22	blood	blood	NOUN
ijpds-3318	13	23	sugar	sugar	NOUN
ijpds-3318	13	24	levels	level	NOUN
ijpds-3318	13	25	(	(	PUNCT
ijpds-3318	13	26	fbs	fbs	PROPN
ijpds-3318	13	27	)	)	PUNCT
ijpds-3318	13	28	,	,	PUNCT
ijpds-3318	13	29	and	and	CCONJ
ijpds-3318	13	30	random	random	ADJ
ijpds-3318	13	31	blood	blood	NOUN
ijpds-3318	13	32	sugar	sugar	NOUN
ijpds-3318	13	33	levels	level	NOUN
ijpds-3318	13	34	(	(	PUNCT
ijpds-3318	13	35	rbs	rbs	PROPN
ijpds-3318	13	36	)	)	PUNCT
ijpds-3318	13	37	parameters	parameter	NOUN
ijpds-3318	13	38	are	be	AUX
ijpds-3318	13	39	taken	take	VERB
ijpds-3318	13	40	as	as	ADP
ijpds-3318	13	41	primary	primary	ADJ
ijpds-3318	13	42	and	and	CCONJ
ijpds-3318	13	43	secondary	secondary	ADJ
ijpds-3318	13	44	endpoints	endpoint	NOUN
ijpds-3318	13	45	to	to	PART
ijpds-3318	13	46	compare	compare	VERB
ijpds-3318	13	47	groups	group	NOUN
ijpds-3318	13	48	as	as	ADP
ijpds-3318	13	49	per	per	ADP
ijpds-3318	13	50	efficacy	efficacy	NOUN
ijpds-3318	13	51	.	.	PUNCT
ijpds-3318	14	1	in	in	ADP
ijpds-3318	14	2	terms	term	NOUN
ijpds-3318	14	3	of	of	ADP
ijpds-3318	14	4	safety	safety	NOUN
ijpds-3318	14	5	weight	weight	NOUN
ijpds-3318	14	6	gain	gain	NOUN
ijpds-3318	14	7	,	,	PUNCT
ijpds-3318	14	8	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	14	9	,	,	PUNCT
ijpds-3318	14	10	and	and	CCONJ
ijpds-3318	14	11	other	other	ADJ
ijpds-3318	14	12	gastrointestinal	gastrointestinal	ADJ
ijpds-3318	14	13	adverse	adverse	ADJ
ijpds-3318	14	14	effects	effect	NOUN
ijpds-3318	14	15	are	be	AUX
ijpds-3318	14	16	considered	consider	VERB
ijpds-3318	14	17	.	.	PUNCT
ijpds-3318	15	1	the	the	DET
ijpds-3318	15	2	difference	difference	NOUN
ijpds-3318	15	3	between	between	ADP
ijpds-3318	15	4	values	value	NOUN
ijpds-3318	15	5	of	of	ADP
ijpds-3318	15	6	baseline	baseline	NOUN
ijpds-3318	15	7	and	and	CCONJ
ijpds-3318	15	8	final	final	ADJ
ijpds-3318	15	9	followup	followup	NOUN
ijpds-3318	15	10	of	of	ADP
ijpds-3318	15	11	hba1c	hba1c	PROPN
ijpds-3318	15	12	,	,	PUNCT
ijpds-3318	15	13	fbs	fbs	PROPN
ijpds-3318	15	14	,	,	PUNCT
ijpds-3318	15	15	rbs	rbs	PROPN
ijpds-3318	15	16	is	be	AUX
ijpds-3318	15	17	0.50	0.50	NUM
ijpds-3318	15	18	%	%	NOUN
ijpds-3318	15	19	,	,	PUNCT
ijpds-3318	15	20	20mg	20mg	PROPN
ijpds-3318	15	21	/	/	SYM
ijpds-3318	15	22	dl	dl	ADJ
ijpds-3318	15	23	,	,	PUNCT
ijpds-3318	15	24	85mg	85mg	ADJ
ijpds-3318	15	25	/	/	SYM
ijpds-3318	15	26	dl	dl	PROPN
ijpds-3318	15	27	in	in	ADP
ijpds-3318	15	28	group	group	NOUN
ijpds-3318	15	29	1	1	NUM
ijpds-3318	15	30	(	(	PUNCT
ijpds-3318	15	31	v	v	NOUN
ijpds-3318	15	32	-	-	PUNCT
ijpds-3318	15	33	m	m	NOUN
ijpds-3318	15	34	)	)	PUNCT
ijpds-3318	15	35	;	;	PUNCT
ijpds-3318	15	36	whereas	whereas	SCONJ
ijpds-3318	15	37	0.35	0.35	NUM
ijpds-3318	15	38	%	%	NOUN
ijpds-3318	15	39	,	,	PUNCT
ijpds-3318	15	40	15mg	15mg	PROPN
ijpds-3318	15	41	/	/	SYM
ijpds-3318	15	42	dl	dl	NOUN
ijpds-3318	15	43	,	,	PUNCT
ijpds-3318	15	44	55mg	55mg	NOUN
ijpds-3318	15	45	/	/	SYM
ijpds-3318	15	46	dl	dl	PROPN
ijpds-3318	15	47	in	in	ADP
ijpds-3318	15	48	group	group	NOUN
ijpds-3318	15	49	2	2	NUM
ijpds-3318	15	50	(	(	PUNCT
ijpds-3318	15	51	gm	gm	PROPN
ijpds-3318	15	52	)	)	PUNCT
ijpds-3318	15	53	respectively	respectively	ADV
ijpds-3318	15	54	.	.	PUNCT
ijpds-3318	16	1	24	24	NUM
ijpds-3318	16	2	adrs	adr	NOUN
ijpds-3318	16	3	with	with	ADP
ijpds-3318	16	4	respect	respect	NOUN
ijpds-3318	16	5	to	to	ADP
ijpds-3318	16	6	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	16	7	,	,	PUNCT
ijpds-3318	16	8	weight	weight	NOUN
ijpds-3318	16	9	gain	gain	NOUN
ijpds-3318	16	10	,	,	PUNCT
ijpds-3318	16	11	abdominal	abdominal	ADJ
ijpds-3318	16	12	pain	pain	NOUN
ijpds-3318	16	13	,	,	PUNCT
ijpds-3318	16	14	muscle	muscle	NOUN
ijpds-3318	16	15	tenderness	tenderness	NOUN
ijpds-3318	16	16	,	,	PUNCT
ijpds-3318	16	17	and	and	CCONJ
ijpds-3318	16	18	diarrhea	diarrhea	NOUN
ijpds-3318	16	19	are	be	AUX
ijpds-3318	16	20	observed	observe	VERB
ijpds-3318	16	21	in	in	ADP
ijpds-3318	16	22	group	group	NOUN
ijpds-3318	16	23	1	1	NUM
ijpds-3318	16	24	(	(	PUNCT
ijpds-3318	16	25	vm	vm	NOUN
ijpds-3318	16	26	)	)	PUNCT
ijpds-3318	16	27	group	group	NOUN
ijpds-3318	16	28	and	and	CCONJ
ijpds-3318	16	29	46	46	NUM
ijpds-3318	16	30	adrs	adr	NOUN
ijpds-3318	16	31	are	be	AUX
ijpds-3318	16	32	observed	observe	VERB
ijpds-3318	16	33	in	in	ADP
ijpds-3318	16	34	group	group	NOUN
ijpds-3318	16	35	2	2	NUM
ijpds-3318	16	36	(	(	PUNCT
ijpds-3318	16	37	g	g	NOUN
ijpds-3318	16	38	-	-	PUNCT
ijpds-3318	16	39	m	m	NOUN
ijpds-3318	16	40	)	)	PUNCT
ijpds-3318	16	41	.	.	PUNCT
ijpds-3318	17	1	conclusion	conclusion	NOUN
ijpds-3318	17	2	:	:	PUNCT
ijpds-3318	17	3	vildagliptinmetformin	vildagliptinmetformin	NOUN
ijpds-3318	17	4	treatment	treatment	NOUN
ijpds-3318	17	5	provided	provide	VERB
ijpds-3318	17	6	favorable	favorable	ADJ
ijpds-3318	17	7	glucose	glucose	NOUN
ijpds-3318	17	8	control	control	NOUN
ijpds-3318	17	9	comparable	comparable	ADJ
ijpds-3318	17	10	to	to	ADP
ijpds-3318	17	11	that	that	PRON
ijpds-3318	17	12	of	of	ADP
ijpds-3318	17	13	glimepiride	glimepiride	NOUN
ijpds-3318	17	14	-	-	PUNCT
ijpds-3318	17	15	metformin	metformin	NOUN
ijpds-3318	17	16	treatment	treatment	NOUN
ijpds-3318	17	17	.	.	PUNCT
ijpds-3318	18	1	it	it	PRON
ijpds-3318	18	2	also	also	ADV
ijpds-3318	18	3	resulted	result	VERB
ijpds-3318	18	4	in	in	ADP
ijpds-3318	18	5	better	well	ADJ
ijpds-3318	18	6	adverse	adverse	ADJ
ijpds-3318	18	7	event	event	NOUN
ijpds-3318	18	8	profiles	profile	NOUN
ijpds-3318	18	9	with	with	ADP
ijpds-3318	18	10	lower	low	ADJ
ijpds-3318	18	11	ris	ris	X
ijpds-3318	18	12	ks	ks	PROPN
ijpds-3318	18	13	of	of	ADP
ijpds-3318	18	14	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	18	15	and	and	CCONJ
ijpds-3318	18	16	weight	weight	NOUN
ijpds-3318	18	17	gain	gain	NOUN
ijpds-3318	18	18	.	.	PUNCT
ijpds-3318	19	1	key	key	ADJ
ijpds-3318	19	2	words	word	NOUN
ijpds-3318	19	3	:	:	PUNCT
ijpds-3318	19	4	type	type	NOUN
ijpds-3318	19	5	2	2	NUM
ijpds-3318	19	6	diabetes	diabetes	NOUN
ijpds-3318	19	7	,	,	PUNCT
ijpds-3318	19	8	metformin	metformin	NOUN
ijpds-3318	19	9	,	,	PUNCT
ijpds-3318	19	10	vildagliptin	vildagliptin	NOUN
ijpds-3318	19	11	,	,	PUNCT
ijpds-3318	19	12	glimepiride	glimepiride	NOUN
ijpds-3318	19	13	,	,	PUNCT
ijpds-3318	19	14	hba1c	hba1c	PROPN
ijpds-3318	19	15	,	,	PUNCT
ijpds-3318	19	16	adr	adr	PROPN
ijpds-3318	19	17	’s	’s	PART
ijpds-3318	19	18	ccording	ccorde	VERB
ijpds-3318	19	19	to	to	ADP
ijpds-3318	19	20	an	an	DET
ijpds-3318	19	21	idf	idf	PROPN
ijpds-3318	19	22	report	report	NOUN
ijpds-3318	19	23	published	publish	VERB
ijpds-3318	19	24	in	in	ADP
ijpds-3318	19	25	2013	2013	NUM
ijpds-3318	19	26	,	,	PUNCT
ijpds-3318	19	27	the	the	DET
ijpds-3318	19	28	global	global	ADJ
ijpds-3318	19	29	prevalence	prevalence	NOUN
ijpds-3318	19	30	of	of	ADP
ijpds-3318	19	31	diabetes	diabetes	NOUN
ijpds-3318	19	32	in	in	ADP
ijpds-3318	19	33	adults	adult	NOUN
ijpds-3318	19	34	(	(	PUNCT
ijpds-3318	19	35	20	20	NUM
ijpds-3318	19	36	-	-	SYM
ijpds-3318	19	37	79	79	NUM
ijpds-3318	19	38	years	year	NOUN
ijpds-3318	19	39	old	old	ADJ
ijpds-3318	19	40	)	)	PUNCT
ijpds-3318	19	41	was	be	AUX
ijpds-3318	19	42	8.3	8.3	NUM
ijpds-3318	19	43	%	%	NOUN
ijpds-3318	19	44	(	(	PUNCT
ijpds-3318	19	45	382	382	NUM
ijpds-3318	19	46	million	million	NUM
ijpds-3318	19	47	people	people	NOUN
ijpds-3318	19	48	)	)	PUNCT
ijpds-3318	19	49	,	,	PUNCT
ijpds-3318	19	50	with	with	ADP
ijpds-3318	19	51	14	14	NUM
ijpds-3318	19	52	million	million	NUM
ijpds-3318	19	53	more	more	ADJ
ijpds-3318	19	54	males	male	NOUN
ijpds-3318	19	55	than	than	ADP
ijpds-3318	19	56	females	female	NOUN
ijpds-3318	19	57	(	(	PUNCT
ijpds-3318	19	58	198	198	NUM
ijpds-3318	19	59	million	million	NUM
ijpds-3318	19	60	males	male	NOUN
ijpds-3318	19	61	vs	vs	ADP
ijpds-3318	19	62	184	184	NUM
ijpds-3318	19	63	million	million	NUM
ijpds-3318	19	64	females	female	NOUN
ijpds-3318	19	65	)	)	PUNCT
ijpds-3318	19	66	.	.	PUNCT
ijpds-3318	20	1	this	this	DET
ijpds-3318	20	2	disease	disease	NOUN
ijpds-3318	20	3	majorly	majorly	ADV
ijpds-3318	20	4	occurs	occur	VERB
ijpds-3318	20	5	between	between	ADP
ijpds-3318	20	6	40	40	NUM
ijpds-3318	20	7	to	to	PART
ijpds-3318	20	8	59	59	NUM
ijpds-3318	20	9	years	year	NOUN
ijpds-3318	20	10	of	of	ADP
ijpds-3318	20	11	age	age	NOUN
ijpds-3318	20	12	and	and	CCONJ
ijpds-3318	20	13	the	the	DET
ijpds-3318	20	14	number	number	NOUN
ijpds-3318	20	15	will	will	AUX
ijpds-3318	20	16	rise	rise	VERB
ijpds-3318	20	17	beyond	beyond	ADP
ijpds-3318	20	18	592	592	NUM
ijpds-3318	20	19	million	million	NUM
ijpds-3318	20	20	by	by	ADP
ijpds-3318	20	21	2035	2035	NUM
ijpds-3318	20	22	with	with	ADP
ijpds-3318	20	23	a	a	DET
ijpds-3318	20	24	10.1	10.1	NUM
ijpds-3318	20	25	%	%	NOUN
ijpds-3318	20	26	global	global	ADJ
ijpds-3318	20	27	prevalence	prevalence	NOUN
ijpds-3318	21	1	[	[	X
ijpds-3318	21	2	1	1	NUM
ijpds-3318	21	3	]	]	PUNCT
ijpds-3318	21	4	.	.	PUNCT
ijpds-3318	22	1	the	the	DET
ijpds-3318	22	2	ada	ada	PROPN
ijpds-3318	22	3	has	have	AUX
ijpds-3318	22	4	developed	develop	VERB
ijpds-3318	22	5	and	and	CCONJ
ijpds-3318	22	6	provided	provide	VERB
ijpds-3318	22	7	diabetes	diabetes	NOUN
ijpds-3318	22	8	care	care	NOUN
ijpds-3318	22	9	guidelines	guideline	NOUN
ijpds-3318	22	10	and	and	CCONJ
ijpds-3318	22	11	related	related	ADJ
ijpds-3318	22	12	documents	document	NOUN
ijpds-3318	22	13	since	since	SCONJ
ijpds-3318	22	14	1989	1989	NUM
ijpds-3318	22	15	.	.	PUNCT
ijpds-3318	23	1	its	its	PRON
ijpds-3318	23	2	clinical	clinical	ADJ
ijpds-3318	23	3	practice	practice	NOUN
ijpds-3318	23	4	guidelines	guideline	NOUN
ijpds-3318	23	5	are	be	AUX
ijpds-3318	23	6	integral	integral	ADJ
ijpds-3318	23	7	resources	resource	NOUN
ijpds-3318	23	8	for	for	ADP
ijpds-3318	23	9	all	all	DET
ijpds-3318	23	10	health	health	NOUN
ijpds-3318	23	11	care	care	NOUN
ijpds-3318	23	12	professionals	professional	NOUN
ijpds-3318	23	13	.	.	PUNCT
ijpds-3318	24	1	according	accord	VERB
ijpds-3318	24	2	to	to	ADP
ijpds-3318	24	3	ada	ada	PROPN
ijpds-3318	24	4	,	,	PUNCT
ijpds-3318	24	5	metformin	metformin	PROPN
ijpds-3318	24	6	is	be	AUX
ijpds-3318	24	7	the	the	DET
ijpds-3318	24	8	preferred	preferred	ADJ
ijpds-3318	24	9	initial	initial	ADJ
ijpds-3318	24	10	pharmacological	pharmacological	ADJ
ijpds-3318	24	11	agent	agent	NOUN
ijpds-3318	24	12	for	for	ADP
ijpds-3318	24	13	the	the	DET
ijpds-3318	24	14	treatment	treatment	NOUN
ijpds-3318	24	15	of	of	ADP
ijpds-3318	24	16	t2	t2	NOUN
ijpds-3318	24	17	dm	dm	NOUN
ijpds-3318	24	18	.	.	PUNCT
ijpds-3318	25	1	if	if	SCONJ
ijpds-3318	25	2	metformin	metformin	NOUN
ijpds-3318	25	3	is	be	AUX
ijpds-3318	25	4	not	not	PART
ijpds-3318	25	5	tolerated	tolerate	VERB
ijpds-3318	25	6	,	,	PUNCT
ijpds-3318	25	7	other	other	ADJ
ijpds-3318	25	8	options	option	NOUN
ijpds-3318	25	9	for	for	ADP
ijpds-3318	25	10	first	first	ADJ
ijpds-3318	25	11	-	-	PUNCT
ijpds-3318	25	12	line	line	NOUN
ijpds-3318	25	13	therapy	therapy	NOUN
ijpds-3318	25	14	include	include	VERB
ijpds-3318	25	15	sulfonylureas	sulfonylurea	NOUN
ijpds-3318	25	16	,	,	PUNCT
ijpds-3318	25	17	dipeptidyl	dipeptidyl	ADJ
ijpds-3318	25	18	peptidase	peptidase	NOUN
ijpds-3318	25	19	4	4	NUM
ijpds-3318	25	20	inhibitor	inhibitor	NOUN
ijpds-3318	25	21	(	(	PUNCT
ijpds-3318	25	22	dpp-4i	dpp-4i	PROPN
ijpds-3318	25	23	)	)	PUNCT
ijpds-3318	25	24	,	,	PUNCT
ijpds-3318	25	25	and	and	CCONJ
ijpds-3318	25	26	sodium	sodium	NOUN
ijpds-3318	25	27	-	-	PUNCT
ijpds-3318	25	28	glucose	glucose	NOUN
ijpds-3318	25	29	linked	link	VERB
ijpds-3318	25	30	transporter	transporter	NOUN
ijpds-3318	25	31	2	2	NUM
ijpds-3318	25	32	inhibitor	inhibitor	NOUN
ijpds-3318	25	33	(	(	PUNCT
ijpds-3318	25	34	sglt2i	sglt2i	PROPN
ijpds-3318	25	35	)	)	PUNCT
ijpds-3318	25	36	,	,	PUNCT
ijpds-3318	25	37	alpha	alpha	NOUN
ijpds-3318	25	38	-	-	PUNCT
ijpds-3318	25	39	glucosidase	glucosidase	ADJ
ijpds-3318	25	40	inhibitors	inhibitor	NOUN
ijpds-3318	25	41	[	[	X
ijpds-3318	25	42	2	2	NUM
ijpds-3318	25	43	]	]	PUNCT
ijpds-3318	25	44	.	.	PUNCT
ijpds-3318	26	1	some	some	DET
ijpds-3318	26	2	studies	study	NOUN
ijpds-3318	26	3	documented	document	VERB
ijpds-3318	26	4	that	that	SCONJ
ijpds-3318	26	5	long	long	ADJ
ijpds-3318	26	6	-	-	PUNCT
ijpds-3318	26	7	term	term	NOUN
ijpds-3318	26	8	vildagliptin	vildagliptin	NOUN
ijpds-3318	26	9	combination	combination	NOUN
ijpds-3318	26	10	therapy	therapy	NOUN
ijpds-3318	26	11	is	be	AUX
ijpds-3318	26	12	safe	safe	ADJ
ijpds-3318	26	13	and	and	CCONJ
ijpds-3318	26	14	effective	effective	ADJ
ijpds-3318	26	15	in	in	ADP
ijpds-3318	26	16	japanese	japanese	ADJ
ijpds-3318	26	17	t2	t2	NOUN
ijpds-3318	26	18	dm	dm	PROPN
ijpds-3318	26	19	patients	patient	NOUN
ijpds-3318	27	1	[	[	X
ijpds-3318	27	2	3	3	NUM
ijpds-3318	27	3	]	]	PUNCT
ijpds-3318	27	4	.	.	PUNCT
ijpds-3318	28	1	sanjay	sanjay	PROPN
ijpds-3318	28	2	et	et	PROPN
ijpds-3318	28	3	al	al	PROPN
ijpds-3318	28	4	.	.	PROPN
ijpds-3318	28	5	concluded	conclude	VERB
ijpds-3318	28	6	that	that	SCONJ
ijpds-3318	28	7	saxagliptin	saxagliptin	NOUN
ijpds-3318	28	8	in	in	ADP
ijpds-3318	28	9	combination	combination	NOUN
ijpds-3318	28	10	with	with	ADP
ijpds-3318	28	11	metformin	metformin	NOUN
ijpds-3318	28	12	was	be	AUX
ijpds-3318	28	13	generally	generally	ADV
ijpds-3318	28	14	well	well	ADV
ijpds-3318	28	15	-	-	PUNCT
ijpds-3318	28	16	tolerated	tolerate	VERB
ijpds-3318	28	17	in	in	ADP
ijpds-3318	28	18	indian	indian	ADJ
ijpds-3318	28	19	t2	t2	PROPN
ijpds-3318	28	20	dm	dm	PROPN
ijpds-3318	28	21	patients	patient	NOUN
ijpds-3318	28	22	[	[	X
ijpds-3318	28	23	4	4	NUM
ijpds-3318	28	24	]	]	PUNCT
ijpds-3318	28	25	.	.	PUNCT
ijpds-3318	29	1	studies	study	NOUN
ijpds-3318	29	2	by	by	ADP
ijpds-3318	29	3	zang	zang	PROPN
ijpds-3318	29	4	et	et	PROPN
ijpds-3318	29	5	al	al	PROPN
ijpds-3318	29	6	.	.	PROPN
ijpds-3318	29	7	concluded	conclude	VERB
ijpds-3318	29	8	that	that	SCONJ
ijpds-3318	29	9	compared	compare	VERB
ijpds-3318	29	10	with	with	ADP
ijpds-3318	29	11	dual	dual	ADJ
ijpds-3318	29	12	oad	oad	NOUN
ijpds-3318	29	13	non	non	ADJ
ijpds-3318	29	14	-	-	ADJ
ijpds-3318	29	15	vildagliptin	vildagliptin	ADJ
ijpds-3318	29	16	combination	combination	NOUN
ijpds-3318	29	17	therapies	therapy	NOUN
ijpds-3318	29	18	,	,	PUNCT
ijpds-3318	29	19	vildagliptin	vildagliptin	NOUN
ijpds-3318	29	20	add	add	NOUN
ijpds-3318	29	21	-	-	PUNCT
ijpds-3318	29	22	on	on	NOUN
ijpds-3318	29	23	to	to	ADP
ijpds-3318	29	24	metformin	metformin	NOUN
ijpds-3318	29	25	is	be	AUX
ijpds-3318	29	26	effective	effective	ADJ
ijpds-3318	29	27	and	and	CCONJ
ijpds-3318	29	28	safe	safe	ADJ
ijpds-3318	29	29	to	to	PART
ijpds-3318	29	30	achieve	achieve	VERB
ijpds-3318	29	31	glycaemic	glycaemic	ADJ
ijpds-3318	29	32	control	control	NOUN
ijpds-3318	29	33	in	in	ADP
ijpds-3318	29	34	chinese	chinese	ADJ
ijpds-3318	29	35	patients	patient	NOUN
ijpds-3318	29	36	with	with	ADP
ijpds-3318	29	37	t2	t2	PROPN
ijpds-3318	29	38	dm	dm	X
ijpds-3318	30	1	[	[	X
ijpds-3318	30	2	5	5	NUM
ijpds-3318	30	3	]	]	PUNCT
ijpds-3318	30	4	.	.	PUNCT
ijpds-3318	30	5	harika	harika	PROPN
ijpds-3318	30	6	et	et	PROPN
ijpds-3318	30	7	al	al	PROPN
ijpds-3318	30	8	.	.	PROPN
ijpds-3318	30	9	concluded	conclude	VERB
ijpds-3318	30	10	that	that	SCONJ
ijpds-3318	30	11	vildagliptin	vildagliptin	NOUN
ijpds-3318	30	12	and	and	CCONJ
ijpds-3318	30	13	metformin	metformin	NOUN
ijpds-3318	30	14	combination	combination	NOUN
ijpds-3318	30	15	provided	provide	VERB
ijpds-3318	30	16	better	well	ADJ
ijpds-3318	30	17	efficacy	efficacy	NOUN
ijpds-3318	30	18	comparable	comparable	ADJ
ijpds-3318	30	19	to	to	ADP
ijpds-3318	30	20	that	that	PRON
ijpds-3318	30	21	of	of	ADP
ijpds-3318	30	22	glimepiride	glimepiride	NOUN
ijpds-3318	30	23	and	and	CCONJ
ijpds-3318	30	24	metformin	metformin	NOUN
ijpds-3318	30	25	combination	combination	NOUN
ijpds-3318	30	26	and	and	CCONJ
ijpds-3318	30	27	resulted	result	VERB
ijpds-3318	30	28	in	in	ADP
ijpds-3318	30	29	a	a	DET
ijpds-3318	30	30	better	well	ADJ
ijpds-3318	30	31	adverse	adverse	ADJ
ijpds-3318	30	32	effect	effect	NOUN
ijpds-3318	30	33	profile	profile	NOUN
ijpds-3318	30	34	with	with	ADP
ijpds-3318	30	35	lower	low	ADJ
ijpds-3318	30	36	risks	risk	NOUN
ijpds-3318	30	37	of	of	ADP
ijpds-3318	30	38	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	30	39	and	and	CCONJ
ijpds-3318	30	40	weight	weight	NOUN
ijpds-3318	30	41	gain	gain	NOUN
ijpds-3318	30	42	[	[	X
ijpds-3318	30	43	6	6	NUM
ijpds-3318	30	44	]	]	PUNCT
ijpds-3318	30	45	.	.	PUNCT
ijpds-3318	31	1	yavropoulou	yavropoulou	PROPN
ijpds-3318	31	2	et	et	PROPN
ijpds-3318	31	3	al	al	PROPN
ijpds-3318	31	4	.	.	PROPN
ijpds-3318	31	5	concluded	conclude	VERB
ijpds-3318	31	6	that	that	SCONJ
ijpds-3318	31	7	vildagliptin	vildagliptin	NOUN
ijpds-3318	31	8	is	be	AUX
ijpds-3318	31	9	well	well	ADV
ijpds-3318	31	10	tolerated	tolerate	VERB
ijpds-3318	31	11	either	either	CCONJ
ijpds-3318	31	12	as	as	ADP
ijpds-3318	31	13	monotherapy	monotherapy	NOUN
ijpds-3318	31	14	or	or	CCONJ
ijpds-3318	31	15	in	in	ADP
ijpds-3318	31	16	combination	combination	NOUN
ijpds-3318	31	17	but	but	CCONJ
ijpds-3318	31	18	the	the	DET
ijpds-3318	31	19	majority	majority	NOUN
ijpds-3318	31	20	of	of	ADP
ijpds-3318	31	21	patients	patient	NOUN
ijpds-3318	31	22	require	require	VERB
ijpds-3318	31	23	add	add	VERB
ijpds-3318	31	24	-	-	PUNCT
ijpds-3318	31	25	on	on	ADP
ijpds-3318	31	26	therapy	therapy	NOUN
ijpds-3318	31	27	shortly	shortly	ADV
ijpds-3318	31	28	after	after	ADP
ijpds-3318	31	29	the	the	DET
ijpds-3318	31	30	beginning	beginning	NOUN
ijpds-3318	31	31	of	of	ADP
ijpds-3318	31	32	treatment	treatment	NOUN
ijpds-3318	31	33	[	[	X
ijpds-3318	31	34	7	7	NUM
ijpds-3318	31	35	]	]	PUNCT
ijpds-3318	31	36	.	.	PUNCT
ijpds-3318	32	1	our	our	PRON
ijpds-3318	32	2	study	study	NOUN
ijpds-3318	32	3	attempted	attempt	VERB
ijpds-3318	32	4	to	to	PART
ijpds-3318	32	5	compare	compare	VERB
ijpds-3318	32	6	the	the	DET
ijpds-3318	32	7	safety	safety	NOUN
ijpds-3318	32	8	and	and	CCONJ
ijpds-3318	32	9	efficacy	efficacy	NOUN
ijpds-3318	32	10	of	of	ADP
ijpds-3318	32	11	vildagliptin	vildagliptin	NOUN
ijpds-3318	32	12	–	–	PUNCT
ijpds-3318	32	13	metformin	metformin	NOUN
ijpds-3318	32	14	with	with	ADP
ijpds-3318	32	15	glimepiride	glimepiride	NOUN
ijpds-3318	32	16	–	–	PUNCT
ijpds-3318	32	17	metformin	metformin	NOUN
ijpds-3318	32	18	in	in	ADP
ijpds-3318	32	19	type	type	NOUN
ijpds-3318	32	20	2	2	NUM
ijpds-3318	32	21	diabetes	diabetes	NOUN
ijpds-3318	32	22	mellitus	mellitus	NOUN
ijpds-3318	32	23	patients	patient	NOUN
ijpds-3318	32	24	.	.	PUNCT
ijpds-3318	33	1	materials	material	NOUN
ijpds-3318	33	2	and	and	CCONJ
ijpds-3318	33	3	methods	method	NOUN
ijpds-3318	33	4	a	a	DET
ijpds-3318	33	5	kareenmulla	kareenmulla	NOUN
ijpds-3318	33	6	et	et	PROPN
ijpds-3318	33	7	al	al	PROPN
ijpds-3318	33	8	efficacy	efficacy	PROPN
ijpds-3318	33	9	,	,	PUNCT
ijpds-3318	33	10	safety	safety	NOUN
ijpds-3318	33	11	of	of	ADP
ijpds-3318	33	12	vildagliptin	vildagliptin	NOUN
ijpds-3318	33	13	-	-	PUNCT
ijpds-3318	33	14	metformin	metformin	NOUN
ijpds-3318	33	15	versus	versus	ADP
ijpds-3318	33	16	glimepiride	glimepiride	NOUN
ijpds-3318	33	17	-	-	PUNCT
ijpds-3318	33	18	metformin	metformin	NOUN
ijpds-3318	33	19	vol	vol	NOUN
ijpds-3318	33	20	1	1	NUM
ijpds-3318	33	21	|	|	NOUN
ijpds-3318	33	22	issue	issue	NOUN
ijpds-3318	33	23	2	2	NUM
ijpds-3318	34	1	|	|	ADV
ijpds-3318	34	2	jul	jul	PROPN
ijpds-3318	34	3	sep	sep	PROPN
ijpds-3318	34	4	2022	2022	NUM
ijpds-3318	34	5	indian	indian	PROPN
ijpds-3318	34	6	j	j	PROPN
ijpds-3318	34	7	pharm	pharm	PROPN
ijpds-3318	34	8	drug	drug	PROPN
ijpds-3318	34	9	studies	study	NOUN
ijpds-3318	34	10	|	|	ADV
ijpds-3318	34	11	64	64	NUM
ijpds-3318	34	12	study	study	NOUN
ijpds-3318	34	13	design	design	NOUN
ijpds-3318	34	14	:	:	PUNCT
ijpds-3318	34	15	this	this	DET
ijpds-3318	34	16	study	study	NOUN
ijpds-3318	34	17	was	be	AUX
ijpds-3318	34	18	a	a	DET
ijpds-3318	34	19	prospective	prospective	ADJ
ijpds-3318	34	20	observational	observational	ADJ
ijpds-3318	34	21	study	study	NOUN
ijpds-3318	34	22	and	and	CCONJ
ijpds-3318	34	23	was	be	AUX
ijpds-3318	34	24	carried	carry	VERB
ijpds-3318	34	25	out	out	ADP
ijpds-3318	34	26	at	at	ADP
ijpds-3318	34	27	a	a	DET
ijpds-3318	34	28	tertiary	tertiary	ADJ
ijpds-3318	34	29	care	care	NOUN
ijpds-3318	34	30	hospital	hospital	NOUN
ijpds-3318	34	31	in	in	ADP
ijpds-3318	34	32	southern	southern	ADJ
ijpds-3318	34	33	india	india	PROPN
ijpds-3318	34	34	over	over	ADP
ijpds-3318	34	35	a	a	DET
ijpds-3318	34	36	period	period	NOUN
ijpds-3318	34	37	of	of	ADP
ijpds-3318	34	38	6	6	NUM
ijpds-3318	34	39	years	year	NOUN
ijpds-3318	34	40	(	(	PUNCT
ijpds-3318	34	41	from	from	ADP
ijpds-3318	34	42	december	december	PROPN
ijpds-3318	34	43	2020	2020	NUM
ijpds-3318	34	44	to	to	PART
ijpds-3318	34	45	may	may	PROPN
ijpds-3318	34	46	2021	2021	NUM
ijpds-3318	34	47	)	)	PUNCT
ijpds-3318	35	1	after	after	ADP
ijpds-3318	35	2	due	due	ADJ
ijpds-3318	35	3	clearance	clearance	NOUN
ijpds-3318	35	4	from	from	ADP
ijpds-3318	35	5	the	the	DET
ijpds-3318	35	6	institutional	institutional	ADJ
ijpds-3318	35	7	ethical	ethical	ADJ
ijpds-3318	35	8	committee	committee	NOUN
ijpds-3318	35	9	.	.	PUNCT
ijpds-3318	36	1	inclusion	inclusion	NOUN
ijpds-3318	36	2	criteria	criterion	NOUN
ijpds-3318	36	3	:	:	PUNCT
ijpds-3318	36	4	male	male	ADJ
ijpds-3318	36	5	and	and	CCONJ
ijpds-3318	36	6	female	female	ADJ
ijpds-3318	36	7	patients	patient	NOUN
ijpds-3318	36	8	aged	age	VERB
ijpds-3318	36	9	from	from	ADP
ijpds-3318	36	10	2070	2070	NUM
ijpds-3318	36	11	years	year	NOUN
ijpds-3318	36	12	who	who	PRON
ijpds-3318	36	13	gave	give	VERB
ijpds-3318	36	14	consent	consent	NOUN
ijpds-3318	36	15	for	for	ADP
ijpds-3318	36	16	participation	participation	NOUN
ijpds-3318	36	17	,	,	PUNCT
ijpds-3318	36	18	who	who	PRON
ijpds-3318	36	19	are	be	AUX
ijpds-3318	36	20	consulting	consult	VERB
ijpds-3318	36	21	both	both	ADV
ijpds-3318	36	22	ip	ip	ADJ
ijpds-3318	36	23	and	and	CCONJ
ijpds-3318	36	24	op	op	PROPN
ijpds-3318	36	25	general	general	ADJ
ijpds-3318	36	26	medicine	medicine	NOUN
ijpds-3318	36	27	departments	department	NOUN
ijpds-3318	36	28	suffering	suffer	VERB
ijpds-3318	36	29	from	from	ADP
ijpds-3318	36	30	type	type	NOUN
ijpds-3318	36	31	2	2	NUM
ijpds-3318	36	32	diabetes	diabetes	NOUN
ijpds-3318	36	33	mellitus	mellitus	NOUN
ijpds-3318	36	34	with	with	ADP
ijpds-3318	36	35	or	or	CCONJ
ijpds-3318	36	36	without	without	ADP
ijpds-3318	36	37	comorbid	comorbid	NOUN
ijpds-3318	36	38	conditions	condition	NOUN
ijpds-3318	36	39	with	with	ADP
ijpds-3318	36	40	respect	respect	NOUN
ijpds-3318	36	41	to	to	ADP
ijpds-3318	36	42	the	the	DET
ijpds-3318	36	43	cardiovascular	cardiovascular	ADJ
ijpds-3318	36	44	system	system	NOUN
ijpds-3318	36	45	and	and	CCONJ
ijpds-3318	36	46	pulmonary	pulmonary	ADJ
ijpds-3318	36	47	system	system	NOUN
ijpds-3318	36	48	and	and	CCONJ
ijpds-3318	36	49	receiving	receive	VERB
ijpds-3318	36	50	vildagliptin	vildagliptin	NOUN
ijpds-3318	36	51	metformin	metformin	NOUN
ijpds-3318	36	52	and	and	CCONJ
ijpds-3318	36	53	glimepiride	glimepiride	NOUN
ijpds-3318	36	54	metformin	metformin	NOUN
ijpds-3318	36	55	as	as	ADP
ijpds-3318	36	56	a	a	DET
ijpds-3318	36	57	treatment	treatment	NOUN
ijpds-3318	36	58	for	for	ADP
ijpds-3318	36	59	type	type	NOUN
ijpds-3318	36	60	2	2	NUM
ijpds-3318	36	61	diabetes	diabetes	NOUN
ijpds-3318	36	62	mellitus	mellitus	NOUN
ijpds-3318	36	63	,	,	PUNCT
ijpds-3318	36	64	are	be	AUX
ijpds-3318	36	65	included	include	VERB
ijpds-3318	36	66	in	in	ADP
ijpds-3318	36	67	the	the	DET
ijpds-3318	36	68	study	study	NOUN
ijpds-3318	36	69	.	.	PUNCT
ijpds-3318	37	1	exclusion	exclusion	NOUN
ijpds-3318	37	2	criteria	criterion	NOUN
ijpds-3318	37	3	:	:	PUNCT
ijpds-3318	37	4	pregnant	pregnant	ADJ
ijpds-3318	37	5	women	woman	NOUN
ijpds-3318	37	6	,	,	PUNCT
ijpds-3318	37	7	breastfeeding	breastfeed	VERB
ijpds-3318	37	8	women	woman	NOUN
ijpds-3318	37	9	,	,	PUNCT
ijpds-3318	37	10	neonates	neonate	NOUN
ijpds-3318	37	11	,	,	PUNCT
ijpds-3318	37	12	children	child	NOUN
ijpds-3318	37	13	,	,	PUNCT
ijpds-3318	37	14	and	and	CCONJ
ijpds-3318	37	15	geriatric	geriatric	ADJ
ijpds-3318	37	16	(	(	PUNCT
ijpds-3318	37	17	>	>	SYM
ijpds-3318	37	18	70	70	NUM
ijpds-3318	37	19	years	year	NOUN
ijpds-3318	37	20	)	)	PUNCT
ijpds-3318	37	21	,	,	PUNCT
ijpds-3318	37	22	those	those	PRON
ijpds-3318	37	23	who	who	PRON
ijpds-3318	37	24	were	be	AUX
ijpds-3318	37	25	not	not	PART
ijpds-3318	37	26	willing	willing	ADJ
ijpds-3318	37	27	to	to	PART
ijpds-3318	37	28	participate	participate	VERB
ijpds-3318	37	29	,	,	PUNCT
ijpds-3318	37	30	and	and	CCONJ
ijpds-3318	37	31	those	those	PRON
ijpds-3318	37	32	who	who	PRON
ijpds-3318	37	33	were	be	AUX
ijpds-3318	37	34	suffering	suffer	VERB
ijpds-3318	37	35	from	from	ADP
ijpds-3318	37	36	type	type	NOUN
ijpds-3318	37	37	1	1	NUM
ijpds-3318	37	38	diabetes	diabetes	NOUN
ijpds-3318	37	39	mellitus	mellitus	NOUN
ijpds-3318	37	40	,	,	PUNCT
ijpds-3318	37	41	chronic	chronic	ADJ
ijpds-3318	37	42	renal	renal	ADJ
ijpds-3318	37	43	or	or	CCONJ
ijpds-3318	37	44	hepatic	hepatic	ADJ
ijpds-3318	37	45	disorders	disorder	NOUN
ijpds-3318	37	46	,	,	PUNCT
ijpds-3318	37	47	and	and	CCONJ
ijpds-3318	37	48	receiving	receive	VERB
ijpds-3318	37	49	insulin	insulin	NOUN
ijpds-3318	37	50	treatment	treatment	NOUN
ijpds-3318	37	51	are	be	AUX
ijpds-3318	37	52	excluded	exclude	VERB
ijpds-3318	37	53	from	from	ADP
ijpds-3318	37	54	the	the	DET
ijpds-3318	37	55	study	study	NOUN
ijpds-3318	37	56	.	.	PUNCT
ijpds-3318	38	1	study	study	NOUN
ijpds-3318	38	2	method	method	VERB
ijpds-3318	38	3	our	our	PRON
ijpds-3318	38	4	study	study	NOUN
ijpds-3318	38	5	was	be	AUX
ijpds-3318	38	6	a	a	DET
ijpds-3318	38	7	prospective	prospective	ADJ
ijpds-3318	38	8	observational	observational	ADJ
ijpds-3318	38	9	study	study	NOUN
ijpds-3318	38	10	conducted	conduct	VERB
ijpds-3318	38	11	on	on	ADP
ijpds-3318	38	12	100	100	NUM
ijpds-3318	38	13	patients	patient	NOUN
ijpds-3318	38	14	with	with	ADP
ijpds-3318	38	15	type	type	NOUN
ijpds-3318	38	16	2	2	NUM
ijpds-3318	38	17	diabetes	diabetes	NOUN
ijpds-3318	38	18	mellitus	mellitus	NOUN
ijpds-3318	38	19	who	who	PRON
ijpds-3318	38	20	were	be	AUX
ijpds-3318	38	21	on	on	ADP
ijpds-3318	38	22	treatment	treatment	NOUN
ijpds-3318	38	23	with	with	ADP
ijpds-3318	38	24	either	either	CCONJ
ijpds-3318	38	25	vildagliptin	vildagliptin	NOUN
ijpds-3318	38	26	metformin	metformin	NOUN
ijpds-3318	38	27	or	or	CCONJ
ijpds-3318	38	28	glimiperide	glimiperide	NOUN
ijpds-3318	38	29	–	–	PUNCT
ijpds-3318	38	30	metformin	metformin	NOUN
ijpds-3318	38	31	at	at	ADP
ijpds-3318	38	32	a	a	DET
ijpds-3318	38	33	government	government	NOUN
ijpds-3318	38	34	general	general	ADJ
ijpds-3318	38	35	tertiary	tertiary	ADJ
ijpds-3318	38	36	care	care	NOUN
ijpds-3318	38	37	hospital	hospital	NOUN
ijpds-3318	38	38	.	.	PUNCT
ijpds-3318	39	1	this	this	DET
ijpds-3318	39	2	study	study	NOUN
ijpds-3318	39	3	was	be	AUX
ijpds-3318	39	4	conducted	conduct	VERB
ijpds-3318	39	5	over	over	ADP
ijpds-3318	39	6	a	a	DET
ijpds-3318	39	7	period	period	NOUN
ijpds-3318	39	8	of	of	ADP
ijpds-3318	39	9	12	12	NUM
ijpds-3318	39	10	weeks	week	NOUN
ijpds-3318	39	11	–	–	PUNCT
ijpds-3318	39	12	follow	follow	VERB
ijpds-3318	39	13	-	-	PUNCT
ijpds-3318	39	14	up	up	NOUN
ijpds-3318	39	15	was	be	AUX
ijpds-3318	39	16	conducted	conduct	VERB
ijpds-3318	39	17	every	every	DET
ijpds-3318	39	18	4	4	NUM
ijpds-3318	39	19	weeks	week	NOUN
ijpds-3318	39	20	and	and	CCONJ
ijpds-3318	39	21	the	the	DET
ijpds-3318	39	22	obtained	obtain	VERB
ijpds-3318	39	23	values	value	NOUN
ijpds-3318	39	24	were	be	AUX
ijpds-3318	39	25	evaluated	evaluate	VERB
ijpds-3318	39	26	.	.	PUNCT
ijpds-3318	40	1	the	the	DET
ijpds-3318	40	2	present	present	ADJ
ijpds-3318	40	3	study	study	NOUN
ijpds-3318	40	4	aimed	aim	VERB
ijpds-3318	40	5	to	to	PART
ijpds-3318	40	6	compare	compare	VERB
ijpds-3318	40	7	the	the	DET
ijpds-3318	40	8	efficacy	efficacy	NOUN
ijpds-3318	40	9	and	and	CCONJ
ijpds-3318	40	10	safety	safety	NOUN
ijpds-3318	40	11	of	of	ADP
ijpds-3318	40	12	the	the	DET
ijpds-3318	40	13	combinations	combination	NOUN
ijpds-3318	40	14	of	of	ADP
ijpds-3318	40	15	two	two	NUM
ijpds-3318	40	16	different	different	ADJ
ijpds-3318	40	17	drug	drug	NOUN
ijpds-3318	40	18	regimens	regimen	NOUN
ijpds-3318	40	19	i.e.	i.e.	X
ijpds-3318	40	20	,	,	PUNCT
ijpds-3318	40	21	vildagliptin	vildagliptin	NOUN
ijpds-3318	40	22	–	–	PUNCT
ijpds-3318	40	23	metformin	metformin	NOUN
ijpds-3318	40	24	and	and	CCONJ
ijpds-3318	40	25	glimiperide	glimiperide	NOUN
ijpds-3318	40	26	–	–	PUNCT
ijpds-3318	40	27	metformin	metformin	NOUN
ijpds-3318	40	28	in	in	ADP
ijpds-3318	40	29	type	type	NOUN
ijpds-3318	40	30	2	2	NUM
ijpds-3318	40	31	diabetic	diabetic	ADJ
ijpds-3318	40	32	patients	patient	NOUN
ijpds-3318	40	33	.	.	PUNCT
ijpds-3318	41	1	patients	patient	NOUN
ijpds-3318	41	2	diagnosed	diagnose	VERB
ijpds-3318	41	3	with	with	ADP
ijpds-3318	41	4	type	type	NOUN
ijpds-3318	41	5	2	2	NUM
ijpds-3318	41	6	diabetes	diabetes	NOUN
ijpds-3318	41	7	mellitus	mellitus	NOUN
ijpds-3318	41	8	and	and	CCONJ
ijpds-3318	41	9	prescribed	prescribe	VERB
ijpds-3318	41	10	metformin	metformin	NOUN
ijpds-3318	41	11	-	-	PUNCT
ijpds-3318	41	12	vildagliptin	vildagliptin	PROPN
ijpds-3318	41	13	(	(	PUNCT
ijpds-3318	41	14	group	group	NOUN
ijpds-3318	41	15	i	i	PROPN
ijpds-3318	41	16	)	)	PUNCT
ijpds-3318	41	17	,	,	PUNCT
ijpds-3318	41	18	and	and	CCONJ
ijpds-3318	41	19	metformin	metformin	NOUN
ijpds-3318	41	20	-	-	PUNCT
ijpds-3318	41	21	glimepiride	glimepiride	NOUN
ijpds-3318	41	22	(	(	PUNCT
ijpds-3318	41	23	group	group	NOUN
ijpds-3318	41	24	ii	ii	PROPN
ijpds-3318	41	25	)	)	PUNCT
ijpds-3318	41	26	were	be	AUX
ijpds-3318	41	27	screened	screen	VERB
ijpds-3318	41	28	.	.	PUNCT
ijpds-3318	42	1	screened	screen	VERB
ijpds-3318	42	2	patients	patient	NOUN
ijpds-3318	42	3	were	be	AUX
ijpds-3318	42	4	recruited	recruit	VERB
ijpds-3318	42	5	after	after	ADP
ijpds-3318	42	6	taking	take	VERB
ijpds-3318	42	7	informed	informed	ADJ
ijpds-3318	42	8	consent	consent	NOUN
ijpds-3318	42	9	and	and	CCONJ
ijpds-3318	42	10	then	then	ADV
ijpds-3318	42	11	,	,	PUNCT
ijpds-3318	42	12	data	datum	NOUN
ijpds-3318	42	13	was	be	AUX
ijpds-3318	42	14	copied	copy	VERB
ijpds-3318	42	15	in	in	ADP
ijpds-3318	42	16	our	our	PRON
ijpds-3318	42	17	data	data	NOUN
ijpds-3318	42	18	collection	collection	NOUN
ijpds-3318	42	19	form	form	NOUN
ijpds-3318	42	20	for	for	ADP
ijpds-3318	42	21	every	every	DET
ijpds-3318	42	22	follow	follow	NOUN
ijpds-3318	42	23	-	-	PUNCT
ijpds-3318	42	24	up	up	NOUN
ijpds-3318	42	25	that	that	PRON
ijpds-3318	42	26	was	be	AUX
ijpds-3318	42	27	conducted	conduct	VERB
ijpds-3318	42	28	once	once	ADV
ijpds-3318	42	29	in	in	ADP
ijpds-3318	42	30	4	4	NUM
ijpds-3318	42	31	weeks	week	NOUN
ijpds-3318	42	32	.	.	PUNCT
ijpds-3318	43	1	group	group	NOUN
ijpds-3318	43	2	i	i	PRON
ijpds-3318	43	3	and	and	CCONJ
ijpds-3318	43	4	group	group	PROPN
ijpds-3318	43	5	ii	ii	PROPN
ijpds-3318	43	6	patients	patient	NOUN
ijpds-3318	43	7	continued	continue	VERB
ijpds-3318	43	8	the	the	DET
ijpds-3318	43	9	treatment	treatment	NOUN
ijpds-3318	43	10	for	for	ADP
ijpds-3318	43	11	a	a	DET
ijpds-3318	43	12	duration	duration	NOUN
ijpds-3318	43	13	of	of	ADP
ijpds-3318	43	14	6	6	NUM
ijpds-3318	43	15	months	month	NOUN
ijpds-3318	43	16	.	.	PUNCT
ijpds-3318	44	1	after	after	ADP
ijpds-3318	44	2	the	the	DET
ijpds-3318	44	3	end	end	NOUN
ijpds-3318	44	4	of	of	ADP
ijpds-3318	44	5	6	6	NUM
ijpds-3318	44	6	months	month	NOUN
ijpds-3318	44	7	,	,	PUNCT
ijpds-3318	44	8	the	the	DET
ijpds-3318	44	9	efficacy	efficacy	NOUN
ijpds-3318	44	10	and	and	CCONJ
ijpds-3318	44	11	safety	safety	NOUN
ijpds-3318	44	12	profiles	profile	NOUN
ijpds-3318	44	13	of	of	ADP
ijpds-3318	44	14	both	both	CCONJ
ijpds-3318	44	15	the	the	DET
ijpds-3318	44	16	groups	group	NOUN
ijpds-3318	44	17	were	be	AUX
ijpds-3318	44	18	estimated	estimate	VERB
ijpds-3318	44	19	and	and	CCONJ
ijpds-3318	44	20	compared	compare	VERB
ijpds-3318	44	21	simultaneously	simultaneously	ADV
ijpds-3318	44	22	.	.	PUNCT
ijpds-3318	45	1	data	datum	NOUN
ijpds-3318	45	2	were	be	AUX
ijpds-3318	45	3	processed	process	VERB
ijpds-3318	45	4	and	and	CCONJ
ijpds-3318	45	5	analyzed	analyze	VERB
ijpds-3318	45	6	,	,	PUNCT
ijpds-3318	45	7	and	and	CCONJ
ijpds-3318	45	8	framing	framing	NOUN
ijpds-3318	45	9	of	of	ADP
ijpds-3318	45	10	results	result	NOUN
ijpds-3318	45	11	,	,	PUNCT
ijpds-3318	45	12	preparation	preparation	NOUN
ijpds-3318	45	13	of	of	ADP
ijpds-3318	45	14	dissertation	dissertation	NOUN
ijpds-3318	45	15	book	book	NOUN
ijpds-3318	45	16	,	,	PUNCT
ijpds-3318	45	17	and	and	CCONJ
ijpds-3318	45	18	communication	communication	NOUN
ijpds-3318	45	19	of	of	ADP
ijpds-3318	45	20	the	the	DET
ijpds-3318	45	21	research	research	NOUN
ijpds-3318	45	22	work	work	NOUN
ijpds-3318	45	23	through	through	ADP
ijpds-3318	45	24	publications	publication	NOUN
ijpds-3318	45	25	were	be	AUX
ijpds-3318	45	26	performed	perform	VERB
ijpds-3318	45	27	.	.	PUNCT
ijpds-3318	46	1	results	result	NOUN
ijpds-3318	46	2	were	be	AUX
ijpds-3318	46	3	represented	represent	VERB
ijpds-3318	46	4	as	as	ADP
ijpds-3318	46	5	frequencies	frequency	NOUN
ijpds-3318	46	6	,	,	PUNCT
ijpds-3318	46	7	percentages	percentage	NOUN
ijpds-3318	46	8	,	,	PUNCT
ijpds-3318	46	9	mean	mean	VERB
ijpds-3318	46	10	,	,	PUNCT
ijpds-3318	46	11	and	and	CCONJ
ijpds-3318	46	12	medians	median	NOUN
ijpds-3318	46	13	.	.	PUNCT
ijpds-3318	47	1	software	software	NOUN
ijpds-3318	47	2	graph	graph	NOUN
ijpds-3318	47	3	pad	pad	NOUN
ijpds-3318	47	4	prism	prism	NOUN
ijpds-3318	47	5	was	be	AUX
ijpds-3318	47	6	applied	apply	VERB
ijpds-3318	47	7	to	to	PART
ijpds-3318	47	8	evaluate	evaluate	VERB
ijpds-3318	47	9	and	and	CCONJ
ijpds-3318	47	10	analyze	analyze	VERB
ijpds-3318	47	11	the	the	DET
ijpds-3318	47	12	data	datum	NOUN
ijpds-3318	47	13	.	.	PUNCT
ijpds-3318	48	1	in	in	ADP
ijpds-3318	48	2	some	some	DET
ijpds-3318	48	3	cases	case	NOUN
ijpds-3318	48	4	,	,	PUNCT
ijpds-3318	48	5	inferential	inferential	ADJ
ijpds-3318	48	6	statistics	statistic	NOUN
ijpds-3318	48	7	like	like	ADP
ijpds-3318	48	8	analysis	analysis	NOUN
ijpds-3318	48	9	of	of	ADP
ijpds-3318	48	10	variance	variance	NOUN
ijpds-3318	48	11	(	(	PUNCT
ijpds-3318	48	12	anova	anova	PROPN
ijpds-3318	48	13	)	)	PUNCT
ijpds-3318	48	14	followed	follow	VERB
ijpds-3318	48	15	by	by	ADP
ijpds-3318	48	16	student	student	NOUN
ijpds-3318	48	17	–	–	PUNCT
ijpds-3318	48	18	tests	test	NOUN
ijpds-3318	48	19	,	,	PUNCT
ijpds-3318	48	20	using	use	VERB
ijpds-3318	48	21	spss	spss	PROPN
ijpds-3318	48	22	software	software	NOUN
ijpds-3318	48	23	version	version	NOUN
ijpds-3318	48	24	21.0	21.0	NUM
ijpds-3318	48	25	were	be	AUX
ijpds-3318	48	26	also	also	ADV
ijpds-3318	48	27	implemented	implement	VERB
ijpds-3318	48	28	.	.	PUNCT
ijpds-3318	49	1	permission	permission	NOUN
ijpds-3318	49	2	for	for	ADP
ijpds-3318	49	3	collecting	collect	VERB
ijpds-3318	49	4	patient	patient	ADJ
ijpds-3318	49	5	data	datum	NOUN
ijpds-3318	49	6	was	be	AUX
ijpds-3318	49	7	approved	approve	VERB
ijpds-3318	49	8	by	by	ADP
ijpds-3318	49	9	the	the	DET
ijpds-3318	49	10	institutional	institutional	ADJ
ijpds-3318	49	11	ethical	ethical	PROPN
ijpds-3318	49	12	committee	committee	NOUN
ijpds-3318	49	13	of	of	ADP
ijpds-3318	49	14	rims	rims	PROPN
ijpds-3318	49	15	hospital	hospital	NOUN
ijpds-3318	49	16	and	and	CCONJ
ijpds-3318	49	17	the	the	DET
ijpds-3318	49	18	clinical	clinical	ADJ
ijpds-3318	49	19	guide	guide	NOUN
ijpds-3318	49	20	of	of	ADP
ijpds-3318	49	21	the	the	DET
ijpds-3318	49	22	general	general	ADJ
ijpds-3318	49	23	medicine	medicine	PROPN
ijpds-3318	49	24	department	department	PROPN
ijpds-3318	49	25	.	.	PUNCT
ijpds-3318	50	1	in	in	ADP
ijpds-3318	50	2	addition	addition	NOUN
ijpds-3318	50	3	,	,	PUNCT
ijpds-3318	50	4	hospital	hospital	NOUN
ijpds-3318	50	5	management	management	NOUN
ijpds-3318	50	6	also	also	ADV
ijpds-3318	50	7	allowed	allow	VERB
ijpds-3318	50	8	us	we	PRON
ijpds-3318	50	9	to	to	PART
ijpds-3318	50	10	utilize	utilize	VERB
ijpds-3318	50	11	the	the	DET
ijpds-3318	50	12	other	other	ADJ
ijpds-3318	50	13	facilities	facility	NOUN
ijpds-3318	50	14	for	for	ADP
ijpds-3318	50	15	the	the	DET
ijpds-3318	50	16	project	project	NOUN
ijpds-3318	50	17	.	.	PUNCT
ijpds-3318	51	1	results	result	VERB
ijpds-3318	51	2	a	a	DET
ijpds-3318	51	3	total	total	NOUN
ijpds-3318	51	4	of	of	ADP
ijpds-3318	51	5	100	100	NUM
ijpds-3318	51	6	patients	patient	NOUN
ijpds-3318	51	7	were	be	AUX
ijpds-3318	51	8	taken	take	VERB
ijpds-3318	51	9	as	as	ADP
ijpds-3318	51	10	the	the	DET
ijpds-3318	51	11	sample	sample	NOUN
ijpds-3318	51	12	size	size	NOUN
ijpds-3318	51	13	in	in	ADP
ijpds-3318	51	14	this	this	DET
ijpds-3318	51	15	study	study	NOUN
ijpds-3318	51	16	.	.	PUNCT
ijpds-3318	52	1	among	among	ADP
ijpds-3318	52	2	them	they	PRON
ijpds-3318	52	3	,	,	PUNCT
ijpds-3318	52	4	65(65	65(65	NUM
ijpds-3318	52	5	%	%	NOUN
ijpds-3318	52	6	)	)	PUNCT
ijpds-3318	52	7	were	be	AUX
ijpds-3318	52	8	male	male	ADJ
ijpds-3318	52	9	patients	patient	NOUN
ijpds-3318	52	10	and	and	CCONJ
ijpds-3318	52	11	35(35	35(35	NUM
ijpds-3318	52	12	%	%	NOUN
ijpds-3318	52	13	)	)	PUNCT
ijpds-3318	52	14	were	be	AUX
ijpds-3318	52	15	female	female	ADJ
ijpds-3318	52	16	patients	patient	NOUN
ijpds-3318	52	17	.	.	PUNCT
ijpds-3318	53	1	based	base	VERB
ijpds-3318	53	2	on	on	ADP
ijpds-3318	53	3	their	their	PRON
ijpds-3318	53	4	treatment	treatment	NOUN
ijpds-3318	53	5	,	,	PUNCT
ijpds-3318	53	6	50	50	NUM
ijpds-3318	53	7	patients	patient	NOUN
ijpds-3318	53	8	were	be	AUX
ijpds-3318	53	9	grouped	group	VERB
ijpds-3318	53	10	in	in	ADP
ijpds-3318	53	11	the	the	DET
ijpds-3318	53	12	v	v	NOUN
ijpds-3318	53	13	-	-	PUNCT
ijpds-3318	53	14	m	m	NOUN
ijpds-3318	53	15	group	group	NOUN
ijpds-3318	53	16	and	and	CCONJ
ijpds-3318	53	17	50	50	NUM
ijpds-3318	53	18	patients	patient	NOUN
ijpds-3318	53	19	were	be	AUX
ijpds-3318	53	20	grouped	group	VERB
ijpds-3318	53	21	in	in	ADP
ijpds-3318	53	22	the	the	DET
ijpds-3318	53	23	g	g	PROPN
ijpds-3318	53	24	-	-	PUNCT
ijpds-3318	53	25	m	m	NOUN
ijpds-3318	53	26	group	group	NOUN
ijpds-3318	53	27	.	.	PUNCT
ijpds-3318	54	1	the	the	DET
ijpds-3318	54	2	in	in	ADP
ijpds-3318	54	3	v	v	PROPN
ijpds-3318	54	4	-	-	PUNCT
ijpds-3318	54	5	m	m	NOUN
ijpds-3318	54	6	group	group	NOUN
ijpds-3318	54	7	,	,	PUNCT
ijpds-3318	54	8	35	35	NUM
ijpds-3318	54	9	(	(	PUNCT
ijpds-3318	54	10	70	70	NUM
ijpds-3318	54	11	%	%	NOUN
ijpds-3318	54	12	)	)	PUNCT
ijpds-3318	54	13	patients	patient	NOUN
ijpds-3318	54	14	were	be	AUX
ijpds-3318	54	15	male	male	ADJ
ijpds-3318	54	16	and	and	CCONJ
ijpds-3318	54	17	15(30	15(30	NUM
ijpds-3318	54	18	%	%	NOUN
ijpds-3318	54	19	)	)	PUNCT
ijpds-3318	54	20	were	be	AUX
ijpds-3318	54	21	female	female	ADJ
ijpds-3318	54	22	patients	patient	NOUN
ijpds-3318	54	23	.	.	PUNCT
ijpds-3318	55	1	in	in	ADP
ijpds-3318	55	2	the	the	DET
ijpds-3318	55	3	g	g	PROPN
ijpds-3318	55	4	-	-	PUNCT
ijpds-3318	55	5	m	m	NOUN
ijpds-3318	55	6	group	group	NOUN
ijpds-3318	55	7	,	,	PUNCT
ijpds-3318	55	8	30(60	30(60	NUM
ijpds-3318	55	9	%	%	NOUN
ijpds-3318	55	10	)	)	PUNCT
ijpds-3318	55	11	were	be	AUX
ijpds-3318	55	12	male	male	ADJ
ijpds-3318	55	13	patients	patient	NOUN
ijpds-3318	55	14	and	and	CCONJ
ijpds-3318	55	15	20(40	20(40	NUM
ijpds-3318	55	16	%	%	NOUN
ijpds-3318	55	17	)	)	PUNCT
ijpds-3318	55	18	were	be	AUX
ijpds-3318	55	19	female	female	ADJ
ijpds-3318	55	20	patients	patient	NOUN
ijpds-3318	55	21	.	.	PUNCT
ijpds-3318	56	1	the	the	DET
ijpds-3318	56	2	details	detail	NOUN
ijpds-3318	56	3	were	be	AUX
ijpds-3318	56	4	shown	show	VERB
ijpds-3318	56	5	in	in	ADP
ijpds-3318	56	6	figure	figure	NOUN
ijpds-3318	56	7	1	1	NUM
ijpds-3318	56	8	.	.	PUNCT
ijpds-3318	56	9	figure	figure	NOUN
ijpds-3318	56	10	1	1	NUM
ijpds-3318	56	11	:	:	PUNCT
ijpds-3318	56	12	graphical	graphical	ADJ
ijpds-3318	56	13	representation	representation	NOUN
ijpds-3318	56	14	of	of	ADP
ijpds-3318	56	15	male	male	ADJ
ijpds-3318	56	16	&	&	CCONJ
ijpds-3318	56	17	female	female	ADJ
ijpds-3318	56	18	patients	patient	NOUN
ijpds-3318	56	19	(	(	PUNCT
ijpds-3318	56	20	v	v	NOUN
ijpds-3318	56	21	-	-	PUNCT
ijpds-3318	56	22	m	m	NOUN
ijpds-3318	56	23	;	;	PUNCT
ijpds-3318	56	24	g	g	PROPN
ijpds-3318	56	25	-	-	PUNCT
ijpds-3318	56	26	m	m	NOUN
ijpds-3318	56	27	)	)	PUNCT
ijpds-3318	56	28	a	a	DET
ijpds-3318	56	29	total	total	NOUN
ijpds-3318	56	30	of	of	ADP
ijpds-3318	56	31	50	50	NUM
ijpds-3318	56	32	patients	patient	NOUN
ijpds-3318	56	33	were	be	AUX
ijpds-3318	56	34	in	in	ADP
ijpds-3318	56	35	the	the	DET
ijpds-3318	56	36	v	v	NOUN
ijpds-3318	56	37	-	-	PUNCT
ijpds-3318	56	38	m	m	NOUN
ijpds-3318	56	39	group	group	NOUN
ijpds-3318	56	40	,	,	PUNCT
ijpds-3318	56	41	the	the	DET
ijpds-3318	56	42	majority	majority	NOUN
ijpds-3318	56	43	of	of	ADP
ijpds-3318	56	44	them	they	PRON
ijpds-3318	56	45	i.e.	i.e.	X
ijpds-3318	56	46	,	,	PUNCT
ijpds-3318	56	47	22	22	NUM
ijpds-3318	56	48	(	(	PUNCT
ijpds-3318	56	49	44	44	NUM
ijpds-3318	56	50	%	%	NOUN
ijpds-3318	56	51	)	)	PUNCT
ijpds-3318	56	52	were	be	AUX
ijpds-3318	56	53	in	in	ADP
ijpds-3318	56	54	the	the	DET
ijpds-3318	56	55	50	50	NUM
ijpds-3318	56	56	-	-	SYM
ijpds-3318	56	57	59	59	NUM
ijpds-3318	56	58	years	year	NOUN
ijpds-3318	56	59	age	age	NOUN
ijpds-3318	56	60	group	group	NOUN
ijpds-3318	56	61	,	,	PUNCT
ijpds-3318	56	62	2(4	2(4	NUM
ijpds-3318	56	63	%	%	NOUN
ijpds-3318	56	64	)	)	PUNCT
ijpds-3318	56	65	patients	patient	NOUN
ijpds-3318	56	66	belonged	belong	VERB
ijpds-3318	56	67	to	to	ADP
ijpds-3318	56	68	the	the	DET
ijpds-3318	56	69	20	20	NUM
ijpds-3318	56	70	-	-	SYM
ijpds-3318	56	71	29	29	NUM
ijpds-3318	56	72	years	year	NOUN
ijpds-3318	56	73	age	age	NOUN
ijpds-3318	56	74	group	group	NOUN
ijpds-3318	56	75	,	,	PUNCT
ijpds-3318	56	76	6(12	6(12	NUM
ijpds-3318	56	77	%	%	NOUN
ijpds-3318	56	78	)	)	PUNCT
ijpds-3318	56	79	patients	patient	NOUN
ijpds-3318	56	80	belonged	belong	VERB
ijpds-3318	56	81	to	to	ADP
ijpds-3318	56	82	30	30	NUM
ijpds-3318	56	83	-	-	SYM
ijpds-3318	56	84	39	39	NUM
ijpds-3318	56	85	years	year	NOUN
ijpds-3318	56	86	age	age	NOUN
ijpds-3318	56	87	group	group	NOUN
ijpds-3318	56	88	,	,	PUNCT
ijpds-3318	56	89	9(18	9(18	NUM
ijpds-3318	56	90	%	%	NOUN
ijpds-3318	56	91	)	)	PUNCT
ijpds-3318	56	92	patients	patient	NOUN
ijpds-3318	56	93	belonged	belong	VERB
ijpds-3318	56	94	to	to	ADP
ijpds-3318	56	95	40	40	NUM
ijpds-3318	56	96	-	-	SYM
ijpds-3318	56	97	49	49	NUM
ijpds-3318	56	98	years	year	NOUN
ijpds-3318	56	99	age	age	NOUN
ijpds-3318	56	100	group	group	NOUN
ijpds-3318	56	101	,	,	PUNCT
ijpds-3318	56	102	and	and	CCONJ
ijpds-3318	56	103	11(22	11(22	NUM
ijpds-3318	56	104	%	%	NOUN
ijpds-3318	56	105	)	)	PUNCT
ijpds-3318	56	106	patients	patient	NOUN
ijpds-3318	56	107	belonged	belong	VERB
ijpds-3318	56	108	to	to	ADP
ijpds-3318	56	109	60	60	NUM
ijpds-3318	56	110	-	-	SYM
ijpds-3318	56	111	69	69	NUM
ijpds-3318	56	112	years	year	NOUN
ijpds-3318	56	113	age	age	NOUN
ijpds-3318	56	114	groups	group	NOUN
ijpds-3318	56	115	.	.	PUNCT
ijpds-3318	57	1	a	a	DET
ijpds-3318	57	2	total	total	NOUN
ijpds-3318	57	3	of	of	ADP
ijpds-3318	57	4	50	50	NUM
ijpds-3318	57	5	patients	patient	NOUN
ijpds-3318	57	6	were	be	AUX
ijpds-3318	57	7	in	in	ADP
ijpds-3318	57	8	the	the	DET
ijpds-3318	57	9	g	g	PROPN
ijpds-3318	57	10	-	-	PUNCT
ijpds-3318	57	11	m	m	NOUN
ijpds-3318	57	12	group	group	NOUN
ijpds-3318	57	13	,	,	PUNCT
ijpds-3318	57	14	the	the	DET
ijpds-3318	57	15	majority	majority	NOUN
ijpds-3318	57	16	of	of	ADP
ijpds-3318	57	17	them	they	PRON
ijpds-3318	57	18	i.e.	i.e.	X
ijpds-3318	57	19	,	,	PUNCT
ijpds-3318	57	20	20(40	20(40	NUM
ijpds-3318	57	21	%	%	NOUN
ijpds-3318	57	22	)	)	PUNCT
ijpds-3318	57	23	were	be	AUX
ijpds-3318	57	24	in	in	ADP
ijpds-3318	57	25	the	the	DET
ijpds-3318	57	26	40	40	NUM
ijpds-3318	57	27	-	-	SYM
ijpds-3318	57	28	49	49	NUM
ijpds-3318	57	29	years	year	NOUN
ijpds-3318	57	30	age	age	NOUN
ijpds-3318	57	31	group	group	NOUN
ijpds-3318	57	32	,	,	PUNCT
ijpds-3318	57	33	4(8	4(8	NUM
ijpds-3318	57	34	%	%	NOUN
ijpds-3318	57	35	)	)	PUNCT
ijpds-3318	57	36	patients	patient	NOUN
ijpds-3318	57	37	belonged	belong	VERB
ijpds-3318	57	38	to	to	ADP
ijpds-3318	57	39	the	the	DET
ijpds-3318	57	40	20	20	NUM
ijpds-3318	57	41	-	-	SYM
ijpds-3318	57	42	29	29	NUM
ijpds-3318	57	43	years	year	NOUN
ijpds-3318	57	44	age	age	NOUN
ijpds-3318	57	45	group	group	NOUN
ijpds-3318	57	46	,	,	PUNCT
ijpds-3318	57	47	2(4	2(4	NUM
ijpds-3318	57	48	%	%	NOUN
ijpds-3318	57	49	)	)	PUNCT
ijpds-3318	57	50	patients	patient	NOUN
ijpds-3318	57	51	belonged	belong	VERB
ijpds-3318	57	52	to	to	ADP
ijpds-3318	57	53	30	30	NUM
ijpds-3318	57	54	-	-	SYM
ijpds-3318	57	55	39	39	NUM
ijpds-3318	57	56	years	year	NOUN
ijpds-3318	57	57	age	age	NOUN
ijpds-3318	57	58	group	group	NOUN
ijpds-3318	57	59	,	,	PUNCT
ijpds-3318	57	60	16(32	16(32	NUM
ijpds-3318	57	61	%	%	NOUN
ijpds-3318	57	62	)	)	PUNCT
ijpds-3318	57	63	patients	patient	NOUN
ijpds-3318	57	64	belonged	belong	VERB
ijpds-3318	57	65	to	to	ADP
ijpds-3318	57	66	50	50	NUM
ijpds-3318	57	67	-	-	SYM
ijpds-3318	57	68	59	59	NUM
ijpds-3318	57	69	years	year	NOUN
ijpds-3318	57	70	age	age	NOUN
ijpds-3318	57	71	group	group	NOUN
ijpds-3318	57	72	and	and	CCONJ
ijpds-3318	57	73	8(16	8(16	NUM
ijpds-3318	57	74	%	%	NOUN
ijpds-3318	57	75	)	)	PUNCT
ijpds-3318	57	76	patients	patient	NOUN
ijpds-3318	57	77	belonged	belong	VERB
ijpds-3318	57	78	to	to	ADP
ijpds-3318	57	79	60	60	NUM
ijpds-3318	57	80	-	-	SYM
ijpds-3318	57	81	69	69	NUM
ijpds-3318	57	82	years	year	NOUN
ijpds-3318	57	83	age	age	NOUN
ijpds-3318	57	84	group	group	NOUN
ijpds-3318	57	85	.	.	PUNCT
ijpds-3318	58	1	of	of	ADP
ijpds-3318	58	2	a	a	DET
ijpds-3318	58	3	total	total	NOUN
ijpds-3318	58	4	of	of	ADP
ijpds-3318	58	5	100	100	NUM
ijpds-3318	58	6	patients	patient	NOUN
ijpds-3318	58	7	,	,	PUNCT
ijpds-3318	58	8	the	the	DET
ijpds-3318	58	9	majority	majority	NOUN
ijpds-3318	58	10	of	of	ADP
ijpds-3318	58	11	them	they	PRON
ijpds-3318	58	12	i.e.	i.e.	X
ijpds-3318	58	13	,	,	PUNCT
ijpds-3318	58	14	38	38	NUM
ijpds-3318	58	15	were	be	AUX
ijpds-3318	58	16	in	in	ADP
ijpds-3318	58	17	the	the	DET
ijpds-3318	58	18	geriatric	geriatric	ADJ
ijpds-3318	58	19	age	age	NOUN
ijpds-3318	58	20	group	group	NOUN
ijpds-3318	58	21	i.e.	i.e.	X
ijpds-3318	58	22	,	,	PUNCT
ijpds-3318	58	23	50	50	NUM
ijpds-3318	58	24	-	-	SYM
ijpds-3318	58	25	59	59	NUM
ijpds-3318	58	26	years	year	NOUN
ijpds-3318	58	27	,	,	PUNCT
ijpds-3318	58	28	6	6	NUM
ijpds-3318	58	29	patients	patient	NOUN
ijpds-3318	58	30	belonged	belong	VERB
ijpds-3318	58	31	to	to	ADP
ijpds-3318	58	32	the	the	DET
ijpds-3318	58	33	20	20	NUM
ijpds-3318	58	34	-	-	SYM
ijpds-3318	58	35	29	29	NUM
ijpds-3318	58	36	years	year	NOUN
ijpds-3318	58	37	age	age	NOUN
ijpds-3318	58	38	group	group	NOUN
ijpds-3318	58	39	,	,	PUNCT
ijpds-3318	58	40	8	8	NUM
ijpds-3318	58	41	patients	patient	NOUN
ijpds-3318	58	42	belonged	belong	VERB
ijpds-3318	58	43	to	to	ADP
ijpds-3318	58	44	the	the	DET
ijpds-3318	58	45	30	30	NUM
ijpds-3318	58	46	-	-	SYM
ijpds-3318	58	47	39	39	NUM
ijpds-3318	58	48	years	year	NOUN
ijpds-3318	58	49	age	age	NOUN
ijpds-3318	58	50	group	group	NOUN
ijpds-3318	58	51	,	,	PUNCT
ijpds-3318	58	52	29	29	NUM
ijpds-3318	58	53	patients	patient	NOUN
ijpds-3318	58	54	belonged	belong	VERB
ijpds-3318	58	55	to	to	ADP
ijpds-3318	58	56	40	40	NUM
ijpds-3318	58	57	-	-	SYM
ijpds-3318	58	58	49	49	NUM
ijpds-3318	58	59	years	year	NOUN
ijpds-3318	58	60	age	age	NOUN
ijpds-3318	58	61	group	group	NOUN
ijpds-3318	58	62	,	,	PUNCT
ijpds-3318	58	63	and	and	CCONJ
ijpds-3318	58	64	19	19	NUM
ijpds-3318	58	65	patients	patient	NOUN
ijpds-3318	58	66	belonged	belong	VERB
ijpds-3318	58	67	to	to	ADP
ijpds-3318	58	68	60	60	NUM
ijpds-3318	58	69	-	-	SYM
ijpds-3318	58	70	69	69	NUM
ijpds-3318	58	71	years	year	NOUN
ijpds-3318	58	72	age	age	NOUN
ijpds-3318	58	73	groups	group	NOUN
ijpds-3318	58	74	.	.	PUNCT
ijpds-3318	59	1	the	the	DET
ijpds-3318	59	2	details	detail	NOUN
ijpds-3318	59	3	have	have	AUX
ijpds-3318	59	4	been	be	AUX
ijpds-3318	59	5	represented	represent	VERB
ijpds-3318	59	6	in	in	ADP
ijpds-3318	59	7	figure	figure	NOUN
ijpds-3318	59	8	2	2	NUM
ijpds-3318	59	9	.	.	PUNCT
ijpds-3318	59	10	figure	figure	NOUN
ijpds-3318	59	11	2	2	NUM
ijpds-3318	59	12	:	:	PUNCT
ijpds-3318	59	13	graphical	graphical	ADJ
ijpds-3318	59	14	representation	representation	NOUN
ijpds-3318	59	15	of	of	ADP
ijpds-3318	59	16	patients	patient	NOUN
ijpds-3318	59	17	-	-	PUNCT
ijpds-3318	59	18	based	base	VERB
ijpds-3318	59	19	age	age	NOUN
ijpds-3318	59	20	groups	group	NOUN
ijpds-3318	59	21	(	(	PUNCT
ijpds-3318	59	22	v	v	NOUN
ijpds-3318	59	23	-	-	PUNCT
ijpds-3318	59	24	m	m	NOUN
ijpds-3318	59	25	;	;	PUNCT
ijpds-3318	59	26	g	g	PROPN
ijpds-3318	59	27	-	-	PUNCT
ijpds-3318	59	28	m	m	NOUN
ijpds-3318	59	29	)	)	PUNCT
ijpds-3318	59	30	v	v	ADP
ijpds-3318	59	31	m	m	PROPN
ijpds-3318	59	32	35	35	NUM
ijpds-3318	59	33	v	v	NUM
ijpds-3318	59	34	m	m	NUM
ijpds-3318	59	35	15	15	NUM
ijpds-3318	59	36	g	g	NOUN
ijpds-3318	59	37	m	m	PROPN
ijpds-3318	59	38	30	30	NUM
ijpds-3318	59	39	g	g	NOUN
ijpds-3318	59	40	m	m	PROPN
ijpds-3318	59	41	20	20	NUM
ijpds-3318	59	42	0	0	NUM
ijpds-3318	59	43	5	5	NUM
ijpds-3318	59	44	10	10	NUM
ijpds-3318	59	45	15	15	NUM
ijpds-3318	59	46	20	20	NUM
ijpds-3318	59	47	25	25	NUM
ijpds-3318	59	48	30	30	NUM
ijpds-3318	59	49	35	35	NUM
ijpds-3318	59	50	40	40	NUM
ijpds-3318	59	51	males	male	NOUN
ijpds-3318	59	52	females	female	NOUN
ijpds-3318	59	53	gender	gender	NOUN
ijpds-3318	59	54	2	2	NUM
ijpds-3318	59	55	6	6	NUM
ijpds-3318	59	56	9	9	NUM
ijpds-3318	59	57	22	22	NUM
ijpds-3318	59	58	11	11	NUM
ijpds-3318	59	59	4	4	NUM
ijpds-3318	59	60	2	2	NUM
ijpds-3318	59	61	20	20	NUM
ijpds-3318	59	62	16	16	NUM
ijpds-3318	59	63	8	8	NUM
ijpds-3318	59	64	0	0	NUM
ijpds-3318	59	65	5	5	NUM
ijpds-3318	59	66	10	10	NUM
ijpds-3318	59	67	15	15	NUM
ijpds-3318	59	68	20	20	NUM
ijpds-3318	59	69	25	25	NUM
ijpds-3318	59	70	20	20	NUM
ijpds-3318	59	71	-	-	SYM
ijpds-3318	59	72	29	29	NUM
ijpds-3318	59	73	30	30	NUM
ijpds-3318	59	74	-	-	SYM
ijpds-3318	59	75	39	39	NUM
ijpds-3318	59	76	40	40	NUM
ijpds-3318	59	77	-	-	SYM
ijpds-3318	59	78	49	49	NUM
ijpds-3318	59	79	50	50	NUM
ijpds-3318	59	80	-	-	SYM
ijpds-3318	59	81	59	59	NUM
ijpds-3318	59	82	60	60	NUM
ijpds-3318	59	83	-	-	SYM
ijpds-3318	59	84	69	69	NUM
ijpds-3318	59	85	age	age	NOUN
ijpds-3318	59	86	groups	group	NOUN
ijpds-3318	59	87	kareenmulla	kareenmulla	PROPN
ijpds-3318	59	88	et	et	PROPN
ijpds-3318	59	89	al	al	PROPN
ijpds-3318	59	90	efficacy	efficacy	PROPN
ijpds-3318	59	91	,	,	PUNCT
ijpds-3318	59	92	safety	safety	NOUN
ijpds-3318	59	93	of	of	ADP
ijpds-3318	59	94	vildagliptin	vildagliptin	NOUN
ijpds-3318	59	95	-	-	PUNCT
ijpds-3318	59	96	metformin	metformin	NOUN
ijpds-3318	59	97	versus	versus	ADP
ijpds-3318	59	98	glimepiride	glimepiride	NOUN
ijpds-3318	59	99	-	-	PUNCT
ijpds-3318	59	100	metformin	metformin	NOUN
ijpds-3318	59	101	vol	vol	NOUN
ijpds-3318	59	102	1	1	NUM
ijpds-3318	60	1	|	|	NOUN
ijpds-3318	60	2	issue	issue	NOUN
ijpds-3318	60	3	2	2	NUM
ijpds-3318	61	1	|	|	ADV
ijpds-3318	61	2	jul	jul	PROPN
ijpds-3318	61	3	sep	sep	PROPN
ijpds-3318	61	4	2022	2022	NUM
ijpds-3318	61	5	indian	indian	PROPN
ijpds-3318	61	6	j	j	PROPN
ijpds-3318	61	7	pharm	pharm	PROPN
ijpds-3318	61	8	drug	drug	PROPN
ijpds-3318	61	9	studies	study	NOUN
ijpds-3318	61	10	|	|	ADV
ijpds-3318	61	11	65	65	NUM
ijpds-3318	61	12	in	in	ADP
ijpds-3318	61	13	the	the	DET
ijpds-3318	61	14	total	total	NOUN
ijpds-3318	61	15	of	of	ADP
ijpds-3318	61	16	50	50	NUM
ijpds-3318	61	17	patients	patient	NOUN
ijpds-3318	61	18	in	in	ADP
ijpds-3318	61	19	the	the	DET
ijpds-3318	61	20	v	v	PROPN
ijpds-3318	61	21	-	-	PUNCT
ijpds-3318	61	22	m	m	NOUN
ijpds-3318	61	23	group	group	NOUN
ijpds-3318	61	24	,	,	PUNCT
ijpds-3318	61	25	33	33	NUM
ijpds-3318	61	26	comorbid	comorbid	NOUN
ijpds-3318	61	27	conditions	condition	NOUN
ijpds-3318	61	28	were	be	AUX
ijpds-3318	61	29	present	present	ADJ
ijpds-3318	61	30	.	.	PUNCT
ijpds-3318	62	1	among	among	ADP
ijpds-3318	62	2	all	all	DET
ijpds-3318	62	3	co	co	NOUN
ijpds-3318	62	4	-	-	NOUN
ijpds-3318	62	5	morbidities	morbidity	NOUN
ijpds-3318	62	6	,	,	PUNCT
ijpds-3318	62	7	majorly	majorly	ADV
ijpds-3318	62	8	i.e.	i.e.	X
ijpds-3318	62	9	,	,	PUNCT
ijpds-3318	62	10	13(40	13(40	NUM
ijpds-3318	62	11	%	%	NOUN
ijpds-3318	62	12	)	)	PUNCT
ijpds-3318	62	13	co	co	NOUN
ijpds-3318	62	14	-	-	NOUN
ijpds-3318	62	15	morbidities	morbidity	NOUN
ijpds-3318	62	16	were	be	AUX
ijpds-3318	62	17	found	find	VERB
ijpds-3318	62	18	to	to	PART
ijpds-3318	62	19	be	be	AUX
ijpds-3318	62	20	hypertension	hypertension	NOUN
ijpds-3318	62	21	,	,	PUNCT
ijpds-3318	62	22	4(12	4(12	NUM
ijpds-3318	62	23	%	%	NOUN
ijpds-3318	62	24	)	)	PUNCT
ijpds-3318	62	25	co	co	NOUN
ijpds-3318	62	26	-	-	NOUN
ijpds-3318	62	27	morbidities	morbidity	NOUN
ijpds-3318	62	28	were	be	AUX
ijpds-3318	62	29	found	find	VERB
ijpds-3318	62	30	to	to	PART
ijpds-3318	62	31	be	be	AUX
ijpds-3318	62	32	cardiac	cardiac	ADJ
ijpds-3318	62	33	arrhythmia	arrhythmia	NOUN
ijpds-3318	62	34	,	,	PUNCT
ijpds-3318	62	35	3(9	3(9	NUM
ijpds-3318	62	36	%	%	NOUN
ijpds-3318	62	37	)	)	PUNCT
ijpds-3318	62	38	comorbidities	comorbiditie	NOUN
ijpds-3318	62	39	were	be	AUX
ijpds-3318	62	40	found	find	VERB
ijpds-3318	62	41	to	to	PART
ijpds-3318	62	42	be	be	AUX
ijpds-3318	62	43	coronary	coronary	ADJ
ijpds-3318	62	44	artery	artery	NOUN
ijpds-3318	62	45	disease	disease	NOUN
ijpds-3318	62	46	,	,	PUNCT
ijpds-3318	62	47	9(27	9(27	NUM
ijpds-3318	62	48	%	%	NOUN
ijpds-3318	62	49	)	)	PUNCT
ijpds-3318	62	50	co	co	NOUN
ijpds-3318	62	51	-	-	NOUN
ijpds-3318	62	52	morbidities	morbidity	NOUN
ijpds-3318	62	53	were	be	AUX
ijpds-3318	62	54	found	find	VERB
ijpds-3318	62	55	to	to	PART
ijpds-3318	62	56	be	be	AUX
ijpds-3318	62	57	copd	copd	NOUN
ijpds-3318	62	58	,	,	PUNCT
ijpds-3318	62	59	and	and	CCONJ
ijpds-3318	62	60	2(6	2(6	NUM
ijpds-3318	62	61	%	%	NOUN
ijpds-3318	62	62	)	)	PUNCT
ijpds-3318	62	63	comorbidities	comorbiditie	NOUN
ijpds-3318	62	64	were	be	AUX
ijpds-3318	62	65	found	find	VERB
ijpds-3318	62	66	to	to	PART
ijpds-3318	62	67	be	be	AUX
ijpds-3318	62	68	pneumonia	pneumonia	NOUN
ijpds-3318	62	69	and	and	CCONJ
ijpds-3318	62	70	asthma	asthma	NOUN
ijpds-3318	62	71	.	.	PUNCT
ijpds-3318	63	1	in	in	ADP
ijpds-3318	63	2	the	the	DET
ijpds-3318	63	3	total	total	NOUN
ijpds-3318	63	4	of	of	ADP
ijpds-3318	63	5	50	50	NUM
ijpds-3318	63	6	patients	patient	NOUN
ijpds-3318	63	7	in	in	ADP
ijpds-3318	63	8	the	the	DET
ijpds-3318	63	9	gm	gm	PROPN
ijpds-3318	63	10	group	group	NOUN
ijpds-3318	63	11	,	,	PUNCT
ijpds-3318	63	12	35	35	NUM
ijpds-3318	63	13	co	co	ADJ
ijpds-3318	63	14	-	-	ADJ
ijpds-3318	63	15	morbid	morbid	ADJ
ijpds-3318	63	16	conditions	condition	NOUN
ijpds-3318	63	17	were	be	AUX
ijpds-3318	63	18	present	present	ADJ
ijpds-3318	63	19	.	.	PUNCT
ijpds-3318	64	1	among	among	ADP
ijpds-3318	64	2	all	all	DET
ijpds-3318	64	3	co	co	NOUN
ijpds-3318	64	4	-	-	NOUN
ijpds-3318	64	5	morbidities	morbidity	NOUN
ijpds-3318	64	6	,	,	PUNCT
ijpds-3318	64	7	majorly	majorly	ADV
ijpds-3318	64	8	i.e.	i.e.	X
ijpds-3318	64	9	,	,	PUNCT
ijpds-3318	64	10	14(40	14(40	NUM
ijpds-3318	64	11	%	%	NOUN
ijpds-3318	64	12	)	)	PUNCT
ijpds-3318	64	13	comorbidities	comorbiditie	NOUN
ijpds-3318	64	14	were	be	AUX
ijpds-3318	64	15	found	find	VERB
ijpds-3318	64	16	to	to	PART
ijpds-3318	64	17	be	be	AUX
ijpds-3318	64	18	hypertension	hypertension	NOUN
ijpds-3318	64	19	,	,	PUNCT
ijpds-3318	64	20	5(14	5(14	NUM
ijpds-3318	64	21	%	%	NOUN
ijpds-3318	64	22	)	)	PUNCT
ijpds-3318	64	23	comorbidities	comorbiditie	NOUN
ijpds-3318	64	24	were	be	AUX
ijpds-3318	64	25	found	find	VERB
ijpds-3318	64	26	to	to	PART
ijpds-3318	64	27	be	be	AUX
ijpds-3318	64	28	coronary	coronary	ADJ
ijpds-3318	64	29	artery	artery	NOUN
ijpds-3318	64	30	disease	disease	NOUN
ijpds-3318	64	31	,	,	PUNCT
ijpds-3318	64	32	10(28	10(28	NUM
ijpds-3318	64	33	%	%	NOUN
ijpds-3318	64	34	)	)	PUNCT
ijpds-3318	64	35	co	co	NOUN
ijpds-3318	64	36	-	-	NOUN
ijpds-3318	64	37	morbidities	morbidity	NOUN
ijpds-3318	64	38	were	be	AUX
ijpds-3318	64	39	found	find	VERB
ijpds-3318	64	40	to	to	PART
ijpds-3318	64	41	be	be	AUX
ijpds-3318	64	42	copd	copd	NOUN
ijpds-3318	64	43	,	,	PUNCT
ijpds-3318	64	44	and	and	CCONJ
ijpds-3318	64	45	2(6	2(6	NUM
ijpds-3318	64	46	%	%	NOUN
ijpds-3318	64	47	)	)	PUNCT
ijpds-3318	64	48	comorbidities	comorbiditie	NOUN
ijpds-3318	64	49	were	be	AUX
ijpds-3318	64	50	found	find	VERB
ijpds-3318	64	51	to	to	PART
ijpds-3318	64	52	be	be	AUX
ijpds-3318	64	53	cardiac	cardiac	ADJ
ijpds-3318	64	54	arrhythmia	arrhythmia	NOUN
ijpds-3318	64	55	,	,	PUNCT
ijpds-3318	64	56	pneumonia	pneumonia	NOUN
ijpds-3318	64	57	,	,	PUNCT
ijpds-3318	64	58	and	and	CCONJ
ijpds-3318	64	59	asthma	asthma	NOUN
ijpds-3318	64	60	.	.	PUNCT
ijpds-3318	65	1	in	in	ADP
ijpds-3318	65	2	the	the	DET
ijpds-3318	65	3	total	total	NOUN
ijpds-3318	65	4	of	of	ADP
ijpds-3318	65	5	100	100	NUM
ijpds-3318	65	6	patients	patient	NOUN
ijpds-3318	65	7	,	,	PUNCT
ijpds-3318	65	8	68	68	NUM
ijpds-3318	65	9	co	co	ADJ
ijpds-3318	65	10	-	-	ADJ
ijpds-3318	65	11	morbid	morbid	ADJ
ijpds-3318	65	12	conditions	condition	NOUN
ijpds-3318	65	13	were	be	AUX
ijpds-3318	65	14	present	present	ADJ
ijpds-3318	65	15	.	.	PUNCT
ijpds-3318	66	1	among	among	ADP
ijpds-3318	66	2	all	all	DET
ijpds-3318	66	3	co	co	NOUN
ijpds-3318	66	4	-	-	NOUN
ijpds-3318	66	5	morbidities	morbidity	NOUN
ijpds-3318	66	6	,	,	PUNCT
ijpds-3318	66	7	majorly	majorly	ADV
ijpds-3318	66	8	i.e.	i.e.	X
ijpds-3318	66	9	,	,	PUNCT
ijpds-3318	66	10	27(40	27(40	NUM
ijpds-3318	66	11	%	%	NOUN
ijpds-3318	66	12	)	)	PUNCT
ijpds-3318	66	13	comorbidities	comorbiditie	NOUN
ijpds-3318	66	14	were	be	AUX
ijpds-3318	66	15	found	find	VERB
ijpds-3318	66	16	to	to	PART
ijpds-3318	66	17	be	be	AUX
ijpds-3318	66	18	hypertension	hypertension	NOUN
ijpds-3318	66	19	,	,	PUNCT
ijpds-3318	66	20	6(9	6(9	NUM
ijpds-3318	66	21	%	%	NOUN
ijpds-3318	66	22	)	)	PUNCT
ijpds-3318	66	23	comorbidities	comorbiditie	NOUN
ijpds-3318	66	24	were	be	AUX
ijpds-3318	66	25	found	find	VERB
ijpds-3318	66	26	to	to	PART
ijpds-3318	66	27	be	be	AUX
ijpds-3318	66	28	cardiac	cardiac	ADJ
ijpds-3318	66	29	arrhythmia	arrhythmia	NOUN
ijpds-3318	66	30	,	,	PUNCT
ijpds-3318	66	31	8(12	8(12	NUM
ijpds-3318	66	32	%	%	NOUN
ijpds-3318	66	33	)	)	PUNCT
ijpds-3318	66	34	comorbidities	comorbiditie	NOUN
ijpds-3318	66	35	were	be	AUX
ijpds-3318	66	36	found	find	VERB
ijpds-3318	66	37	to	to	PART
ijpds-3318	66	38	be	be	AUX
ijpds-3318	66	39	coronary	coronary	ADJ
ijpds-3318	66	40	artery	artery	NOUN
ijpds-3318	66	41	disease	disease	NOUN
ijpds-3318	66	42	,	,	PUNCT
ijpds-3318	66	43	19(27	19(27	NUM
ijpds-3318	66	44	%	%	NOUN
ijpds-3318	66	45	)	)	PUNCT
ijpds-3318	66	46	co	co	NOUN
ijpds-3318	66	47	-	-	NOUN
ijpds-3318	66	48	morbidities	morbidity	NOUN
ijpds-3318	66	49	were	be	AUX
ijpds-3318	66	50	found	find	VERB
ijpds-3318	66	51	to	to	PART
ijpds-3318	66	52	be	be	AUX
ijpds-3318	66	53	copd	copd	NOUN
ijpds-3318	66	54	,	,	PUNCT
ijpds-3318	66	55	and	and	CCONJ
ijpds-3318	66	56	4(6	4(6	NUM
ijpds-3318	66	57	%	%	NOUN
ijpds-3318	66	58	)	)	PUNCT
ijpds-3318	66	59	comorbidities	comorbiditie	NOUN
ijpds-3318	66	60	were	be	AUX
ijpds-3318	66	61	found	find	VERB
ijpds-3318	66	62	to	to	PART
ijpds-3318	66	63	be	be	AUX
ijpds-3318	66	64	pneumonia	pneumonia	NOUN
ijpds-3318	66	65	and	and	CCONJ
ijpds-3318	66	66	asthma	asthma	NOUN
ijpds-3318	66	67	.	.	PUNCT
ijpds-3318	67	1	details	detail	NOUN
ijpds-3318	67	2	with	with	ADP
ijpds-3318	67	3	regards	regard	NOUN
ijpds-3318	67	4	to	to	ADP
ijpds-3318	67	5	co	co	NOUN
ijpds-3318	67	6	-	-	NOUN
ijpds-3318	67	7	morbidities	morbidity	NOUN
ijpds-3318	67	8	were	be	AUX
ijpds-3318	67	9	represented	represent	VERB
ijpds-3318	67	10	in	in	ADP
ijpds-3318	67	11	figure	figure	NOUN
ijpds-3318	67	12	3	3	NUM
ijpds-3318	67	13	.	.	PUNCT
ijpds-3318	67	14	figure	figure	VERB
ijpds-3318	67	15	3	3	NUM
ijpds-3318	67	16	:	:	PUNCT
ijpds-3318	67	17	graphical	graphical	ADJ
ijpds-3318	67	18	representation	representation	NOUN
ijpds-3318	67	19	of	of	ADP
ijpds-3318	67	20	patients	patient	NOUN
ijpds-3318	67	21	based	base	VERB
ijpds-3318	67	22	on	on	ADP
ijpds-3318	67	23	comorbidities	comorbiditie	NOUN
ijpds-3318	67	24	(	(	PUNCT
ijpds-3318	67	25	v	v	NOUN
ijpds-3318	67	26	-	-	PUNCT
ijpds-3318	67	27	m	m	NOUN
ijpds-3318	67	28	;	;	PUNCT
ijpds-3318	67	29	g	g	PROPN
ijpds-3318	67	30	-	-	PUNCT
ijpds-3318	67	31	m	m	NOUN
ijpds-3318	67	32	)	)	PUNCT
ijpds-3318	67	33	discussion	discussion	NOUN
ijpds-3318	67	34	on	on	ADP
ijpds-3318	67	35	evaluation	evaluation	NOUN
ijpds-3318	67	36	,	,	PUNCT
ijpds-3318	67	37	it	it	PRON
ijpds-3318	67	38	was	be	AUX
ijpds-3318	67	39	found	find	VERB
ijpds-3318	67	40	that	that	SCONJ
ijpds-3318	67	41	a	a	DET
ijpds-3318	67	42	significant	significant	ADJ
ijpds-3318	67	43	reduction	reduction	NOUN
ijpds-3318	67	44	of	of	ADP
ijpds-3318	67	45	hba1c	hba1c	PROPN
ijpds-3318	67	46	,	,	PUNCT
ijpds-3318	67	47	fbs	fbs	PROPN
ijpds-3318	67	48	,	,	PUNCT
ijpds-3318	67	49	and	and	CCONJ
ijpds-3318	67	50	rbs	rbs	PROPN
ijpds-3318	67	51	levels	level	NOUN
ijpds-3318	67	52	was	be	AUX
ijpds-3318	67	53	noted	note	VERB
ijpds-3318	67	54	in	in	ADP
ijpds-3318	67	55	vm	vm	PROPN
ijpds-3318	67	56	group	group	NOUN
ijpds-3318	67	57	patients	patient	NOUN
ijpds-3318	67	58	when	when	SCONJ
ijpds-3318	67	59	compared	compare	VERB
ijpds-3318	67	60	to	to	ADP
ijpds-3318	67	61	gm	gm	PROPN
ijpds-3318	67	62	group	group	NOUN
ijpds-3318	67	63	patients	patient	NOUN
ijpds-3318	67	64	.	.	PUNCT
ijpds-3318	68	1	in	in	ADP
ijpds-3318	68	2	terms	term	NOUN
ijpds-3318	68	3	of	of	ADP
ijpds-3318	68	4	the	the	DET
ijpds-3318	68	5	safety	safety	NOUN
ijpds-3318	68	6	profile	profile	NOUN
ijpds-3318	68	7	,	,	PUNCT
ijpds-3318	68	8	more	more	ADJ
ijpds-3318	68	9	adrs	adr	NOUN
ijpds-3318	68	10	were	be	AUX
ijpds-3318	68	11	noted	note	VERB
ijpds-3318	68	12	in	in	ADP
ijpds-3318	68	13	gm	gm	PROPN
ijpds-3318	68	14	group	group	NOUN
ijpds-3318	68	15	patients	patient	NOUN
ijpds-3318	68	16	than	than	ADP
ijpds-3318	68	17	in	in	ADP
ijpds-3318	68	18	vm	vm	PROPN
ijpds-3318	68	19	group	group	NOUN
ijpds-3318	68	20	patients	patient	NOUN
ijpds-3318	68	21	.	.	PUNCT
ijpds-3318	69	1	we	we	PRON
ijpds-3318	69	2	observed	observe	VERB
ijpds-3318	69	3	that	that	SCONJ
ijpds-3318	69	4	the	the	DET
ijpds-3318	69	5	vildagliptinmetformin	vildagliptinmetformin	NOUN
ijpds-3318	69	6	combination	combination	NOUN
ijpds-3318	69	7	is	be	AUX
ijpds-3318	69	8	a	a	DET
ijpds-3318	69	9	more	more	ADV
ijpds-3318	69	10	effective	effective	ADJ
ijpds-3318	69	11	safety	safety	NOUN
ijpds-3318	69	12	treatment	treatment	NOUN
ijpds-3318	69	13	for	for	ADP
ijpds-3318	69	14	type	type	NOUN
ijpds-3318	69	15	2	2	NUM
ijpds-3318	69	16	diabetes	diabetes	NOUN
ijpds-3318	69	17	mellitus	mellitus	NOUN
ijpds-3318	69	18	than	than	ADP
ijpds-3318	69	19	glimepiridemetformin	glimepiridemetformin	NOUN
ijpds-3318	69	20	combination	combination	NOUN
ijpds-3318	69	21	.	.	PUNCT
ijpds-3318	70	1	metformin	metformin	NOUN
ijpds-3318	70	2	is	be	AUX
ijpds-3318	70	3	the	the	DET
ijpds-3318	70	4	first	first	ADJ
ijpds-3318	70	5	-	-	PUNCT
ijpds-3318	70	6	line	line	NOUN
ijpds-3318	70	7	drug	drug	NOUN
ijpds-3318	70	8	used	use	VERB
ijpds-3318	70	9	to	to	PART
ijpds-3318	70	10	treat	treat	VERB
ijpds-3318	70	11	diabetes	diabetes	NOUN
ijpds-3318	70	12	mellitus	mellitus	NOUN
ijpds-3318	70	13	.	.	PUNCT
ijpds-3318	71	1	it	it	PRON
ijpds-3318	71	2	suppresses	suppress	VERB
ijpds-3318	71	3	hepatic	hepatic	ADJ
ijpds-3318	71	4	gluconeogenesis	gluconeogenesis	NOUN
ijpds-3318	71	5	and	and	CCONJ
ijpds-3318	71	6	glucose	glucose	NOUN
ijpds-3318	71	7	output	output	NOUN
ijpds-3318	71	8	from	from	ADP
ijpds-3318	71	9	the	the	DET
ijpds-3318	71	10	liver	liver	NOUN
ijpds-3318	71	11	and	and	CCONJ
ijpds-3318	71	12	enhances	enhance	VERB
ijpds-3318	71	13	insulin	insulin	NOUN
ijpds-3318	71	14	-	-	PUNCT
ijpds-3318	71	15	mediated	mediate	VERB
ijpds-3318	71	16	glucose	glucose	NOUN
ijpds-3318	71	17	uptake	uptake	NOUN
ijpds-3318	71	18	and	and	CCONJ
ijpds-3318	71	19	disposal	disposal	NOUN
ijpds-3318	71	20	in	in	ADP
ijpds-3318	71	21	skeletal	skeletal	ADJ
ijpds-3318	71	22	muscle	muscle	NOUN
ijpds-3318	71	23	and	and	CCONJ
ijpds-3318	71	24	fat	fat	NOUN
ijpds-3318	71	25	.	.	PUNCT
ijpds-3318	72	1	thus	thus	ADV
ijpds-3318	72	2	,	,	PUNCT
ijpds-3318	72	3	insulin	insulin	NOUN
ijpds-3318	72	4	resistance	resistance	NOUN
ijpds-3318	72	5	exhibited	exhibit	VERB
ijpds-3318	72	6	by	by	ADP
ijpds-3318	72	7	type-2	type-2	NUM
ijpds-3318	72	8	diabetes	diabetes	NOUN
ijpds-3318	72	9	is	be	AUX
ijpds-3318	72	10	overcome	overcome	VERB
ijpds-3318	72	11	.	.	PUNCT
ijpds-3318	73	1	episodes	episode	NOUN
ijpds-3318	73	2	of	of	ADP
ijpds-3318	73	3	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	73	4	are	be	AUX
ijpds-3318	73	5	rare	rare	ADJ
ijpds-3318	73	6	while	while	SCONJ
ijpds-3318	73	7	using	use	VERB
ijpds-3318	73	8	metformin	metformin	NOUN
ijpds-3318	73	9	[	[	X
ijpds-3318	73	10	8	8	NUM
ijpds-3318	73	11	]	]	PUNCT
ijpds-3318	73	12	.	.	PUNCT
ijpds-3318	74	1	if	if	SCONJ
ijpds-3318	74	2	blood	blood	NOUN
ijpds-3318	74	3	sugar	sugar	NOUN
ijpds-3318	74	4	levels	level	NOUN
ijpds-3318	74	5	are	be	AUX
ijpds-3318	74	6	not	not	PART
ijpds-3318	74	7	controlled	control	VERB
ijpds-3318	74	8	by	by	ADP
ijpds-3318	74	9	metformin	metformin	NOUN
ijpds-3318	74	10	,	,	PUNCT
ijpds-3318	74	11	then	then	ADV
ijpds-3318	74	12	dual	dual	ADJ
ijpds-3318	74	13	therapy	therapy	NOUN
ijpds-3318	74	14	will	will	AUX
ijpds-3318	74	15	be	be	AUX
ijpds-3318	74	16	recommended	recommend	VERB
ijpds-3318	74	17	.	.	PUNCT
ijpds-3318	75	1	sulfonylureas	sulfonylureas	PROPN
ijpds-3318	75	2	(	(	PUNCT
ijpds-3318	75	3	glimepiride	glimepiride	PROPN
ijpds-3318	75	4	)	)	PUNCT
ijpds-3318	75	5	is	be	AUX
ijpds-3318	75	6	the	the	DET
ijpds-3318	75	7	first	first	ADJ
ijpds-3318	75	8	add	add	VERB
ijpds-3318	75	9	-	-	PUNCT
ijpds-3318	75	10	on	on	ADP
ijpds-3318	75	11	drug	drug	NOUN
ijpds-3318	75	12	to	to	PART
ijpds-3318	75	13	metformin	metformin	VERB
ijpds-3318	75	14	in	in	ADP
ijpds-3318	75	15	glucose	glucose	NOUN
ijpds-3318	75	16	intolerance	intolerance	NOUN
ijpds-3318	75	17	.	.	PUNCT
ijpds-3318	76	1	glimepiride	glimepiride	NOUN
ijpds-3318	76	2	will	will	AUX
ijpds-3318	76	3	increase	increase	VERB
ijpds-3318	76	4	insulin	insulin	NOUN
ijpds-3318	76	5	secretion	secretion	NOUN
ijpds-3318	76	6	.	.	PUNCT
ijpds-3318	77	1	they	they	PRON
ijpds-3318	77	2	are	be	AUX
ijpds-3318	77	3	widely	widely	ADV
ijpds-3318	77	4	used	use	VERB
ijpds-3318	77	5	for	for	ADP
ijpds-3318	77	6	type	type	NOUN
ijpds-3318	77	7	2	2	NUM
ijpds-3318	77	8	diabetes	diabetes	NOUN
ijpds-3318	77	9	because	because	SCONJ
ijpds-3318	77	10	they	they	PRON
ijpds-3318	77	11	improve	improve	VERB
ijpds-3318	77	12	glycemic	glycemic	ADJ
ijpds-3318	77	13	control	control	NOUN
ijpds-3318	77	14	,	,	PUNCT
ijpds-3318	77	15	and	and	CCONJ
ijpds-3318	77	16	lack	lack	VERB
ijpds-3318	77	17	stomatic	stomatic	ADJ
ijpds-3318	77	18	side	side	NOUN
ijpds-3318	77	19	effects	effect	NOUN
ijpds-3318	77	20	other	other	ADJ
ijpds-3318	77	21	than	than	ADP
ijpds-3318	77	22	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	77	23	,	,	PUNCT
ijpds-3318	77	24	and	and	CCONJ
ijpds-3318	77	25	are	be	AUX
ijpds-3318	77	26	very	very	ADV
ijpds-3318	77	27	inexpensive	inexpensive	ADJ
ijpds-3318	78	1	[	[	X
ijpds-3318	78	2	9	9	NUM
ijpds-3318	78	3	]	]	PUNCT
ijpds-3318	78	4	.	.	PUNCT
ijpds-3318	79	1	insulin	insulin	NOUN
ijpds-3318	79	2	production	production	NOUN
ijpds-3318	79	3	is	be	AUX
ijpds-3318	79	4	not	not	PART
ijpds-3318	79	5	provoked	provoke	VERB
ijpds-3318	79	6	even	even	ADV
ijpds-3318	79	7	at	at	ADP
ijpds-3318	79	8	low	low	ADJ
ijpds-3318	79	9	-	-	PUNCT
ijpds-3318	79	10	glucose	glucose	NOUN
ijpds-3318	79	11	concentrations	concentration	NOUN
ijpds-3318	79	12	risking	risk	VERB
ijpds-3318	79	13	the	the	DET
ijpds-3318	79	14	production	production	NOUN
ijpds-3318	79	15	of	of	ADP
ijpds-3318	79	16	severe	severe	ADJ
ijpds-3318	79	17	and	and	CCONJ
ijpds-3318	79	18	unpredictable	unpredictable	ADJ
ijpds-3318	79	19	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	79	20	,	,	PUNCT
ijpds-3318	79	21	which	which	PRON
ijpds-3318	79	22	may	may	AUX
ijpds-3318	79	23	increase	increase	VERB
ijpds-3318	79	24	the	the	DET
ijpds-3318	79	25	mortality	mortality	NOUN
ijpds-3318	79	26	rates	rate	NOUN
ijpds-3318	79	27	.	.	PUNCT
ijpds-3318	80	1	to	to	PART
ijpds-3318	80	2	overcome	overcome	VERB
ijpds-3318	80	3	this	this	DET
ijpds-3318	80	4	effect	effect	NOUN
ijpds-3318	80	5	,	,	PUNCT
ijpds-3318	80	6	some	some	DET
ijpds-3318	80	7	other	other	ADJ
ijpds-3318	80	8	add	add	VERB
ijpds-3318	80	9	-	-	PUNCT
ijpds-3318	80	10	on	on	ADP
ijpds-3318	80	11	therapies	therapy	NOUN
ijpds-3318	80	12	are	be	AUX
ijpds-3318	80	13	recommended	recommend	VERB
ijpds-3318	80	14	.	.	PUNCT
ijpds-3318	81	1	dpp-4	dpp-4	VERB
ijpds-3318	81	2	inhibitors	inhibitor	NOUN
ijpds-3318	81	3	are	be	AUX
ijpds-3318	81	4	one	one	NUM
ijpds-3318	81	5	of	of	ADP
ijpds-3318	81	6	the	the	DET
ijpds-3318	81	7	therapies	therapy	NOUN
ijpds-3318	81	8	among	among	ADP
ijpds-3318	81	9	them	they	PRON
ijpds-3318	81	10	,	,	PUNCT
ijpds-3318	81	11	however	however	ADV
ijpds-3318	81	12	,	,	PUNCT
ijpds-3318	81	13	they	they	PRON
ijpds-3318	81	14	are	be	AUX
ijpds-3318	81	15	considered	consider	VERB
ijpds-3318	81	16	adjuvant	adjuvant	ADJ
ijpds-3318	81	17	therapy	therapy	NOUN
ijpds-3318	81	18	agents	agent	NOUN
ijpds-3318	81	19	.	.	PUNCT
ijpds-3318	82	1	vildagliptin	vildagliptin	NOUN
ijpds-3318	82	2	is	be	AUX
ijpds-3318	82	3	an	an	DET
ijpds-3318	82	4	active	active	ADJ
ijpds-3318	82	5	and	and	CCONJ
ijpds-3318	82	6	potent	potent	ADJ
ijpds-3318	82	7	dpp-4	dpp-4	ADJ
ijpds-3318	82	8	inhibitor	inhibitor	NOUN
ijpds-3318	82	9	that	that	PRON
ijpds-3318	82	10	binds	bind	VERB
ijpds-3318	82	11	to	to	ADP
ijpds-3318	82	12	enzymes	enzyme	NOUN
ijpds-3318	82	13	covalently	covalently	ADV
ijpds-3318	82	14	.	.	PUNCT
ijpds-3318	83	1	this	this	DET
ijpds-3318	83	2	complex	complex	ADJ
ijpds-3318	83	3	dissociates	dissociate	NOUN
ijpds-3318	83	4	very	very	ADV
ijpds-3318	83	5	slowly	slowly	ADV
ijpds-3318	83	6	resulting	result	VERB
ijpds-3318	83	7	in	in	ADP
ijpds-3318	83	8	the	the	DET
ijpds-3318	83	9	persistent	persistent	ADJ
ijpds-3318	83	10	dpp-4	dpp-4	ADJ
ijpds-3318	83	11	inhibition	inhibition	NOUN
ijpds-3318	83	12	even	even	ADV
ijpds-3318	83	13	after	after	ADP
ijpds-3318	83	14	the	the	DET
ijpds-3318	83	15	clearance	clearance	NOUN
ijpds-3318	83	16	of	of	ADP
ijpds-3318	83	17	the	the	DET
ijpds-3318	83	18	free	free	ADJ
ijpds-3318	83	19	drug	drug	NOUN
ijpds-3318	83	20	from	from	ADP
ijpds-3318	83	21	circulation	circulation	NOUN
ijpds-3318	83	22	.	.	PUNCT
ijpds-3318	84	1	it	it	PRON
ijpds-3318	84	2	decreases	decrease	VERB
ijpds-3318	84	3	the	the	DET
ijpds-3318	84	4	degradation	degradation	NOUN
ijpds-3318	84	5	of	of	ADP
ijpds-3318	84	6	the	the	DET
ijpds-3318	84	7	incretin	incretin	ADJ
ijpds-3318	84	8	hormones	hormone	NOUN
ijpds-3318	84	9	glucagon	glucagon	NOUN
ijpds-3318	84	10	-	-	PUNCT
ijpds-3318	84	11	likepeptide1(glp-1	likepeptide1(glp-1	NOUN
ijpds-3318	84	12	)	)	PUNCT
ijpds-3318	84	13	and	and	CCONJ
ijpds-3318	84	14	glucose	glucose	NOUN
ijpds-3318	84	15	-	-	PUNCT
ijpds-3318	84	16	dependent	dependent	ADJ
ijpds-3318	84	17	insulinotropic	insulinotropic	NOUN
ijpds-3318	84	18	peptide	peptide	NOUN
ijpds-3318	84	19	(	(	PUNCT
ijpds-3318	84	20	gip	gip	NOUN
ijpds-3318	84	21	)	)	PUNCT
ijpds-3318	84	22	.	.	PUNCT
ijpds-3318	85	1	this	this	DET
ijpds-3318	85	2	activity	activity	NOUN
ijpds-3318	85	3	increases	increase	VERB
ijpds-3318	85	4	levels	level	NOUN
ijpds-3318	85	5	of	of	ADP
ijpds-3318	85	6	active	active	ADJ
ijpds-3318	85	7	incretins	incretin	NOUN
ijpds-3318	85	8	and	and	CCONJ
ijpds-3318	85	9	enhances	enhance	VERB
ijpds-3318	85	10	pancreatic	pancreatic	ADJ
ijpds-3318	85	11	islet	islet	NOUN
ijpds-3318	85	12	cell	cell	NOUN
ijpds-3318	85	13	responsiveness	responsiveness	NOUN
ijpds-3318	85	14	to	to	ADP
ijpds-3318	85	15	glucose	glucose	NOUN
ijpds-3318	85	16	,	,	PUNCT
ijpds-3318	85	17	thus	thus	ADV
ijpds-3318	85	18	improving	improve	VERB
ijpds-3318	85	19	insulin	insulin	NOUN
ijpds-3318	85	20	secretion	secretion	NOUN
ijpds-3318	85	21	and	and	CCONJ
ijpds-3318	85	22	reducing	reduce	VERB
ijpds-3318	85	23	inappropriate	inappropriate	ADJ
ijpds-3318	85	24	glucagon	glucagon	NOUN
ijpds-3318	85	25	production	production	NOUN
ijpds-3318	85	26	,	,	PUNCT
ijpds-3318	85	27	improving	improve	VERB
ijpds-3318	85	28	insulin	insulin	NOUN
ijpds-3318	85	29	sensitivity	sensitivity	NOUN
ijpds-3318	85	30	,	,	PUNCT
ijpds-3318	85	31	reducing	reduce	VERB
ijpds-3318	85	32	fasting	fasting	NOUN
ijpds-3318	85	33	,	,	PUNCT
ijpds-3318	85	34	postprandial	postprandial	ADJ
ijpds-3318	85	35	glucose	glucose	NOUN
ijpds-3318	85	36	,	,	PUNCT
ijpds-3318	85	37	and	and	CCONJ
ijpds-3318	85	38	hba1c	hba1c	PROPN
ijpds-3318	85	39	.	.	PUNCT
ijpds-3318	86	1	vildagliptin	vildagliptin	NOUN
ijpds-3318	86	2	treatment	treatment	NOUN
ijpds-3318	86	3	is	be	AUX
ijpds-3318	86	4	charcharacterizedweightneutral	charcharacterizedweightneutral	ADJ
ijpds-3318	86	5	and	and	CCONJ
ijpds-3318	86	6	lipid	lipid	NOUN
ijpds-3318	86	7	-	-	PUNCT
ijpds-3318	86	8	neutral	neutral	ADJ
ijpds-3318	86	9	effects	effect	NOUN
ijpds-3318	86	10	,	,	PUNCT
ijpds-3318	86	11	a	a	DET
ijpds-3318	86	12	very	very	ADV
ijpds-3318	86	13	low	low	ADJ
ijpds-3318	86	14	risk	risk	NOUN
ijpds-3318	86	15	of	of	ADP
ijpds-3318	86	16	edema	edema	NOUN
ijpds-3318	86	17	[	[	X
ijpds-3318	86	18	10	10	NUM
ijpds-3318	86	19	]	]	PUNCT
ijpds-3318	86	20	.	.	PUNCT
ijpds-3318	87	1	the	the	DET
ijpds-3318	87	2	episodes	episode	NOUN
ijpds-3318	87	3	of	of	ADP
ijpds-3318	87	4	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	87	5	are	be	AUX
ijpds-3318	87	6	also	also	ADV
ijpds-3318	87	7	rare	rare	ADJ
ijpds-3318	87	8	in	in	ADP
ijpds-3318	87	9	dpp-4	dpp-4	NUM
ijpds-3318	87	10	inhibitors	inhibitor	NOUN
ijpds-3318	87	11	treatment	treatment	NOUN
ijpds-3318	87	12	.	.	PUNCT
ijpds-3318	88	1	nasopharyngitis	nasopharyngitis	NOUN
ijpds-3318	88	2	and	and	CCONJ
ijpds-3318	88	3	cough	cough	NOUN
ijpds-3318	88	4	are	be	AUX
ijpds-3318	88	5	common	common	ADJ
ijpds-3318	88	6	side	side	NOUN
ijpds-3318	88	7	effects	effect	NOUN
ijpds-3318	88	8	of	of	ADP
ijpds-3318	88	9	dpp-4	dpp-4	DET
ijpds-3318	88	10	inhibitors	inhibitor	NOUN
ijpds-3318	88	11	.	.	PUNCT
ijpds-3318	89	1	angioedema	angioedema	ADV
ijpds-3318	89	2	,	,	PUNCT
ijpds-3318	89	3	acute	acute	ADJ
ijpds-3318	89	4	pancreatitis	pancreatitis	NOUN
ijpds-3318	89	5	,	,	PUNCT
ijpds-3318	89	6	and	and	CCONJ
ijpds-3318	89	7	skin	skin	NOUN
ijpds-3318	89	8	lesion	lesion	NOUN
ijpds-3318	89	9	are	be	AUX
ijpds-3318	89	10	rare	rare	ADJ
ijpds-3318	89	11	side	side	ADJ
ijpds-3318	89	12	effects	effect	NOUN
ijpds-3318	89	13	of	of	ADP
ijpds-3318	89	14	dpp-4	dpp-4	DET
ijpds-3318	89	15	inhibitors	inhibitor	NOUN
ijpds-3318	89	16	.	.	PUNCT
ijpds-3318	90	1	hba1c	hba1c	NOUN
ijpds-3318	90	2	levels	level	NOUN
ijpds-3318	90	3	have	have	AUX
ijpds-3318	90	4	been	be	AUX
ijpds-3318	90	5	decreased	decrease	VERB
ijpds-3318	90	6	rapidly	rapidly	ADV
ijpds-3318	90	7	within	within	ADP
ijpds-3318	90	8	the	the	DET
ijpds-3318	90	9	initial	initial	ADJ
ijpds-3318	90	10	three	three	NUM
ijpds-3318	90	11	months	month	NOUN
ijpds-3318	90	12	of	of	ADP
ijpds-3318	90	13	vildagliptin	vildagliptin	NOUN
ijpds-3318	90	14	[	[	X
ijpds-3318	90	15	11	11	NUM
ijpds-3318	90	16	]	]	PUNCT
ijpds-3318	90	17	.	.	PUNCT
ijpds-3318	91	1	biswanath	biswanath	PROPN
ijpds-3318	91	2	et	et	PROPN
ijpds-3318	91	3	al	al	PROPN
ijpds-3318	91	4	.	.	PROPN
ijpds-3318	91	5	,	,	PUNCT
ijpds-3318	91	6	cheli	cheli	PROPN
ijpds-3318	91	7	et	et	PROPN
ijpds-3318	91	8	al	al	PROPN
ijpds-3318	91	9	.	.	PROPN
ijpds-3318	91	10	,	,	PUNCT
ijpds-3318	91	11	conducted	conduct	VERB
ijpds-3318	91	12	studies	study	NOUN
ijpds-3318	91	13	that	that	PRON
ijpds-3318	91	14	concluded	conclude	VERB
ijpds-3318	91	15	that	that	SCONJ
ijpds-3318	91	16	vildagliptin	vildagliptin	NOUN
ijpds-3318	91	17	and	and	CCONJ
ijpds-3318	91	18	metformin	metformin	NOUN
ijpds-3318	91	19	combination	combination	NOUN
ijpds-3318	91	20	provided	provide	VERB
ijpds-3318	91	21	better	well	ADJ
ijpds-3318	91	22	efficacy	efficacy	NOUN
ijpds-3318	91	23	comparable	comparable	ADJ
ijpds-3318	91	24	to	to	ADP
ijpds-3318	91	25	that	that	PRON
ijpds-3318	91	26	of	of	ADP
ijpds-3318	91	27	glimepiride	glimepiride	NOUN
ijpds-3318	91	28	and	and	CCONJ
ijpds-3318	91	29	metformin	metformin	NOUN
ijpds-3318	91	30	combination	combination	NOUN
ijpds-3318	91	31	and	and	CCONJ
ijpds-3318	91	32	resulted	result	VERB
ijpds-3318	91	33	in	in	ADP
ijpds-3318	91	34	better	well	ADJ
ijpds-3318	91	35	adverse	adverse	ADJ
ijpds-3318	91	36	effect	effect	NOUN
ijpds-3318	91	37	profile	profile	NOUN
ijpds-3318	91	38	with	with	ADP
ijpds-3318	91	39	lower	low	ADJ
ijpds-3318	91	40	risks	risk	NOUN
ijpds-3318	91	41	of	of	ADP
ijpds-3318	91	42	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	91	43	and	and	CCONJ
ijpds-3318	91	44	weight	weight	NOUN
ijpds-3318	91	45	gain	gain	NOUN
ijpds-3318	91	46	[	[	X
ijpds-3318	91	47	12	12	NUM
ijpds-3318	91	48	,	,	PUNCT
ijpds-3318	91	49	13	13	NUM
ijpds-3318	91	50	]	]	PUNCT
ijpds-3318	91	51	.	.	PUNCT
ijpds-3318	92	1	a	a	DET
ijpds-3318	92	2	study	study	NOUN
ijpds-3318	92	3	conducted	conduct	VERB
ijpds-3318	92	4	by	by	ADP
ijpds-3318	92	5	li	li	PROPN
ijpds-3318	92	6	-	-	PROPN
ijpds-3318	92	7	nong	nong	PROPN
ijpds-3318	92	8	ji	ji	PROPN
ijpds-3318	92	9	et	et	PROPN
ijpds-3318	92	10	al	al	PROPN
ijpds-3318	92	11	.	.	PROPN
ijpds-3318	92	12	concluded	conclude	VERB
ijpds-3318	92	13	that	that	SCONJ
ijpds-3318	92	14	the	the	DET
ijpds-3318	92	15	use	use	NOUN
ijpds-3318	92	16	of	of	ADP
ijpds-3318	92	17	combination	combination	NOUN
ijpds-3318	92	18	therapy	therapy	NOUN
ijpds-3318	92	19	with	with	ADP
ijpds-3318	92	20	vildagliptin	vildagliptin	NOUN
ijpds-3318	92	21	and	and	CCONJ
ijpds-3318	92	22	metformin	metformin	NOUN
ijpds-3318	92	23	will	will	AUX
ijpds-3318	92	24	provide	provide	VERB
ijpds-3318	92	25	good	good	ADJ
ijpds-3318	92	26	glycemic	glycemic	ADJ
ijpds-3318	92	27	control	control	NOUN
ijpds-3318	92	28	and	and	CCONJ
ijpds-3318	92	29	will	will	AUX
ijpds-3318	92	30	be	be	AUX
ijpds-3318	92	31	better	well	ADV
ijpds-3318	92	32	tolerated	tolerate	VERB
ijpds-3318	92	33	than	than	ADP
ijpds-3318	92	34	up	up	ADP
ijpds-3318	92	35	-	-	PUNCT
ijpds-3318	92	36	titration	titration	NOUN
ijpds-3318	92	37	of	of	ADP
ijpds-3318	92	38	metformin	metformin	NOUN
ijpds-3318	92	39	monotherapy	monotherapy	NOUN
ijpds-3318	93	1	[	[	X
ijpds-3318	93	2	14	14	NUM
ijpds-3318	93	3	]	]	PUNCT
ijpds-3318	93	4	.	.	PUNCT
ijpds-3318	94	1	a	a	DET
ijpds-3318	94	2	study	study	NOUN
ijpds-3318	94	3	conducted	conduct	VERB
ijpds-3318	94	4	by	by	ADP
ijpds-3318	94	5	hye	hye	PROPN
ijpds-3318	94	6	-	-	PUNCT
ijpds-3318	94	7	soon	soon	ADV
ijpds-3318	94	8	kim	kim	PROPN
ijpds-3318	94	9	et	et	PROPN
ijpds-3318	94	10	al	al	PROPN
ijpds-3318	94	11	.	.	PROPN
ijpds-3318	94	12	,	,	PUNCT
ijpds-3318	94	13	concluded	conclude	VERB
ijpds-3318	94	14	that	that	SCONJ
ijpds-3318	94	15	glimepiride	glimepiride	NOUN
ijpds-3318	94	16	metformin	metformin	NOUN
ijpds-3318	94	17	combination	combination	NOUN
ijpds-3318	94	18	therapy	therapy	NOUN
ijpds-3318	94	19	was	be	AUX
ijpds-3318	94	20	more	more	ADV
ijpds-3318	94	21	effective	effective	ADJ
ijpds-3318	94	22	in	in	ADP
ijpds-3318	94	23	glycemic	glycemic	ADJ
ijpds-3318	94	24	control	control	NOUN
ijpds-3318	94	25	than	than	ADP
ijpds-3318	94	26	metformin	metformin	VERB
ijpds-3318	94	27	up	up	ADP
ijpds-3318	94	28	-	-	PUNCT
ijpds-3318	94	29	titration	titration	NOUN
ijpds-3318	94	30	and	and	CCONJ
ijpds-3318	94	31	was	be	AUX
ijpds-3318	94	32	well	well	ADV
ijpds-3318	94	33	tolerated	tolerate	VERB
ijpds-3318	94	34	in	in	ADP
ijpds-3318	94	35	type	type	NOUN
ijpds-3318	94	36	2	2	NUM
ijpds-3318	94	37	diabetes	diabetes	NOUN
ijpds-3318	94	38	mellitus	mellitus	NOUN
ijpds-3318	94	39	patients	patient	NOUN
ijpds-3318	94	40	inadequately	inadequately	ADV
ijpds-3318	94	41	controlled	control	VERB
ijpds-3318	94	42	by	by	ADP
ijpds-3318	94	43	lowdose	lowdose	ADJ
ijpds-3318	94	44	metformin	metformin	NOUN
ijpds-3318	94	45	monotherapy	monotherapy	NOUN
ijpds-3318	95	1	[	[	X
ijpds-3318	95	2	15	15	NUM
ijpds-3318	95	3	]	]	PUNCT
ijpds-3318	95	4	.	.	PUNCT
ijpds-3318	96	1	a	a	DET
ijpds-3318	96	2	study	study	NOUN
ijpds-3318	96	3	conducted	conduct	VERB
ijpds-3318	96	4	by	by	ADP
ijpds-3318	96	5	manuel	manuel	PROPN
ijpds-3318	96	6	gonzalez	gonzalez	PROPN
ijpds-3318	96	7	et	et	PROPN
ijpds-3318	96	8	al	al	PROPN
ijpds-3318	96	9	.	.	PROPN
ijpds-3318	96	10	showed	show	VERB
ijpds-3318	96	11	that	that	SCONJ
ijpds-3318	96	12	glimepiridemetformin	glimepiridemetformin	NOUN
ijpds-3318	96	13	demonstrated	demonstrate	VERB
ijpds-3318	96	14	to	to	PART
ijpds-3318	96	15	be	be	AUX
ijpds-3318	96	16	more	more	ADV
ijpds-3318	96	17	efficacious	efficacious	ADJ
ijpds-3318	96	18	than	than	ADP
ijpds-3318	96	19	glibenclamide	glibenclamide	NOUN
ijpds-3318	96	20	metformin	metformin	NOUN
ijpds-3318	96	21	at	at	ADP
ijpds-3318	96	22	reaching	reach	VERB
ijpds-3318	96	23	the	the	DET
ijpds-3318	96	24	glycemic	glycemic	ADJ
ijpds-3318	96	25	control	control	NOUN
ijpds-3318	96	26	goals	goal	NOUN
ijpds-3318	96	27	with	with	ADP
ijpds-3318	96	28	less	less	ADJ
ijpds-3318	96	29	hypoglycemic	hypoglycemic	ADJ
ijpds-3318	96	30	events	event	NOUN
ijpds-3318	96	31	in	in	ADP
ijpds-3318	96	32	patients	patient	NOUN
ijpds-3318	96	33	with	with	ADP
ijpds-3318	96	34	uncontrolled	uncontrolled	ADJ
ijpds-3318	96	35	type	type	NOUN
ijpds-3318	96	36	2	2	NUM
ijpds-3318	96	37	diabetes	diabetes	NOUN
ijpds-3318	96	38	mellitus	mellitus	NOUN
ijpds-3318	97	1	[	[	X
ijpds-3318	97	2	16	16	NUM
ijpds-3318	97	3	]	]	PUNCT
ijpds-3318	97	4	.	.	PUNCT
ijpds-3318	98	1	in	in	ADP
ijpds-3318	98	2	the	the	DET
ijpds-3318	98	3	present	present	ADJ
ijpds-3318	98	4	study	study	NOUN
ijpds-3318	98	5	,	,	PUNCT
ijpds-3318	98	6	the	the	DET
ijpds-3318	98	7	average	average	ADJ
ijpds-3318	98	8	hba1c	hba1c	PROPN
ijpds-3318	98	9	levels	level	NOUN
ijpds-3318	98	10	of	of	ADP
ijpds-3318	98	11	v	v	NOUN
ijpds-3318	98	12	-	-	PUNCT
ijpds-3318	98	13	m	m	NOUN
ijpds-3318	98	14	group	group	NOUN
ijpds-3318	98	15	patients	patient	NOUN
ijpds-3318	98	16	were	be	AUX
ijpds-3318	98	17	7.25	7.25	NUM
ijpds-3318	98	18	%	%	NOUN
ijpds-3318	98	19	at	at	ADP
ijpds-3318	98	20	the	the	DET
ijpds-3318	98	21	start	start	NOUN
ijpds-3318	98	22	of	of	ADP
ijpds-3318	98	23	the	the	DET
ijpds-3318	98	24	study	study	NOUN
ijpds-3318	98	25	and	and	CCONJ
ijpds-3318	98	26	6.75	6.75	NUM
ijpds-3318	98	27	%	%	NOUN
ijpds-3318	98	28	at	at	ADP
ijpds-3318	98	29	the	the	DET
ijpds-3318	98	30	end	end	NOUN
ijpds-3318	98	31	of	of	ADP
ijpds-3318	98	32	the	the	DET
ijpds-3318	98	33	study	study	NOUN
ijpds-3318	98	34	.	.	PUNCT
ijpds-3318	99	1	the	the	DET
ijpds-3318	99	2	average	average	ADJ
ijpds-3318	99	3	hba1c	hba1c	PROPN
ijpds-3318	99	4	levels	level	NOUN
ijpds-3318	99	5	of	of	ADP
ijpds-3318	99	6	g	g	PROPN
ijpds-3318	99	7	-	-	PUNCT
ijpds-3318	99	8	m	m	NOUN
ijpds-3318	99	9	patients	patient	NOUN
ijpds-3318	99	10	were	be	AUX
ijpds-3318	99	11	7.50	7.50	NUM
ijpds-3318	99	12	%	%	NOUN
ijpds-3318	99	13	at	at	ADP
ijpds-3318	99	14	the	the	DET
ijpds-3318	99	15	start	start	NOUN
ijpds-3318	99	16	of	of	ADP
ijpds-3318	99	17	the	the	DET
ijpds-3318	99	18	study	study	NOUN
ijpds-3318	99	19	and	and	CCONJ
ijpds-3318	99	20	7.15	7.15	NUM
ijpds-3318	99	21	%	%	NOUN
ijpds-3318	99	22	at	at	ADP
ijpds-3318	99	23	the	the	DET
ijpds-3318	99	24	end	end	NOUN
ijpds-3318	99	25	of	of	ADP
ijpds-3318	99	26	the	the	DET
ijpds-3318	99	27	study	study	NOUN
ijpds-3318	99	28	.	.	PUNCT
ijpds-3318	100	1	the	the	DET
ijpds-3318	100	2	difference	difference	NOUN
ijpds-3318	100	3	between	between	ADP
ijpds-3318	100	4	initial	initial	ADJ
ijpds-3318	100	5	i.e.	i.e.	ADV
ijpds-3318	100	6	,	,	PUNCT
ijpds-3318	100	7	at	at	ADP
ijpds-3318	100	8	the	the	DET
ijpds-3318	100	9	start	start	NOUN
ijpds-3318	100	10	of	of	ADP
ijpds-3318	100	11	the	the	DET
ijpds-3318	100	12	study	study	NOUN
ijpds-3318	100	13	kareenmulla	kareenmulla	PROPN
ijpds-3318	100	14	et	et	PROPN
ijpds-3318	100	15	al	al	PROPN
ijpds-3318	100	16	efficacy	efficacy	PROPN
ijpds-3318	100	17	,	,	PUNCT
ijpds-3318	100	18	safety	safety	NOUN
ijpds-3318	100	19	of	of	ADP
ijpds-3318	100	20	vildagliptin	vildagliptin	NOUN
ijpds-3318	100	21	-	-	PUNCT
ijpds-3318	100	22	metformin	metformin	NOUN
ijpds-3318	100	23	versus	versus	ADP
ijpds-3318	100	24	glimepiride	glimepiride	NOUN
ijpds-3318	100	25	-	-	PUNCT
ijpds-3318	100	26	metformin	metformin	NOUN
ijpds-3318	100	27	vol	vol	NOUN
ijpds-3318	100	28	1	1	NUM
ijpds-3318	100	29	|	|	NOUN
ijpds-3318	100	30	issue	issue	NOUN
ijpds-3318	100	31	2	2	NUM
ijpds-3318	101	1	|	|	ADV
ijpds-3318	101	2	jul	jul	PROPN
ijpds-3318	101	3	sep	sep	PROPN
ijpds-3318	101	4	2022	2022	NUM
ijpds-3318	101	5	indian	indian	PROPN
ijpds-3318	101	6	j	j	PROPN
ijpds-3318	101	7	pharm	pharm	PROPN
ijpds-3318	101	8	drug	drug	PROPN
ijpds-3318	101	9	studies	study	NOUN
ijpds-3318	101	10	|	|	ADV
ijpds-3318	101	11	66	66	NUM
ijpds-3318	101	12	(	(	PUNCT
ijpds-3318	101	13	week	week	NOUN
ijpds-3318	101	14	0	0	NUM
ijpds-3318	101	15	)	)	PUNCT
ijpds-3318	101	16	and	and	CCONJ
ijpds-3318	101	17	final	final	ADJ
ijpds-3318	101	18	i.e.	i.e.	X
ijpds-3318	101	19	,	,	PUNCT
ijpds-3318	101	20	at	at	ADP
ijpds-3318	101	21	the	the	DET
ijpds-3318	101	22	end	end	NOUN
ijpds-3318	101	23	of	of	ADP
ijpds-3318	101	24	the	the	DET
ijpds-3318	101	25	study	study	NOUN
ijpds-3318	101	26	(	(	PUNCT
ijpds-3318	101	27	week	week	NOUN
ijpds-3318	101	28	12	12	NUM
ijpds-3318	101	29	)	)	PUNCT
ijpds-3318	101	30	of	of	ADP
ijpds-3318	101	31	both	both	DET
ijpds-3318	101	32	groups	group	NOUN
ijpds-3318	101	33	were	be	AUX
ijpds-3318	101	34	0.50	0.50	NUM
ijpds-3318	101	35	%	%	NOUN
ijpds-3318	101	36	and	and	CCONJ
ijpds-3318	101	37	0.35	0.35	NUM
ijpds-3318	101	38	%	%	NOUN
ijpds-3318	101	39	respectively	respectively	ADV
ijpds-3318	101	40	.	.	PUNCT
ijpds-3318	102	1	we	we	PRON
ijpds-3318	102	2	observed	observe	VERB
ijpds-3318	102	3	that	that	SCONJ
ijpds-3318	102	4	there	there	PRON
ijpds-3318	102	5	was	be	VERB
ijpds-3318	102	6	a	a	DET
ijpds-3318	102	7	significant	significant	ADJ
ijpds-3318	102	8	reduction	reduction	NOUN
ijpds-3318	102	9	of	of	ADP
ijpds-3318	102	10	hba1c	hba1c	PROPN
ijpds-3318	102	11	levels	level	NOUN
ijpds-3318	102	12	in	in	ADP
ijpds-3318	102	13	v	v	ADP
ijpds-3318	102	14	-	-	PUNCT
ijpds-3318	102	15	m	m	NOUN
ijpds-3318	102	16	group	group	NOUN
ijpds-3318	102	17	patients	patient	NOUN
ijpds-3318	102	18	than	than	ADP
ijpds-3318	102	19	in	in	ADP
ijpds-3318	102	20	gm	gm	PROPN
ijpds-3318	102	21	group	group	NOUN
ijpds-3318	102	22	patients	patient	NOUN
ijpds-3318	102	23	,	,	PUNCT
ijpds-3318	102	24	represented	represent	VERB
ijpds-3318	102	25	in	in	ADP
ijpds-3318	102	26	table	table	NOUN
ijpds-3318	102	27	1	1	NUM
ijpds-3318	102	28	.	.	PUNCT
ijpds-3318	102	29	table	table	NOUN
ijpds-3318	102	30	1	1	NUM
ijpds-3318	102	31	:	:	PUNCT
ijpds-3318	102	32	comparison	comparison	NOUN
ijpds-3318	102	33	of	of	ADP
ijpds-3318	102	34	average	average	ADJ
ijpds-3318	102	35	hba1c	hba1c	PROPN
ijpds-3318	102	36	levels	level	NOUN
ijpds-3318	102	37	(	(	PUNCT
ijpds-3318	102	38	v	v	NOUN
ijpds-3318	102	39	-	-	PUNCT
ijpds-3318	102	40	m	m	NOUN
ijpds-3318	102	41	;	;	PUNCT
ijpds-3318	102	42	gm	gm	PROPN
ijpds-3318	102	43	)	)	PUNCT
ijpds-3318	103	1	hba1c	hba1c	PROPN
ijpds-3318	103	2	levels	level	NOUN
ijpds-3318	103	3	monitoring	monitor	VERB
ijpds-3318	103	4	group	group	NOUN
ijpds-3318	103	5	at	at	ADP
ijpds-3318	103	6	week	week	NOUN
ijpds-3318	103	7	0	0	NUM
ijpds-3318	103	8	at	at	ADP
ijpds-3318	103	9	week	week	NOUN
ijpds-3318	103	10	12	12	NUM
ijpds-3318	103	11	difference	difference	NOUN
ijpds-3318	103	12	v	v	ADP
ijpds-3318	103	13	-	-	PUNCT
ijpds-3318	103	14	m	m	NOUN
ijpds-3318	103	15	7.25	7.25	NUM
ijpds-3318	103	16	%	%	NOUN
ijpds-3318	103	17	6.75	6.75	NUM
ijpds-3318	103	18	%	%	NOUN
ijpds-3318	103	19	0.50	0.50	NUM
ijpds-3318	103	20	%	%	NOUN
ijpds-3318	103	21	g	g	NOUN
ijpds-3318	103	22	-	-	NOUN
ijpds-3318	103	23	m	m	NOUN
ijpds-3318	103	24	7.50	7.50	NUM
ijpds-3318	103	25	%	%	NOUN
ijpds-3318	103	26	7.15	7.15	NUM
ijpds-3318	103	27	%	%	NOUN
ijpds-3318	103	28	0.35	0.35	NUM
ijpds-3318	103	29	%	%	NOUN
ijpds-3318	103	30	while	while	SCONJ
ijpds-3318	103	31	fbs	fbs	ADJ
ijpds-3318	103	32	monitoring	monitoring	NOUN
ijpds-3318	103	33	,	,	PUNCT
ijpds-3318	103	34	the	the	DET
ijpds-3318	103	35	average	average	ADJ
ijpds-3318	103	36	value	value	NOUN
ijpds-3318	103	37	at	at	ADP
ijpds-3318	103	38	the	the	DET
ijpds-3318	103	39	initial	initial	ADJ
ijpds-3318	103	40	reading	reading	NOUN
ijpds-3318	103	41	(	(	PUNCT
ijpds-3318	103	42	week	week	NOUN
ijpds-3318	103	43	0	0	NUM
ijpds-3318	103	44	)	)	PUNCT
ijpds-3318	103	45	was	be	AUX
ijpds-3318	103	46	145	145	NUM
ijpds-3318	103	47	mg	mg	PROPN
ijpds-3318	103	48	/	/	SYM
ijpds-3318	103	49	dl	dl	PROPN
ijpds-3318	103	50	and	and	CCONJ
ijpds-3318	103	51	138mg	138mg	PROPN
ijpds-3318	103	52	/	/	SYM
ijpds-3318	103	53	dl	dl	PROPN
ijpds-3318	103	54	,	,	PUNCT
ijpds-3318	103	55	133mg	133mg	PROPN
ijpds-3318	103	56	/	/	SYM
ijpds-3318	103	57	dl	dl	PROPN
ijpds-3318	103	58	,	,	PUNCT
ijpds-3318	103	59	125mg	125mg	PROPN
ijpds-3318	103	60	/	/	SYM
ijpds-3318	103	61	dl	dl	PROPN
ijpds-3318	103	62	on	on	ADP
ijpds-3318	103	63	subsequent	subsequent	ADJ
ijpds-3318	103	64	i.e.	i.e.	X
ijpds-3318	103	65	,	,	PUNCT
ijpds-3318	103	66	1	1	NUM
ijpds-3318	103	67	st	st	PROPN
ijpds-3318	103	68	,	,	PUNCT
ijpds-3318	103	69	2nd	2nd	PROPN
ijpds-3318	103	70	,	,	PUNCT
ijpds-3318	103	71	3rd	3rd	ADJ
ijpds-3318	103	72	follow	follow	NOUN
ijpds-3318	103	73	-	-	PUNCT
ijpds-3318	103	74	ups	up	NOUN
ijpds-3318	103	75	respectively	respectively	ADV
ijpds-3318	103	76	in	in	ADP
ijpds-3318	103	77	v	v	ADP
ijpds-3318	103	78	-	-	PUNCT
ijpds-3318	103	79	m	m	NOUN
ijpds-3318	103	80	group	group	NOUN
ijpds-3318	103	81	patients	patient	NOUN
ijpds-3318	103	82	.	.	PUNCT
ijpds-3318	104	1	the	the	DET
ijpds-3318	104	2	average	average	ADJ
ijpds-3318	104	3	value	value	NOUN
ijpds-3318	104	4	at	at	ADP
ijpds-3318	104	5	the	the	DET
ijpds-3318	104	6	initial	initial	ADJ
ijpds-3318	104	7	reading	reading	NOUN
ijpds-3318	104	8	(	(	PUNCT
ijpds-3318	104	9	week	week	NOUN
ijpds-3318	104	10	0	0	NUM
ijpds-3318	104	11	)	)	PUNCT
ijpds-3318	104	12	was	be	AUX
ijpds-3318	104	13	142mg	142mg	ADJ
ijpds-3318	104	14	/	/	SYM
ijpds-3318	104	15	dl	dl	PROPN
ijpds-3318	104	16	and	and	CCONJ
ijpds-3318	104	17	137mg	137mg	PROPN
ijpds-3318	104	18	/	/	SYM
ijpds-3318	104	19	dl	dl	PROPN
ijpds-3318	104	20	,	,	PUNCT
ijpds-3318	104	21	135mg	135mg	PROPN
ijpds-3318	104	22	/	/	SYM
ijpds-3318	104	23	dl	dl	PROPN
ijpds-3318	104	24	,	,	PUNCT
ijpds-3318	104	25	130mg	130mg	PROPN
ijpds-3318	104	26	/	/	SYM
ijpds-3318	104	27	dl	dl	PROPN
ijpds-3318	104	28	on	on	ADP
ijpds-3318	104	29	subsequent	subsequent	ADJ
ijpds-3318	104	30	follow	follow	NOUN
ijpds-3318	104	31	-	-	PUNCT
ijpds-3318	104	32	ups	up	NOUN
ijpds-3318	104	33	i.e.	i.e.	X
ijpds-3318	104	34	,	,	PUNCT
ijpds-3318	104	35	1	1	NUM
ijpds-3318	104	36	st	st	PROPN
ijpds-3318	104	37	,	,	PUNCT
ijpds-3318	104	38	2nd	2nd	PROPN
ijpds-3318	104	39	,	,	PUNCT
ijpds-3318	104	40	3	3	NUM
ijpds-3318	104	41	rd	rd	NOUN
ijpds-3318	104	42	follow	follow	NOUN
ijpds-3318	104	43	-	-	PUNCT
ijpds-3318	104	44	ups	up	NOUN
ijpds-3318	104	45	respectively	respectively	ADV
ijpds-3318	104	46	in	in	ADP
ijpds-3318	104	47	g	g	PROPN
ijpds-3318	104	48	-	-	PUNCT
ijpds-3318	104	49	m	m	NOUN
ijpds-3318	104	50	group	group	NOUN
ijpds-3318	104	51	patients	patient	NOUN
ijpds-3318	104	52	.	.	PUNCT
ijpds-3318	105	1	the	the	DET
ijpds-3318	105	2	difference	difference	NOUN
ijpds-3318	105	3	between	between	ADP
ijpds-3318	105	4	the	the	DET
ijpds-3318	105	5	initial	initial	ADJ
ijpds-3318	105	6	reading	reading	NOUN
ijpds-3318	105	7	and	and	CCONJ
ijpds-3318	105	8	final	final	ADJ
ijpds-3318	105	9	follow	follow	NOUN
ijpds-3318	105	10	-	-	PUNCT
ijpds-3318	105	11	up	up	NOUN
ijpds-3318	105	12	was	be	AUX
ijpds-3318	105	13	20mg	20mg	ADJ
ijpds-3318	105	14	/	/	SYM
ijpds-3318	105	15	dl	dl	PROPN
ijpds-3318	105	16	in	in	ADP
ijpds-3318	105	17	the	the	DET
ijpds-3318	105	18	v	v	PROPN
ijpds-3318	105	19	-	-	PUNCT
ijpds-3318	105	20	m	m	NOUN
ijpds-3318	105	21	group	group	NOUN
ijpds-3318	105	22	and	and	CCONJ
ijpds-3318	105	23	12mg	12mg	ADJ
ijpds-3318	105	24	/	/	SYM
ijpds-3318	105	25	dl	dl	PROPN
ijpds-3318	105	26	in	in	ADP
ijpds-3318	105	27	g	g	PROPN
ijpds-3318	105	28	-	-	PUNCT
ijpds-3318	105	29	m	m	NOUN
ijpds-3318	105	30	group	group	NOUN
ijpds-3318	105	31	patients	patient	NOUN
ijpds-3318	105	32	.	.	PUNCT
ijpds-3318	106	1	it	it	PRON
ijpds-3318	106	2	was	be	AUX
ijpds-3318	106	3	evaluated	evaluate	VERB
ijpds-3318	106	4	that	that	SCONJ
ijpds-3318	106	5	fbs	fbs	ADJ
ijpds-3318	106	6	reduction	reduction	NOUN
ijpds-3318	106	7	was	be	AUX
ijpds-3318	106	8	significantly	significantly	ADV
ijpds-3318	106	9	higher	high	ADJ
ijpds-3318	106	10	in	in	ADP
ijpds-3318	106	11	v	v	ADP
ijpds-3318	106	12	-	-	PUNCT
ijpds-3318	106	13	m	m	NOUN
ijpds-3318	106	14	group	group	NOUN
ijpds-3318	106	15	patients	patient	NOUN
ijpds-3318	106	16	than	than	ADP
ijpds-3318	106	17	in	in	ADP
ijpds-3318	106	18	g	g	PROPN
ijpds-3318	106	19	-	-	PUNCT
ijpds-3318	106	20	m	m	NOUN
ijpds-3318	106	21	group	group	NOUN
ijpds-3318	106	22	patients	patient	NOUN
ijpds-3318	106	23	,	,	PUNCT
ijpds-3318	106	24	tabulated	tabulate	VERB
ijpds-3318	106	25	in	in	ADP
ijpds-3318	106	26	table	table	NOUN
ijpds-3318	106	27	2	2	NUM
ijpds-3318	106	28	.	.	PUNCT
ijpds-3318	106	29	table	table	NOUN
ijpds-3318	106	30	2	2	NUM
ijpds-3318	106	31	:	:	PUNCT
ijpds-3318	106	32	comparison	comparison	NOUN
ijpds-3318	106	33	of	of	ADP
ijpds-3318	106	34	average	average	ADJ
ijpds-3318	106	35	fbs	fbs	PROPN
ijpds-3318	106	36	levels	level	NOUN
ijpds-3318	106	37	(	(	PUNCT
ijpds-3318	106	38	v	v	NOUN
ijpds-3318	106	39	-	-	PUNCT
ijpds-3318	106	40	m	m	NOUN
ijpds-3318	106	41	;	;	PUNCT
ijpds-3318	106	42	g	g	PROPN
ijpds-3318	106	43	-	-	PUNCT
ijpds-3318	106	44	m	m	NOUN
ijpds-3318	106	45	)	)	PUNCT
ijpds-3318	106	46	fbs	fbs	PROPN
ijpds-3318	106	47	(	(	PUNCT
ijpds-3318	106	48	mg	mg	PROPN
ijpds-3318	106	49	/	/	SYM
ijpds-3318	106	50	dl	dl	NOUN
ijpds-3318	106	51	)	)	PUNCT
ijpds-3318	106	52	monitoring	monitoring	NOUN
ijpds-3318	106	53	group	group	NOUN
ijpds-3318	106	54	initial	initial	ADJ
ijpds-3318	106	55	reading	reading	NOUN
ijpds-3318	106	56	1st	1st	PROPN
ijpds-3318	106	57	follow	follow	VERB
ijpds-3318	106	58	up	up	ADP
ijpds-3318	106	59	2nd	2nd	ADJ
ijpds-3318	106	60	follow	follow	VERB
ijpds-3318	106	61	up	up	ADP
ijpds-3318	106	62	3rd	3rd	ADJ
ijpds-3318	106	63	follow	follow	VERB
ijpds-3318	106	64	up	up	ADP
ijpds-3318	106	65	difference	difference	NOUN
ijpds-3318	106	66	between	between	ADP
ijpds-3318	106	67	initial	initial	ADJ
ijpds-3318	106	68	reading	reading	NOUN
ijpds-3318	106	69	and	and	CCONJ
ijpds-3318	106	70	3rd	3rd	NOUN
ijpds-3318	106	71	follow	follow	VERB
ijpds-3318	106	72	up	up	ADP
ijpds-3318	106	73	v	v	ADP
ijpds-3318	106	74	-	-	PUNCT
ijpds-3318	106	75	m	m	NOUN
ijpds-3318	106	76	145	145	NUM
ijpds-3318	106	77	138	138	NUM
ijpds-3318	106	78	133	133	NUM
ijpds-3318	106	79	125	125	NUM
ijpds-3318	106	80	20	20	NUM
ijpds-3318	106	81	g	g	NOUN
ijpds-3318	106	82	-	-	PUNCT
ijpds-3318	106	83	m	m	VERB
ijpds-3318	106	84	142	142	NUM
ijpds-3318	106	85	137	137	NUM
ijpds-3318	106	86	135	135	NUM
ijpds-3318	106	87	130	130	NUM
ijpds-3318	106	88	12	12	NUM
ijpds-3318	106	89	the	the	DET
ijpds-3318	106	90	average	average	ADJ
ijpds-3318	106	91	value	value	NOUN
ijpds-3318	106	92	of	of	ADP
ijpds-3318	106	93	rbs	rbs	NOUN
ijpds-3318	106	94	levels	level	NOUN
ijpds-3318	106	95	at	at	ADP
ijpds-3318	106	96	the	the	DET
ijpds-3318	106	97	initial	initial	ADJ
ijpds-3318	106	98	reading	reading	NOUN
ijpds-3318	106	99	(	(	PUNCT
ijpds-3318	106	100	week	week	NOUN
ijpds-3318	106	101	0	0	NUM
ijpds-3318	106	102	)	)	PUNCT
ijpds-3318	106	103	was	be	AUX
ijpds-3318	106	104	270	270	NUM
ijpds-3318	106	105	mg	mg	PROPN
ijpds-3318	106	106	/	/	SYM
ijpds-3318	106	107	dl	dl	PROPN
ijpds-3318	106	108	and	and	CCONJ
ijpds-3318	106	109	245mg	245mg	PROPN
ijpds-3318	106	110	/	/	SYM
ijpds-3318	106	111	dl	dl	PROPN
ijpds-3318	106	112	,	,	PUNCT
ijpds-3318	106	113	210mg	210mg	PROPN
ijpds-3318	106	114	/	/	SYM
ijpds-3318	106	115	dl	dl	PROPN
ijpds-3318	106	116	,	,	PUNCT
ijpds-3318	106	117	185mg	185mg	PROPN
ijpds-3318	106	118	/	/	SYM
ijpds-3318	106	119	dl	dl	PROPN
ijpds-3318	106	120	on	on	ADP
ijpds-3318	106	121	subsequent	subsequent	ADJ
ijpds-3318	106	122	i.e.	i.e.	ADV
ijpds-3318	106	123	,	,	PUNCT
ijpds-3318	106	124	1st	1st	ADJ
ijpds-3318	106	125	,	,	PUNCT
ijpds-3318	106	126	2nd	2nd	ADJ
ijpds-3318	106	127	,	,	PUNCT
ijpds-3318	106	128	3rd	3rd	ADJ
ijpds-3318	106	129	follow	follow	NOUN
ijpds-3318	106	130	-	-	PUNCT
ijpds-3318	106	131	ups	up	NOUN
ijpds-3318	106	132	respectively	respectively	ADV
ijpds-3318	106	133	in	in	ADP
ijpds-3318	106	134	the	the	DET
ijpds-3318	106	135	v	v	PROPN
ijpds-3318	106	136	-	-	PUNCT
ijpds-3318	106	137	m	m	NOUN
ijpds-3318	106	138	group	group	NOUN
ijpds-3318	106	139	patients	patient	NOUN
ijpds-3318	106	140	.	.	PUNCT
ijpds-3318	107	1	the	the	DET
ijpds-3318	107	2	average	average	ADJ
ijpds-3318	107	3	value	value	NOUN
ijpds-3318	107	4	of	of	ADP
ijpds-3318	107	5	rbs	rbs	NOUN
ijpds-3318	107	6	levels	level	NOUN
ijpds-3318	107	7	at	at	ADP
ijpds-3318	107	8	the	the	DET
ijpds-3318	107	9	initial	initial	ADJ
ijpds-3318	107	10	reading	reading	NOUN
ijpds-3318	107	11	(	(	PUNCT
ijpds-3318	107	12	week	week	NOUN
ijpds-3318	107	13	0	0	NUM
ijpds-3318	107	14	)	)	PUNCT
ijpds-3318	107	15	was	be	AUX
ijpds-3318	107	16	250mg	250mg	PROPN
ijpds-3318	107	17	/	/	SYM
ijpds-3318	107	18	dl	dl	PROPN
ijpds-3318	107	19	and	and	CCONJ
ijpds-3318	107	20	235mg	235mg	PROPN
ijpds-3318	107	21	/	/	SYM
ijpds-3318	107	22	dl	dl	PROPN
ijpds-3318	107	23	,	,	PUNCT
ijpds-3318	107	24	205mg	205mg	PROPN
ijpds-3318	107	25	/	/	SYM
ijpds-3318	107	26	dl	dl	PROPN
ijpds-3318	107	27	,	,	PUNCT
ijpds-3318	107	28	195mg	195mg	PROPN
ijpds-3318	107	29	/	/	SYM
ijpds-3318	107	30	dl	dl	PROPN
ijpds-3318	107	31	on	on	ADP
ijpds-3318	107	32	subsequent	subsequent	ADJ
ijpds-3318	107	33	follow	follow	NOUN
ijpds-3318	107	34	-	-	PUNCT
ijpds-3318	107	35	ups	up	NOUN
ijpds-3318	107	36	i.e.	i.e.	X
ijpds-3318	107	37	,	,	PUNCT
ijpds-3318	107	38	1st	1st	ADJ
ijpds-3318	107	39	,	,	PUNCT
ijpds-3318	107	40	2nd	2nd	ADJ
ijpds-3318	107	41	,	,	PUNCT
ijpds-3318	107	42	3rd	3rd	ADJ
ijpds-3318	107	43	follow	follow	NOUN
ijpds-3318	107	44	-	-	PUNCT
ijpds-3318	107	45	ups	up	NOUN
ijpds-3318	107	46	respectively	respectively	ADV
ijpds-3318	107	47	in	in	ADP
ijpds-3318	107	48	g	g	PROPN
ijpds-3318	107	49	-	-	PUNCT
ijpds-3318	107	50	m	m	NOUN
ijpds-3318	107	51	group	group	NOUN
ijpds-3318	107	52	patients	patient	NOUN
ijpds-3318	107	53	.	.	PUNCT
ijpds-3318	108	1	the	the	DET
ijpds-3318	108	2	difference	difference	NOUN
ijpds-3318	108	3	between	between	ADP
ijpds-3318	108	4	the	the	DET
ijpds-3318	108	5	initial	initial	ADJ
ijpds-3318	108	6	reading	reading	NOUN
ijpds-3318	108	7	and	and	CCONJ
ijpds-3318	108	8	final	final	ADJ
ijpds-3318	108	9	follow	follow	NOUN
ijpds-3318	108	10	-	-	PUNCT
ijpds-3318	108	11	up	up	NOUN
ijpds-3318	108	12	was	be	AUX
ijpds-3318	108	13	85mg	85mg	ADJ
ijpds-3318	108	14	/	/	SYM
ijpds-3318	108	15	dl	dl	PROPN
ijpds-3318	108	16	in	in	ADP
ijpds-3318	108	17	the	the	DET
ijpds-3318	108	18	v	v	PROPN
ijpds-3318	108	19	-	-	PUNCT
ijpds-3318	108	20	m	m	NOUN
ijpds-3318	108	21	group	group	NOUN
ijpds-3318	108	22	and	and	CCONJ
ijpds-3318	108	23	55mg	55mg	ADJ
ijpds-3318	108	24	/	/	SYM
ijpds-3318	108	25	dl	dl	PROPN
ijpds-3318	108	26	in	in	ADP
ijpds-3318	108	27	the	the	DET
ijpds-3318	108	28	g	g	PROPN
ijpds-3318	108	29	-	-	PUNCT
ijpds-3318	108	30	m	m	NOUN
ijpds-3318	108	31	group	group	NOUN
ijpds-3318	108	32	patients	patient	NOUN
ijpds-3318	108	33	.	.	PUNCT
ijpds-3318	109	1	it	it	PRON
ijpds-3318	109	2	was	be	AUX
ijpds-3318	109	3	noticed	notice	VERB
ijpds-3318	109	4	that	that	SCONJ
ijpds-3318	109	5	rbs	rbs	PROPN
ijpds-3318	109	6	was	be	AUX
ijpds-3318	109	7	notably	notably	ADV
ijpds-3318	109	8	depleted	deplete	VERB
ijpds-3318	109	9	in	in	ADP
ijpds-3318	109	10	v	v	ADP
ijpds-3318	109	11	-	-	PUNCT
ijpds-3318	109	12	m	m	NOUN
ijpds-3318	109	13	group	group	NOUN
ijpds-3318	109	14	patients	patient	NOUN
ijpds-3318	109	15	than	than	ADP
ijpds-3318	109	16	in	in	ADP
ijpds-3318	109	17	gm	gm	PROPN
ijpds-3318	109	18	group	group	NOUN
ijpds-3318	109	19	patients	patient	NOUN
ijpds-3318	109	20	.	.	PUNCT
ijpds-3318	110	1	the	the	DET
ijpds-3318	110	2	details	detail	NOUN
ijpds-3318	110	3	were	be	AUX
ijpds-3318	110	4	summarized	summarize	VERB
ijpds-3318	110	5	in	in	ADP
ijpds-3318	110	6	table	table	NOUN
ijpds-3318	110	7	3	3	NUM
ijpds-3318	110	8	.	.	PUNCT
ijpds-3318	111	1	in	in	ADP
ijpds-3318	111	2	terms	term	NOUN
ijpds-3318	111	3	of	of	ADP
ijpds-3318	111	4	safety	safety	NOUN
ijpds-3318	111	5	profile	profile	NOUN
ijpds-3318	111	6	,	,	PUNCT
ijpds-3318	111	7	adrs	adr	NOUN
ijpds-3318	111	8	were	be	AUX
ijpds-3318	111	9	considered	consider	VERB
ijpds-3318	111	10	.	.	PUNCT
ijpds-3318	112	1	in	in	ADP
ijpds-3318	112	2	the	the	DET
ijpds-3318	112	3	total	total	NOUN
ijpds-3318	112	4	of	of	ADP
ijpds-3318	112	5	50	50	NUM
ijpds-3318	112	6	patients	patient	NOUN
ijpds-3318	112	7	in	in	ADP
ijpds-3318	112	8	the	the	DET
ijpds-3318	112	9	v	v	PROPN
ijpds-3318	112	10	-	-	PUNCT
ijpds-3318	112	11	m	m	NOUN
ijpds-3318	112	12	group	group	NOUN
ijpds-3318	112	13	,	,	PUNCT
ijpds-3318	112	14	24	24	NUM
ijpds-3318	112	15	adverse	adverse	ADJ
ijpds-3318	112	16	drug	drug	NOUN
ijpds-3318	112	17	reactions	reaction	NOUN
ijpds-3318	112	18	were	be	AUX
ijpds-3318	112	19	noted	note	VERB
ijpds-3318	112	20	in	in	ADP
ijpds-3318	112	21	18	18	NUM
ijpds-3318	112	22	patients	patient	NOUN
ijpds-3318	112	23	.	.	PUNCT
ijpds-3318	113	1	the	the	DET
ijpds-3318	113	2	number	number	NOUN
ijpds-3318	113	3	of	of	ADP
ijpds-3318	113	4	adrs	adr	NOUN
ijpds-3318	113	5	with	with	ADP
ijpds-3318	113	6	respect	respect	NOUN
ijpds-3318	113	7	to	to	ADP
ijpds-3318	113	8	abdominal	abdominal	ADJ
ijpds-3318	113	9	pain	pain	NOUN
ijpds-3318	113	10	was	be	AUX
ijpds-3318	113	11	8	8	NUM
ijpds-3318	113	12	,	,	PUNCT
ijpds-3318	113	13	adrs	adr	NOUN
ijpds-3318	113	14	of	of	ADP
ijpds-3318	113	15	muscle	muscle	NOUN
ijpds-3318	113	16	tenderness	tenderness	NOUN
ijpds-3318	113	17	were	be	AUX
ijpds-3318	113	18	6	6	NUM
ijpds-3318	113	19	,	,	PUNCT
ijpds-3318	113	20	adrs	adr	NOUN
ijpds-3318	113	21	of	of	ADP
ijpds-3318	113	22	weight	weight	NOUN
ijpds-3318	113	23	gain	gain	NOUN
ijpds-3318	113	24	,	,	PUNCT
ijpds-3318	113	25	and	and	CCONJ
ijpds-3318	113	26	diarrhea	diarrhea	NOUN
ijpds-3318	113	27	were	be	AUX
ijpds-3318	113	28	4	4	NUM
ijpds-3318	113	29	,	,	PUNCT
ijpds-3318	113	30	and	and	CCONJ
ijpds-3318	113	31	adr	adr	PROPN
ijpds-3318	113	32	of	of	ADP
ijpds-3318	113	33	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	113	34	was	be	AUX
ijpds-3318	113	35	2	2	NUM
ijpds-3318	113	36	.	.	PUNCT
ijpds-3318	113	37	table	table	NOUN
ijpds-3318	113	38	3	3	NUM
ijpds-3318	113	39	:	:	PUNCT
ijpds-3318	113	40	comparison	comparison	NOUN
ijpds-3318	113	41	of	of	ADP
ijpds-3318	113	42	average	average	ADJ
ijpds-3318	113	43	rbs	rbs	NOUN
ijpds-3318	113	44	levels	level	NOUN
ijpds-3318	113	45	(	(	PUNCT
ijpds-3318	113	46	v	v	NOUN
ijpds-3318	113	47	-	-	PUNCT
ijpds-3318	113	48	m	m	NOUN
ijpds-3318	113	49	;	;	PUNCT
ijpds-3318	113	50	g	g	PROPN
ijpds-3318	113	51	-	-	PUNCT
ijpds-3318	113	52	m	m	NOUN
ijpds-3318	113	53	)	)	PUNCT
ijpds-3318	113	54	rbs	rbs	NOUN
ijpds-3318	113	55	(	(	PUNCT
ijpds-3318	113	56	mg	mg	PROPN
ijpds-3318	113	57	/	/	SYM
ijpds-3318	113	58	dl	dl	NOUN
ijpds-3318	113	59	)	)	PUNCT
ijpds-3318	113	60	monitoring	monitoring	NOUN
ijpds-3318	113	61	group	group	NOUN
ijpds-3318	113	62	initial	initial	ADJ
ijpds-3318	113	63	reading	reading	NOUN
ijpds-3318	113	64	1st	1st	PROPN
ijpds-3318	113	65	follow	follow	VERB
ijpds-3318	113	66	up	up	ADP
ijpds-3318	113	67	2nd	2nd	ADJ
ijpds-3318	113	68	follow	follow	VERB
ijpds-3318	113	69	up	up	ADP
ijpds-3318	113	70	3rd	3rd	ADJ
ijpds-3318	113	71	follow	follow	VERB
ijpds-3318	113	72	up	up	ADP
ijpds-3318	113	73	difference	difference	NOUN
ijpds-3318	113	74	between	between	ADP
ijpds-3318	113	75	initial	initial	ADJ
ijpds-3318	113	76	reading	reading	NOUN
ijpds-3318	113	77	and	and	CCONJ
ijpds-3318	113	78	3rd	3rd	NOUN
ijpds-3318	113	79	follow	follow	VERB
ijpds-3318	113	80	up	up	ADP
ijpds-3318	113	81	v	v	ADP
ijpds-3318	113	82	-	-	PUNCT
ijpds-3318	113	83	m	m	VERB
ijpds-3318	113	84	270	270	NUM
ijpds-3318	113	85	(	(	PUNCT
ijpds-3318	113	86	mg	mg	PROPN
ijpds-3318	113	87	/	/	SYM
ijpds-3318	113	88	dl	dl	NOUN
ijpds-3318	113	89	)	)	PUNCT
ijpds-3318	113	90	245	245	NUM
ijpds-3318	113	91	(	(	PUNCT
ijpds-3318	113	92	mg	mg	PROPN
ijpds-3318	113	93	/	/	SYM
ijpds-3318	113	94	dl	dl	NOUN
ijpds-3318	113	95	)	)	PUNCT
ijpds-3318	113	96	210	210	NUM
ijpds-3318	113	97	(	(	PUNCT
ijpds-3318	113	98	mg	mg	PROPN
ijpds-3318	113	99	/	/	SYM
ijpds-3318	113	100	dl	dl	NOUN
ijpds-3318	113	101	)	)	PUNCT
ijpds-3318	113	102	185	185	NUM
ijpds-3318	113	103	(	(	PUNCT
ijpds-3318	113	104	mg	mg	PROPN
ijpds-3318	113	105	/	/	SYM
ijpds-3318	113	106	dl	dl	NOUN
ijpds-3318	113	107	)	)	PUNCT
ijpds-3318	113	108	85	85	NUM
ijpds-3318	113	109	(	(	PUNCT
ijpds-3318	113	110	mg	mg	PROPN
ijpds-3318	113	111	/	/	SYM
ijpds-3318	113	112	dl	dl	NOUN
ijpds-3318	113	113	)	)	PUNCT
ijpds-3318	113	114	g	g	PROPN
ijpds-3318	113	115	-	-	PUNCT
ijpds-3318	113	116	m	m	VERB
ijpds-3318	113	117	250	250	NUM
ijpds-3318	113	118	(	(	PUNCT
ijpds-3318	113	119	mg	mg	PROPN
ijpds-3318	113	120	/	/	SYM
ijpds-3318	113	121	dl	dl	PROPN
ijpds-3318	113	122	)	)	PUNCT
ijpds-3318	113	123	235	235	NUM
ijpds-3318	113	124	(	(	PUNCT
ijpds-3318	113	125	mg	mg	PROPN
ijpds-3318	113	126	/	/	SYM
ijpds-3318	113	127	dl	dl	PROPN
ijpds-3318	113	128	)	)	PUNCT
ijpds-3318	113	129	205	205	NUM
ijpds-3318	113	130	(	(	PUNCT
ijpds-3318	113	131	mg	mg	PROPN
ijpds-3318	113	132	/	/	SYM
ijpds-3318	113	133	dl	dl	NOUN
ijpds-3318	113	134	)	)	PUNCT
ijpds-3318	113	135	195	195	NUM
ijpds-3318	113	136	(	(	PUNCT
ijpds-3318	113	137	mg	mg	PROPN
ijpds-3318	113	138	/	/	SYM
ijpds-3318	113	139	dl	dl	NOUN
ijpds-3318	113	140	)	)	PUNCT
ijpds-3318	113	141	55	55	NUM
ijpds-3318	113	142	(	(	PUNCT
ijpds-3318	113	143	mg	mg	PROPN
ijpds-3318	113	144	/	/	SYM
ijpds-3318	113	145	dl	dl	NOUN
ijpds-3318	113	146	)	)	PUNCT
ijpds-3318	113	147	in	in	ADP
ijpds-3318	113	148	the	the	DET
ijpds-3318	113	149	total	total	NOUN
ijpds-3318	113	150	of	of	ADP
ijpds-3318	113	151	50	50	NUM
ijpds-3318	113	152	patients	patient	NOUN
ijpds-3318	113	153	in	in	ADP
ijpds-3318	113	154	the	the	DET
ijpds-3318	113	155	g	g	PROPN
ijpds-3318	113	156	-	-	PUNCT
ijpds-3318	113	157	m	m	NOUN
ijpds-3318	113	158	group	group	NOUN
ijpds-3318	113	159	,	,	PUNCT
ijpds-3318	113	160	46	46	NUM
ijpds-3318	113	161	adverse	adverse	ADJ
ijpds-3318	113	162	drug	drug	NOUN
ijpds-3318	113	163	reactions	reaction	NOUN
ijpds-3318	113	164	were	be	AUX
ijpds-3318	113	165	noted	note	VERB
ijpds-3318	113	166	in	in	ADP
ijpds-3318	113	167	32	32	NUM
ijpds-3318	113	168	patients	patient	NOUN
ijpds-3318	113	169	.	.	PUNCT
ijpds-3318	114	1	the	the	DET
ijpds-3318	114	2	number	number	NOUN
ijpds-3318	114	3	of	of	ADP
ijpds-3318	114	4	adrs	adr	NOUN
ijpds-3318	114	5	with	with	ADP
ijpds-3318	114	6	respect	respect	NOUN
ijpds-3318	114	7	to	to	ADP
ijpds-3318	114	8	abdominal	abdominal	ADJ
ijpds-3318	114	9	pain	pain	NOUN
ijpds-3318	114	10	was	be	AUX
ijpds-3318	114	11	12	12	NUM
ijpds-3318	114	12	,	,	PUNCT
ijpds-3318	114	13	adrs	adr	NOUN
ijpds-3318	114	14	of	of	ADP
ijpds-3318	114	15	muscle	muscle	NOUN
ijpds-3318	114	16	tenderness	tenderness	NOUN
ijpds-3318	114	17	were	be	AUX
ijpds-3318	114	18	6	6	NUM
ijpds-3318	114	19	,	,	PUNCT
ijpds-3318	114	20	adrs	adr	NOUN
ijpds-3318	114	21	of	of	ADP
ijpds-3318	114	22	weight	weight	NOUN
ijpds-3318	114	23	gain	gain	NOUN
ijpds-3318	114	24	,	,	PUNCT
ijpds-3318	114	25	and	and	CCONJ
ijpds-3318	114	26	diarrhea	diarrhea	NOUN
ijpds-3318	114	27	were	be	AUX
ijpds-3318	114	28	10	10	NUM
ijpds-3318	114	29	,	,	PUNCT
ijpds-3318	114	30	and	and	CCONJ
ijpds-3318	114	31	adrs	adr	NOUN
ijpds-3318	114	32	of	of	ADP
ijpds-3318	114	33	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	114	34	was	be	AUX
ijpds-3318	114	35	8	8	NUM
ijpds-3318	114	36	,	,	PUNCT
ijpds-3318	114	37	which	which	PRON
ijpds-3318	114	38	were	be	AUX
ijpds-3318	114	39	represented	represent	VERB
ijpds-3318	114	40	in	in	ADP
ijpds-3318	114	41	table	table	NOUN
ijpds-3318	114	42	4	4	NUM
ijpds-3318	114	43	.	.	PUNCT
ijpds-3318	114	44	table	table	NOUN
ijpds-3318	114	45	4	4	NUM
ijpds-3318	114	46	:	:	PUNCT
ijpds-3318	114	47	comparison	comparison	NOUN
ijpds-3318	114	48	of	of	ADP
ijpds-3318	114	49	adverse	adverse	ADJ
ijpds-3318	114	50	drug	drug	NOUN
ijpds-3318	114	51	reactions	reaction	NOUN
ijpds-3318	114	52	(	(	PUNCT
ijpds-3318	114	53	v	v	NOUN
ijpds-3318	114	54	-	-	PUNCT
ijpds-3318	114	55	m	m	NOUN
ijpds-3318	114	56	;	;	PUNCT
ijpds-3318	114	57	g	g	PROPN
ijpds-3318	114	58	-	-	PUNCT
ijpds-3318	114	59	m	m	NOUN
ijpds-3318	114	60	)	)	PUNCT
ijpds-3318	114	61	adverserug	adverserug	NOUN
ijpds-3318	114	62	reactions	reaction	NOUN
ijpds-3318	114	63	v	v	PROPN
ijpds-3318	114	64	-	-	PUNCT
ijpds-3318	114	65	m	m	PROPN
ijpds-3318	114	66	(	(	PUNCT
ijpds-3318	114	67	n=24	n=24	PROPN
ijpds-3318	114	68	)	)	PUNCT
ijpds-3318	114	69	g	g	PROPN
ijpds-3318	114	70	-	-	PUNCT
ijpds-3318	114	71	m	m	PROPN
ijpds-3318	114	72	(	(	PUNCT
ijpds-3318	114	73	n=46	n=46	NOUN
ijpds-3318	114	74	)	)	PUNCT
ijpds-3318	114	75	number	number	NOUN
ijpds-3318	114	76	of	of	ADP
ijpds-3318	114	77	adr’s(n=70	adr’s(n=70	NOUN
ijpds-3318	114	78	)	)	PUNCT
ijpds-3318	114	79	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	114	80	2	2	NUM
ijpds-3318	114	81	8	8	NUM
ijpds-3318	114	82	10	10	NUM
ijpds-3318	114	83	weight	weight	NOUN
ijpds-3318	114	84	gain	gain	NOUN
ijpds-3318	114	85	4	4	NUM
ijpds-3318	114	86	10	10	NUM
ijpds-3318	114	87	14	14	NUM
ijpds-3318	114	88	muscle	muscle	NOUN
ijpds-3318	114	89	tenderness	tenderness	NOUN
ijpds-3318	114	90	6	6	NUM
ijpds-3318	114	91	6	6	NUM
ijpds-3318	114	92	12	12	NUM
ijpds-3318	114	93	abdominal	abdominal	ADJ
ijpds-3318	114	94	pain	pain	NOUN
ijpds-3318	114	95	8	8	NUM
ijpds-3318	114	96	12	12	NUM
ijpds-3318	114	97	20	20	NUM
ijpds-3318	114	98	diarrhea	diarrhea	NOUN
ijpds-3318	114	99	4	4	NUM
ijpds-3318	114	100	10	10	NUM
ijpds-3318	114	101	14	14	NUM
ijpds-3318	114	102	in	in	ADP
ijpds-3318	114	103	a	a	DET
ijpds-3318	114	104	total	total	NOUN
ijpds-3318	114	105	of	of	ADP
ijpds-3318	114	106	100	100	NUM
ijpds-3318	114	107	diabetic	diabetic	ADJ
ijpds-3318	114	108	patients	patient	NOUN
ijpds-3318	114	109	who	who	PRON
ijpds-3318	114	110	were	be	AUX
ijpds-3318	114	111	on	on	ADP
ijpds-3318	114	112	the	the	DET
ijpds-3318	114	113	treatment	treatment	NOUN
ijpds-3318	114	114	of	of	ADP
ijpds-3318	114	115	either	either	CCONJ
ijpds-3318	114	116	vildagliptinmetformin	vildagliptinmetformin	NOUN
ijpds-3318	114	117	or	or	CCONJ
ijpds-3318	114	118	glimepiridemetformin	glimepiridemetformin	NOUN
ijpds-3318	114	119	;	;	PUNCT
ijpds-3318	114	120	70	70	NUM
ijpds-3318	114	121	adverse	adverse	ADJ
ijpds-3318	114	122	drug	drug	NOUN
ijpds-3318	114	123	reactions	reaction	NOUN
ijpds-3318	114	124	were	be	AUX
ijpds-3318	114	125	experienced	experience	VERB
ijpds-3318	114	126	by	by	ADP
ijpds-3318	114	127	50	50	NUM
ijpds-3318	114	128	patients	patient	NOUN
ijpds-3318	114	129	.	.	PUNCT
ijpds-3318	115	1	the	the	DET
ijpds-3318	115	2	number	number	NOUN
ijpds-3318	115	3	of	of	ADP
ijpds-3318	115	4	adrs	adr	NOUN
ijpds-3318	115	5	with	with	ADP
ijpds-3318	115	6	respect	respect	NOUN
ijpds-3318	115	7	to	to	ADP
ijpds-3318	115	8	abdominal	abdominal	ADJ
ijpds-3318	115	9	pain	pain	NOUN
ijpds-3318	115	10	was	be	AUX
ijpds-3318	115	11	20	20	NUM
ijpds-3318	115	12	,	,	PUNCT
ijpds-3318	115	13	adrs	adr	NOUN
ijpds-3318	115	14	of	of	ADP
ijpds-3318	115	15	muscle	muscle	NOUN
ijpds-3318	115	16	tenderness	tenderness	NOUN
ijpds-3318	115	17	were	be	AUX
ijpds-3318	115	18	12	12	NUM
ijpds-3318	115	19	,	,	PUNCT
ijpds-3318	115	20	adrs	adr	NOUN
ijpds-3318	115	21	of	of	ADP
ijpds-3318	115	22	weight	weight	NOUN
ijpds-3318	115	23	gain	gain	NOUN
ijpds-3318	115	24	,	,	PUNCT
ijpds-3318	115	25	diarrhea	diarrhea	PROPN
ijpds-3318	115	26	were	be	AUX
ijpds-3318	115	27	14	14	NUM
ijpds-3318	115	28	,	,	PUNCT
ijpds-3318	115	29	and	and	CCONJ
ijpds-3318	115	30	adrs	adr	NOUN
ijpds-3318	115	31	of	of	ADP
ijpds-3318	115	32	hypoglycemia	hypoglycemia	NOUN
ijpds-3318	115	33	wwas10	wwas10	NOUN
ijpds-3318	115	34	.	.	PUNCT
ijpds-3318	116	1	in	in	ADP
ijpds-3318	116	2	comparison	comparison	NOUN
ijpds-3318	116	3	,	,	PUNCT
ijpds-3318	116	4	it	it	PRON
ijpds-3318	116	5	was	be	AUX
ijpds-3318	116	6	found	find	VERB
ijpds-3318	116	7	that	that	SCONJ
ijpds-3318	116	8	24	24	NUM
ijpds-3318	116	9	adverse	adverse	ADJ
ijpds-3318	116	10	drug	drug	NOUN
ijpds-3318	116	11	reactions	reaction	NOUN
ijpds-3318	116	12	were	be	AUX
ijpds-3318	116	13	experienced	experience	VERB
ijpds-3318	116	14	in	in	ADP
ijpds-3318	116	15	the	the	DET
ijpds-3318	116	16	v	v	NOUN
ijpds-3318	116	17	-	-	PUNCT
ijpds-3318	116	18	m	m	NOUN
ijpds-3318	116	19	group	group	NOUN
ijpds-3318	116	20	,	,	PUNCT
ijpds-3318	116	21	while	while	SCONJ
ijpds-3318	116	22	46	46	NUM
ijpds-3318	116	23	adverse	adverse	ADJ
ijpds-3318	116	24	drug	drug	NOUN
ijpds-3318	116	25	reactions	reaction	NOUN
ijpds-3318	116	26	were	be	AUX
ijpds-3318	116	27	experienced	experience	VERB
ijpds-3318	116	28	in	in	ADP
ijpds-3318	116	29	the	the	DET
ijpds-3318	116	30	g	g	PROPN
ijpds-3318	116	31	-	-	PUNCT
ijpds-3318	116	32	m	m	NOUN
ijpds-3318	116	33	group	group	NOUN
ijpds-3318	116	34	.	.	PUNCT
ijpds-3318	117	1	details	detail	NOUN
ijpds-3318	117	2	were	be	AUX
ijpds-3318	117	3	outlined	outline	VERB
ijpds-3318	117	4	in	in	ADP
ijpds-3318	117	5	table	table	NOUN
ijpds-3318	117	6	5	5	NUM
ijpds-3318	117	7	.	.	PUNCT
ijpds-3318	118	1	on	on	ADP
ijpds-3318	118	2	evaluation	evaluation	NOUN
ijpds-3318	118	3	,	,	PUNCT
ijpds-3318	118	4	it	it	PRON
ijpds-3318	118	5	was	be	AUX
ijpds-3318	118	6	observed	observe	VERB
ijpds-3318	118	7	that	that	SCONJ
ijpds-3318	118	8	there	there	PRON
ijpds-3318	118	9	was	be	VERB
ijpds-3318	118	10	a	a	DET
ijpds-3318	118	11	significant	significant	ADJ
ijpds-3318	118	12	variation	variation	NOUN
ijpds-3318	118	13	between	between	ADP
ijpds-3318	118	14	the	the	DET
ijpds-3318	118	15	average	average	ADJ
ijpds-3318	118	16	hba1c	hba1c	PROPN
ijpds-3318	118	17	levels	level	NOUN
ijpds-3318	118	18	at	at	ADP
ijpds-3318	118	19	the	the	DET
ijpds-3318	118	20	initial	initial	ADJ
ijpds-3318	118	21	reading	reading	NOUN
ijpds-3318	118	22	and	and	CCONJ
ijpds-3318	118	23	at	at	ADP
ijpds-3318	118	24	the	the	DET
ijpds-3318	118	25	end	end	NOUN
ijpds-3318	118	26	of	of	ADP
ijpds-3318	118	27	the	the	DET
ijpds-3318	118	28	study	study	NOUN
ijpds-3318	118	29	i.e.	i.e.	ADV
ijpds-3318	118	30	,	,	PUNCT
ijpds-3318	118	31	at	at	ADP
ijpds-3318	118	32	the	the	DET
ijpds-3318	118	33	end	end	NOUN
ijpds-3318	118	34	of	of	ADP
ijpds-3318	118	35	12	12	NUM
ijpds-3318	118	36	weeks	week	NOUN
ijpds-3318	118	37	in	in	ADP
ijpds-3318	118	38	both	both	DET
ijpds-3318	118	39	groups	group	NOUN
ijpds-3318	118	40	and	and	CCONJ
ijpds-3318	118	41	the	the	DET
ijpds-3318	118	42	greatest	great	ADJ
ijpds-3318	118	43	reduction	reduction	NOUN
ijpds-3318	118	44	was	be	AUX
ijpds-3318	118	45	observed	observe	VERB
ijpds-3318	118	46	in	in	ADP
ijpds-3318	118	47	v	v	ADP
ijpds-3318	118	48	-	-	PUNCT
ijpds-3318	118	49	m	m	NOUN
ijpds-3318	118	50	group	group	NOUN
ijpds-3318	118	51	patients	patient	NOUN
ijpds-3318	118	52	than	than	ADP
ijpds-3318	118	53	in	in	ADP
ijpds-3318	118	54	g	g	PROPN
ijpds-3318	118	55	-	-	PUNCT
ijpds-3318	118	56	m	m	NOUN
ijpds-3318	118	57	group	group	NOUN
ijpds-3318	118	58	patients	patient	NOUN
ijpds-3318	118	59	.	.	PUNCT
ijpds-3318	119	1	table	table	NOUN
ijpds-3318	119	2	5	5	NUM
ijpds-3318	119	3	:	:	PUNCT
ijpds-3318	119	4	comparison	comparison	NOUN
ijpds-3318	119	5	of	of	ADP
ijpds-3318	119	6	overall	overall	ADJ
ijpds-3318	119	7	adverse	adverse	ADJ
ijpds-3318	119	8	drug	drug	NOUN
ijpds-3318	119	9	reactions	reaction	NOUN
ijpds-3318	119	10	(	(	PUNCT
ijpds-3318	119	11	vm	vm	NOUN
ijpds-3318	119	12	;	;	PUNCT
ijpds-3318	119	13	g	g	PROPN
ijpds-3318	119	14	-	-	PUNCT
ijpds-3318	119	15	m	m	NOUN
ijpds-3318	119	16	)	)	PUNCT
ijpds-3318	119	17	regimen	regimen	NOUN
ijpds-3318	119	18	number	number	NOUN
ijpds-3318	119	19	of	of	ADP
ijpds-3318	119	20	adrs	adrs	ADJ
ijpds-3318	119	21	percentage	percentage	NOUN
ijpds-3318	119	22	of	of	ADP
ijpds-3318	119	23	adrs	adrs	PROPN
ijpds-3318	119	24	v	v	PROPN
ijpds-3318	119	25	-	-	PUNCT
ijpds-3318	119	26	m	m	PROPN
ijpds-3318	119	27	24	24	NUM
ijpds-3318	119	28	36	36	NUM
ijpds-3318	119	29	%	%	NOUN
ijpds-3318	119	30	g	g	NOUN
ijpds-3318	119	31	-	-	PUNCT
ijpds-3318	119	32	m	m	VERB
ijpds-3318	119	33	46	46	NUM
ijpds-3318	119	34	65	65	NUM
ijpds-3318	119	35	%	%	NOUN
ijpds-3318	119	36	there	there	PRON
ijpds-3318	119	37	was	be	VERB
ijpds-3318	119	38	a	a	DET
ijpds-3318	119	39	significant	significant	ADJ
ijpds-3318	119	40	reduction	reduction	NOUN
ijpds-3318	119	41	in	in	ADP
ijpds-3318	119	42	fbs	fbs	PROPN
ijpds-3318	119	43	and	and	CCONJ
ijpds-3318	119	44	rbs	rbs	PROPN
ijpds-3318	119	45	levels	level	NOUN
ijpds-3318	119	46	on	on	ADP
ijpds-3318	119	47	subsequent	subsequent	ADJ
ijpds-3318	119	48	follow	follow	NOUN
ijpds-3318	119	49	-	-	PUNCT
ijpds-3318	119	50	ups	up	NOUN
ijpds-3318	119	51	in	in	ADP
ijpds-3318	119	52	each	each	DET
ijpds-3318	119	53	group	group	NOUN
ijpds-3318	119	54	and	and	CCONJ
ijpds-3318	119	55	a	a	DET
ijpds-3318	119	56	slightly	slightly	ADV
ijpds-3318	119	57	highest	high	ADJ
ijpds-3318	119	58	reduction	reduction	NOUN
ijpds-3318	119	59	was	be	AUX
ijpds-3318	119	60	observed	observe	VERB
ijpds-3318	119	61	in	in	ADP
ijpds-3318	119	62	the	the	DET
ijpds-3318	119	63	v	v	NOUN
ijpds-3318	119	64	-	-	PUNCT
ijpds-3318	119	65	m	m	NOUN
ijpds-3318	119	66	group	group	NOUN
ijpds-3318	119	67	than	than	ADP
ijpds-3318	119	68	in	in	ADP
ijpds-3318	119	69	gm	gm	PROPN
ijpds-3318	119	70	group	group	NOUN
ijpds-3318	119	71	patients	patient	NOUN
ijpds-3318	119	72	.	.	PUNCT
ijpds-3318	120	1	in	in	ADP
ijpds-3318	120	2	safety	safety	NOUN
ijpds-3318	120	3	profile	profile	NOUN
ijpds-3318	120	4	,	,	PUNCT
ijpds-3318	120	5	there	there	PRON
ijpds-3318	120	6	was	be	VERB
ijpds-3318	120	7	a	a	DET
ijpds-3318	120	8	significant	significant	ADJ
ijpds-3318	120	9	difference	difference	NOUN
ijpds-3318	120	10	between	between	ADP
ijpds-3318	120	11	both	both	DET
ijpds-3318	120	12	groups	group	NOUN
ijpds-3318	120	13	,	,	PUNCT
ijpds-3318	120	14	and	and	CCONJ
ijpds-3318	120	15	most	most	ADJ
ijpds-3318	120	16	of	of	ADP
ijpds-3318	120	17	the	the	DET
ijpds-3318	120	18	adrs	adr	NOUN
ijpds-3318	120	19	were	be	AUX
ijpds-3318	120	20	observed	observe	VERB
ijpds-3318	120	21	in	in	ADP
ijpds-3318	120	22	kareenmulla	kareenmulla	PROPN
ijpds-3318	120	23	et	et	PROPN
ijpds-3318	120	24	al	al	PROPN
ijpds-3318	120	25	efficacy	efficacy	PROPN
ijpds-3318	120	26	,	,	PUNCT
ijpds-3318	120	27	safety	safety	NOUN
ijpds-3318	120	28	of	of	ADP
ijpds-3318	120	29	vildagliptin	vildagliptin	NOUN
ijpds-3318	120	30	-	-	PUNCT
ijpds-3318	120	31	metformin	metformin	NOUN
ijpds-3318	120	32	versus	versus	ADP
ijpds-3318	120	33	glimepiride	glimepiride	NOUN
ijpds-3318	120	34	-	-	PUNCT
ijpds-3318	120	35	metformin	metformin	NOUN
ijpds-3318	120	36	vol	vol	NOUN
ijpds-3318	120	37	1	1	NUM
ijpds-3318	121	1	|	|	NOUN
ijpds-3318	121	2	issue	issue	NOUN
ijpds-3318	121	3	2	2	NUM
ijpds-3318	122	1	|	|	ADV
ijpds-3318	122	2	jul	jul	PROPN
ijpds-3318	122	3	sep	sep	PROPN
ijpds-3318	122	4	2022	2022	NUM
ijpds-3318	122	5	indian	indian	PROPN
ijpds-3318	122	6	j	j	PROPN
ijpds-3318	122	7	pharm	pharm	PROPN
ijpds-3318	122	8	drug	drug	PROPN
ijpds-3318	122	9	studies	study	NOUN
ijpds-3318	122	10	|	|	ADV
ijpds-3318	122	11	67	67	NUM
ijpds-3318	122	12	g	g	NOUN
ijpds-3318	122	13	-	-	PUNCT
ijpds-3318	122	14	m	m	NOUN
ijpds-3318	122	15	group	group	NOUN
ijpds-3318	122	16	patients	patient	NOUN
ijpds-3318	122	17	than	than	ADP
ijpds-3318	122	18	in	in	ADP
ijpds-3318	122	19	v	v	ADP
ijpds-3318	122	20	-	-	PUNCT
ijpds-3318	122	21	m	m	NOUN
ijpds-3318	122	22	group	group	NOUN
ijpds-3318	122	23	patients	patient	NOUN
ijpds-3318	122	24	.	.	PUNCT
ijpds-3318	123	1	for	for	ADP
ijpds-3318	123	2	years	year	NOUN
ijpds-3318	123	3	,	,	PUNCT
ijpds-3318	123	4	the	the	DET
ijpds-3318	123	5	american	american	ADJ
ijpds-3318	123	6	diabetes	diabetes	PROPN
ijpds-3318	123	7	association	association	PROPN
ijpds-3318	123	8	(	(	PUNCT
ijpds-3318	123	9	ada	ada	PROPN
ijpds-3318	123	10	)	)	PUNCT
ijpds-3318	123	11	has	have	AUX
ijpds-3318	123	12	recommended	recommend	VERB
ijpds-3318	123	13	that	that	SCONJ
ijpds-3318	123	14	all	all	DET
ijpds-3318	123	15	people	people	NOUN
ijpds-3318	123	16	with	with	ADP
ijpds-3318	123	17	diabetes	diabetes	NOUN
ijpds-3318	123	18	aim	aim	VERB
ijpds-3318	123	19	for	for	ADP
ijpds-3318	123	20	a	a	DET
ijpds-3318	123	21	target	target	NOUN
ijpds-3318	123	22	hemoglobin	hemoglobin	NOUN
ijpds-3318	124	1	hba1c	hba1c	NOUN
ijpds-3318	124	2	level	level	NOUN
ijpds-3318	124	3	below	below	ADP
ijpds-3318	124	4	7	7	NUM
ijpds-3318	124	5	percent	percent	NOUN
ijpds-3318	124	6	.	.	PUNCT
ijpds-3318	125	1	even	even	ADV
ijpds-3318	125	2	more	more	ADV
ijpds-3318	125	3	stringent	stringent	ADJ
ijpds-3318	125	4	,	,	PUNCT
ijpds-3318	125	5	the	the	DET
ijpds-3318	125	6	american	american	PROPN
ijpds-3318	125	7	association	association	PROPN
ijpds-3318	125	8	of	of	ADP
ijpds-3318	125	9	clinical	clinical	ADJ
ijpds-3318	125	10	endocrinologists	endocrinologist	NOUN
ijpds-3318	125	11	(	(	PUNCT
ijpds-3318	125	12	aace	aace	NOUN
ijpds-3318	125	13	)	)	PUNCT
ijpds-3318	125	14	recommends	recommend	VERB
ijpds-3318	125	15	hba1c	hba1c	PRON
ijpds-3318	125	16	targets	target	NOUN
ijpds-3318	125	17	below	below	ADP
ijpds-3318	125	18	6.5	6.5	NUM
ijpds-3318	125	19	percent	percent	NOUN
ijpds-3318	125	20	.	.	PUNCT
ijpds-3318	126	1	although	although	SCONJ
ijpds-3318	126	2	there	there	PRON
ijpds-3318	126	3	's	be	VERB
ijpds-3318	126	4	no	no	DET
ijpds-3318	126	5	cure	cure	NOUN
ijpds-3318	126	6	for	for	ADP
ijpds-3318	126	7	type	type	NOUN
ijpds-3318	126	8	2	2	NUM
ijpds-3318	126	9	diabetes	diabetes	NOUN
ijpds-3318	126	10	.	.	PUNCT
ijpds-3318	127	1	studies	study	NOUN
ijpds-3318	127	2	show	show	VERB
ijpds-3318	127	3	that	that	SCONJ
ijpds-3318	127	4	it	it	PRON
ijpds-3318	127	5	is	be	AUX
ijpds-3318	127	6	possible	possible	ADJ
ijpds-3318	127	7	to	to	PART
ijpds-3318	127	8	reverse	reverse	VERB
ijpds-3318	127	9	diabetes	diabetes	NOUN
ijpds-3318	127	10	through	through	ADP
ijpds-3318	127	11	diet	diet	NOUN
ijpds-3318	127	12	changes	change	NOUN
ijpds-3318	127	13	and	and	CCONJ
ijpds-3318	127	14	weight	weight	NOUN
ijpds-3318	127	15	loss	loss	NOUN
ijpds-3318	127	16	can	can	AUX
ijpds-3318	127	17	hold	hold	VERB
ijpds-3318	127	18	normal	normal	ADJ
ijpds-3318	127	19	blood	blood	NOUN
ijpds-3318	127	20	sugar	sugar	NOUN
ijpds-3318	127	21	levels	level	NOUN
ijpds-3318	127	22	without	without	ADP
ijpds-3318	127	23	medication	medication	NOUN
ijpds-3318	127	24	.	.	PUNCT
ijpds-3318	128	1	comparing	compare	VERB
ijpds-3318	128	2	the	the	DET
ijpds-3318	128	3	efficacy	efficacy	NOUN
ijpds-3318	128	4	and	and	CCONJ
ijpds-3318	128	5	safety	safety	NOUN
ijpds-3318	128	6	profiles	profile	NOUN
ijpds-3318	128	7	of	of	ADP
ijpds-3318	128	8	the	the	DET
ijpds-3318	128	9	metformin	metformin	NOUN
ijpds-3318	128	10	-	-	PUNCT
ijpds-3318	128	11	vildagliptin	vildagliptin	NOUN
ijpds-3318	128	12	regimen	regimen	NOUN
ijpds-3318	128	13	with	with	ADP
ijpds-3318	128	14	metforminglimepiride	metforminglimepiride	NOUN
ijpds-3318	128	15	regimen	regimen	NOUN
ijpds-3318	128	16	is	be	AUX
ijpds-3318	128	17	the	the	DET
ijpds-3318	128	18	main	main	ADJ
ijpds-3318	128	19	objective	objective	NOUN
ijpds-3318	128	20	of	of	ADP
ijpds-3318	128	21	the	the	DET
ijpds-3318	128	22	research	research	NOUN
ijpds-3318	128	23	study	study	NOUN
ijpds-3318	128	24	.	.	PUNCT
ijpds-3318	129	1	this	this	DET
ijpds-3318	129	2	research	research	NOUN
ijpds-3318	129	3	study	study	NOUN
ijpds-3318	129	4	may	may	AUX
ijpds-3318	129	5	contribute	contribute	VERB
ijpds-3318	129	6	to	to	ADP
ijpds-3318	129	7	clinical	clinical	ADJ
ijpds-3318	129	8	oriental	oriental	ADJ
ijpds-3318	129	9	sails	sail	NOUN
ijpds-3318	129	10	in	in	ADP
ijpds-3318	129	11	the	the	DET
ijpds-3318	129	12	future	future	NOUN
ijpds-3318	129	13	.	.	PUNCT
ijpds-3318	130	1	yet	yet	ADV
ijpds-3318	130	2	,	,	PUNCT
ijpds-3318	130	3	some	some	PRON
ijpds-3318	130	4	more	more	ADJ
ijpds-3318	130	5	studies	study	NOUN
ijpds-3318	130	6	are	be	AUX
ijpds-3318	130	7	needed	need	VERB
ijpds-3318	130	8	to	to	PART
ijpds-3318	130	9	make	make	VERB
ijpds-3318	130	10	statistically	statistically	ADV
ijpds-3318	130	11	significant	significant	ADJ
ijpds-3318	130	12	conclusions	conclusion	NOUN
ijpds-3318	130	13	.	.	PUNCT
ijpds-3318	131	1	conclusion	conclusion	NOUN
ijpds-3318	131	2	clearly	clearly	ADV
ijpds-3318	131	3	,	,	PUNCT
ijpds-3318	131	4	it	it	PRON
ijpds-3318	131	5	is	be	AUX
ijpds-3318	131	6	proved	prove	VERB
ijpds-3318	131	7	that	that	SCONJ
ijpds-3318	131	8	a	a	DET
ijpds-3318	131	9	combination	combination	NOUN
ijpds-3318	131	10	of	of	ADP
ijpds-3318	131	11	vildagliptin	vildagliptin	NOUN
ijpds-3318	131	12	and	and	CCONJ
ijpds-3318	131	13	metformin	metformin	NOUN
ijpds-3318	131	14	provided	provide	VERB
ijpds-3318	131	15	better	well	ADJ
ijpds-3318	131	16	blood	blood	NOUN
ijpds-3318	131	17	glucose	glucose	NOUN
ijpds-3318	131	18	control	control	NOUN
ijpds-3318	131	19	,	,	PUNCT
ijpds-3318	131	20	compared	compare	VERB
ijpds-3318	131	21	to	to	ADP
ijpds-3318	131	22	that	that	PRON
ijpds-3318	131	23	of	of	ADP
ijpds-3318	131	24	glimepiride	glimepiride	NOUN
ijpds-3318	131	25	-	-	PUNCT
ijpds-3318	131	26	metformin	metformin	NOUN
ijpds-3318	131	27	treatment	treatment	NOUN
ijpds-3318	131	28	.	.	PUNCT
ijpds-3318	132	1	on	on	ADP
ijpds-3318	132	2	evaluating	evaluate	VERB
ijpds-3318	132	3	the	the	DET
ijpds-3318	132	4	adverse	adverse	ADJ
ijpds-3318	132	5	drug	drug	NOUN
ijpds-3318	132	6	reactions	reaction	NOUN
ijpds-3318	132	7	,	,	PUNCT
ijpds-3318	132	8	treatment	treatment	NOUN
ijpds-3318	132	9	with	with	ADP
ijpds-3318	132	10	vildagliptinmetformin	vildagliptinmetformin	NOUN
ijpds-3318	132	11	does	do	AUX
ijpds-3318	132	12	not	not	PART
ijpds-3318	132	13	appear	appear	VERB
ijpds-3318	132	14	to	to	PART
ijpds-3318	132	15	be	be	AUX
ijpds-3318	132	16	associated	associate	VERB
ijpds-3318	132	17	with	with	ADP
ijpds-3318	132	18	many	many	ADJ
ijpds-3318	132	19	adverse	adverse	ADJ
ijpds-3318	132	20	events	event	NOUN
ijpds-3318	132	21	as	as	ADP
ijpds-3318	132	22	treatment	treatment	NOUN
ijpds-3318	132	23	with	with	ADP
ijpds-3318	132	24	glimepiride	glimepiride	NOUN
ijpds-3318	132	25	-	-	PUNCT
ijpds-3318	132	26	metformin	metformin	NOUN
ijpds-3318	132	27	.	.	PUNCT
ijpds-3318	133	1	also	also	ADV
ijpds-3318	133	2	,	,	PUNCT
ijpds-3318	133	3	the	the	DET
ijpds-3318	133	4	risk	risk	NOUN
ijpds-3318	133	5	of	of	ADP
ijpds-3318	133	6	weightgain	weightgain	PROPN
ijpds-3318	133	7	is	be	AUX
ijpds-3318	133	8	lower	low	ADJ
ijpds-3318	133	9	in	in	ADP
ijpds-3318	133	10	v	v	ADP
ijpds-3318	133	11	-	-	PUNCT
ijpds-3318	133	12	m	m	NOUN
ijpds-3318	133	13	group	group	NOUN
ijpds-3318	133	14	when	when	SCONJ
ijpds-3318	133	15	compared	compare	VERB
ijpds-3318	133	16	to	to	ADP
ijpds-3318	133	17	g	g	PROPN
ijpds-3318	133	18	-	-	PUNCT
ijpds-3318	133	19	m	m	NOUN
ijpds-3318	133	20	group	group	NOUN
ijpds-3318	133	21	.	.	PUNCT
ijpds-3318	134	1	the	the	DET
ijpds-3318	134	2	investigators	investigator	NOUN
ijpds-3318	134	3	concluded	conclude	VERB
ijpds-3318	134	4	vildagliptin	vildagliptin	NOUN
ijpds-3318	134	5	-	-	PUNCT
ijpds-3318	134	6	metformin	metformin	NOUN
ijpds-3318	134	7	regimen	regimen	NOUN
ijpds-3318	134	8	is	be	AUX
ijpds-3318	134	9	not	not	PART
ijpds-3318	134	10	only	only	ADV
ijpds-3318	134	11	safer	safe	ADJ
ijpds-3318	134	12	but	but	CCONJ
ijpds-3318	134	13	also	also	ADV
ijpds-3318	134	14	more	more	ADV
ijpds-3318	134	15	effective	effective	ADJ
ijpds-3318	134	16	than	than	ADP
ijpds-3318	134	17	glimepiride	glimepiride	NOUN
ijpds-3318	134	18	-	-	PUNCT
ijpds-3318	134	19	metformin	metformin	NOUN
ijpds-3318	134	20	regimen	regiman	NOUN
ijpds-3318	134	21	.	.	PUNCT
ijpds-3318	135	1	although	although	SCONJ
ijpds-3318	135	2	there	there	PRON
ijpds-3318	135	3	is	be	VERB
ijpds-3318	135	4	no	no	DET
ijpds-3318	135	5	permanent	permanent	ADJ
ijpds-3318	135	6	cure	cure	NOUN
ijpds-3318	135	7	for	for	ADP
ijpds-3318	135	8	type	type	NOUN
ijpds-3318	135	9	2	2	NUM
ijpds-3318	135	10	diabetic	diabetic	ADJ
ijpds-3318	135	11	patients	patient	NOUN
ijpds-3318	135	12	it	it	PRON
ijpds-3318	135	13	is	be	AUX
ijpds-3318	135	14	recommended	recommend	VERB
ijpds-3318	135	15	that	that	SCONJ
ijpds-3318	135	16	,	,	PUNCT
ijpds-3318	135	17	people	people	NOUN
ijpds-3318	135	18	with	with	ADP
ijpds-3318	135	19	diabetes	diabetes	NOUN
ijpds-3318	135	20	should	should	AUX
ijpds-3318	135	21	choose	choose	VERB
ijpds-3318	135	22	a	a	DET
ijpds-3318	135	23	variety	variety	NOUN
ijpds-3318	135	24	of	of	ADP
ijpds-3318	135	25	fiber	fiber	NOUN
ijpds-3318	135	26	-	-	PUNCT
ijpds-3318	135	27	foods	food	NOUN
ijpds-3318	135	28	such	such	ADJ
ijpds-3318	135	29	as	as	ADP
ijpds-3318	135	30	legumes	legume	NOUN
ijpds-3318	135	31	,	,	PUNCT
ijpds-3318	135	32	fiber	fiber	NOUN
ijpds-3318	135	33	-	-	PUNCT
ijpds-3318	135	34	rich	rich	ADJ
ijpds-3318	135	35	cereals	cereal	NOUN
ijpds-3318	135	36	(	(	PUNCT
ijpds-3318	135	37	≥	≥	NUM
ijpds-3318	135	38	8	8	NUM
ijpds-3318	135	39	gm	gm	PROPN
ijpds-3318	135	40	fiber	fiber	NOUN
ijpds-3318	135	41	/	/	SYM
ijpds-3318	135	42	serving	serve	VERB
ijpds-3318	135	43	)	)	PUNCT
ijpds-3318	135	44	,	,	PUNCT
ijpds-3318	135	45	fruits	fruit	NOUN
ijpds-3318	135	46	,	,	PUNCT
ijpds-3318	135	47	vegetables	vegetable	NOUN
ijpds-3318	135	48	,	,	PUNCT
ijpds-3318	135	49	and	and	CCONJ
ijpds-3318	135	50	whole	whole	ADJ
ijpds-3318	135	51	grain	grain	NOUN
ijpds-3318	135	52	products	product	NOUN
ijpds-3318	135	53	as	as	SCONJ
ijpds-3318	135	54	they	they	PRON
ijpds-3318	135	55	provide	provide	VERB
ijpds-3318	135	56	vitamins	vitamin	NOUN
ijpds-3318	135	57	,	,	PUNCT
ijpds-3318	135	58	minerals	mineral	NOUN
ijpds-3318	135	59	and	and	CCONJ
ijpds-3318	135	60	other	other	ADJ
ijpds-3318	135	61	substances	substance	NOUN
ijpds-3318	135	62	important	important	ADJ
ijpds-3318	135	63	for	for	ADP
ijpds-3318	135	64	good	good	ADJ
ijpds-3318	135	65	health	health	NOUN
ijpds-3318	135	66	.	.	PUNCT
ijpds-3318	136	1	studies	study	NOUN
ijpds-3318	136	2	shows	show	VERB
ijpds-3318	136	3	that	that	SCONJ
ijpds-3318	136	4	it	it	PRON
ijpds-3318	136	5	is	be	AUX
ijpds-3318	136	6	possible	possible	ADJ
ijpds-3318	136	7	to	to	PART
ijpds-3318	136	8	reverse	reverse	VERB
ijpds-3318	136	9	diabetes	diabetes	NOUN
ijpds-3318	136	10	and	and	CCONJ
ijpds-3318	136	11	maintain	maintain	VERB
ijpds-3318	136	12	normal	normal	ADJ
ijpds-3318	136	13	blood	blood	NOUN
ijpds-3318	136	14	sugar	sugar	NOUN
ijpds-3318	136	15	levels	level	NOUN
ijpds-3318	136	16	without	without	ADP
ijpds-3318	136	17	medication	medication	NOUN
ijpds-3318	136	18	through	through	ADP
ijpds-3318	136	19	diet	diet	NOUN
ijpds-3318	136	20	changes	change	NOUN
ijpds-3318	136	21	and	and	CCONJ
ijpds-3318	136	22	weight	weight	NOUN
ijpds-3318	136	23	loss	loss	NOUN
ijpds-3318	136	24	.	.	PUNCT
ijpds-3318	137	1	this	this	DET
ijpds-3318	137	2	research	research	NOUN
ijpds-3318	137	3	study	study	NOUN
ijpds-3318	137	4	may	may	AUX
ijpds-3318	137	5	contribute	contribute	VERB
ijpds-3318	137	6	clinical	clinical	ADJ
ijpds-3318	137	7	oriented	orient	VERB
ijpds-3318	137	8	trails	trail	NOUN
ijpds-3318	137	9	in	in	ADP
ijpds-3318	137	10	future	future	NOUN
ijpds-3318	137	11	.	.	PUNCT
ijpds-3318	138	1	yet	yet	ADV
ijpds-3318	138	2	,	,	PUNCT
ijpds-3318	138	3	some	some	PRON
ijpds-3318	138	4	more	more	ADJ
ijpds-3318	138	5	studies	study	NOUN
ijpds-3318	138	6	are	be	AUX
ijpds-3318	138	7	needed	need	VERB
ijpds-3318	138	8	to	to	PART
ijpds-3318	138	9	make	make	VERB
ijpds-3318	138	10	statistically	statistically	ADV
ijpds-3318	138	11	significant	significant	ADJ
ijpds-3318	138	12	conclusions	conclusion	NOUN
ijpds-3318	138	13	.	.	PUNCT
ijpds-3318	139	1	abbrevatons	abbrevaton	NOUN
ijpds-3318	139	2	ada	ada	PROPN
ijpds-3318	139	3	:	:	PUNCT
ijpds-3318	139	4	american	american	ADJ
ijpds-3318	139	5	diabetes	diabetes	PROPN
ijpds-3318	139	6	association	association	PROPN
ijpds-3318	139	7	;	;	PUNCT
ijpds-3318	139	8	adr	adr	PROPN
ijpds-3318	139	9	:	:	PUNCT
ijpds-3318	139	10	adverse	adverse	ADJ
ijpds-3318	139	11	drug	drug	NOUN
ijpds-3318	139	12	reaction	reaction	NOUN
ijpds-3318	139	13	;	;	PUNCT
ijpds-3318	139	14	anova	anova	X
ijpds-3318	139	15	:	:	PUNCT
ijpds-3318	139	16	analysis	analysis	NOUN
ijpds-3318	139	17	of	of	ADP
ijpds-3318	139	18	variance	variance	NOUN
ijpds-3318	139	19	;	;	PUNCT
ijpds-3318	139	20	bmd	bmd	PROPN
ijpds-3318	139	21	:	:	PUNCT
ijpds-3318	139	22	bone	bone	NOUN
ijpds-3318	139	23	mineral	mineral	NOUN
ijpds-3318	139	24	density	density	NOUN
ijpds-3318	139	25	;	;	PUNCT
ijpds-3318	139	26	bmi	bmi	PROPN
ijpds-3318	139	27	:	:	PUNCT
ijpds-3318	139	28	body	body	NOUN
ijpds-3318	139	29	mass	mass	PROPN
ijpds-3318	139	30	index	index	NOUN
ijpds-3318	139	31	;	;	PUNCT
ijpds-3318	139	32	cdc	cdc	PROPN
ijpds-3318	139	33	:	:	PUNCT
ijpds-3318	139	34	centres	centre	NOUN
ijpds-3318	139	35	for	for	ADP
ijpds-3318	139	36	disease	disease	NOUN
ijpds-3318	139	37	control	control	NOUN
ijpds-3318	139	38	and	and	CCONJ
ijpds-3318	139	39	prevention	prevention	NOUN
ijpds-3318	139	40	;	;	PUNCT
ijpds-3318	139	41	chd	chd	NOUN
ijpds-3318	139	42	:	:	PUNCT
ijpds-3318	139	43	coronary	coronary	ADJ
ijpds-3318	139	44	heart	heart	NOUN
ijpds-3318	139	45	disease	disease	NOUN
ijpds-3318	139	46	;	;	PUNCT
ijpds-3318	139	47	ci	ci	NOUN
ijpds-3318	139	48	:	:	PUNCT
ijpds-3318	139	49	class	class	NOUN
ijpds-3318	139	50	interval	interval	NOUN
ijpds-3318	139	51	;	;	PUNCT
ijpds-3318	139	52	cvd	cvd	NOUN
ijpds-3318	139	53	:	:	PUNCT
ijpds-3318	139	54	cardio	cardio	ADJ
ijpds-3318	139	55	vascular	vascular	ADJ
ijpds-3318	139	56	diseases	disease	NOUN
ijpds-3318	139	57	;	;	PUNCT
ijpds-3318	139	58	dm	dm	NUM
ijpds-3318	139	59	:	:	PUNCT
ijpds-3318	139	60	diabetes	diabetes	NOUN
ijpds-3318	139	61	mellitus	mellitus	NOUN
ijpds-3318	139	62	;	;	PUNCT
ijpds-3318	139	63	dme	dme	PROPN
ijpds-3318	139	64	:	:	PUNCT
ijpds-3318	139	65	diabetic	diabetic	ADJ
ijpds-3318	139	66	macular	macular	ADJ
ijpds-3318	139	67	edema	edema	NOUN
ijpds-3318	139	68	;	;	PUNCT
ijpds-3318	139	69	dpp4	dpp4	PROPN
ijpds-3318	139	70	:	:	PUNCT
ijpds-3318	139	71	di	di	NOUN
ijpds-3318	139	72	peptidyl	peptidyl	PROPN
ijpds-3318	139	73	peptidase	peptidase	NOUN
ijpds-3318	139	74	inhibitor	inhibitor	NOUN
ijpds-3318	139	75	;	;	PUNCT
ijpds-3318	139	76	fda	fda	PROPN
ijpds-3318	139	77	:	:	PUNCT
ijpds-3318	139	78	food	food	NOUN
ijpds-3318	139	79	and	and	CCONJ
ijpds-3318	139	80	drug	drug	NOUN
ijpds-3318	139	81	administration	administration	NOUN
ijpds-3318	139	82	;	;	PUNCT
ijpds-3318	139	83	fpg	fpg	PROPN
ijpds-3318	139	84	:	:	PUNCT
ijpds-3318	139	85	fasting	fast	VERB
ijpds-3318	139	86	plasma	plasma	NOUN
ijpds-3318	139	87	glucose	glucose	NOUN
ijpds-3318	139	88	;	;	PUNCT
ijpds-3318	139	89	gcp	gcp	ADJ
ijpds-3318	139	90	:	:	PUNCT
ijpds-3318	139	91	good	good	ADJ
ijpds-3318	139	92	clinical	clinical	ADJ
ijpds-3318	139	93	practice	practice	NOUN
ijpds-3318	139	94	;	;	PUNCT
ijpds-3318	139	95	gfr	gfr	ADJ
ijpds-3318	139	96	:	:	PUNCT
ijpds-3318	139	97	glomerular	glomerular	ADJ
ijpds-3318	139	98	filtration	filtration	NOUN
ijpds-3318	139	99	rate	rate	NOUN
ijpds-3318	139	100	;	;	PUNCT
ijpds-3318	139	101	ggh	ggh	NOUN
ijpds-3318	139	102	:	:	PUNCT
ijpds-3318	139	103	government	government	NOUN
ijpds-3318	139	104	general	general	ADJ
ijpds-3318	139	105	hospital	hospital	NOUN
ijpds-3318	139	106	;	;	PUNCT
ijpds-3318	139	107	gm	gm	PROPN
ijpds-3318	139	108	:	:	PUNCT
ijpds-3318	139	109	glimepiride	glimepiride	NOUN
ijpds-3318	139	110	–	–	PUNCT
ijpds-3318	139	111	metformin	metformin	NOUN
ijpds-3318	139	112	;	;	PUNCT
ijpds-3318	139	113	hba1c	hba1c	PROPN
ijpds-3318	139	114	:	:	PUNCT
ijpds-3318	139	115	haemoglobin	haemoglobin	PROPN
ijpds-3318	139	116	a	a	PROPN
ijpds-3318	139	117	,	,	PUNCT
ijpds-3318	139	118	c	c	PROPN
ijpds-3318	139	119	glucohemoglobin	glucohemoglobin	NOUN
ijpds-3318	139	120	;	;	PUNCT
ijpds-3318	139	121	icd	icd	PROPN
ijpds-3318	139	122	:	:	PUNCT
ijpds-3318	139	123	informed	inform	VERB
ijpds-3318	139	124	consent	consent	NOUN
ijpds-3318	139	125	document	document	NOUN
ijpds-3318	139	126	;	;	PUNCT
ijpds-3318	139	127	ich	ich	NOUN
ijpds-3318	139	128	:	:	PUNCT
ijpds-3318	139	129	international	international	ADJ
ijpds-3318	139	130	council	council	PROPN
ijpds-3318	139	131	of	of	ADP
ijpds-3318	139	132	harmonisation	harmonisation	NOUN
ijpds-3318	139	133	;	;	PUNCT
ijpds-3318	139	134	iddm	iddm	NOUN
ijpds-3318	139	135	:	:	PUNCT
ijpds-3318	139	136	insulin	insulin	NOUN
ijpds-3318	139	137	dependent	dependent	ADJ
ijpds-3318	139	138	diabetes	diabetes	NOUN
ijpds-3318	139	139	mellitus	mellitus	NOUN
ijpds-3318	139	140	;	;	PUNCT
ijpds-3318	139	141	idf	idf	PROPN
ijpds-3318	139	142	:	:	PUNCT
ijpds-3318	139	143	international	international	ADJ
ijpds-3318	139	144	diabetes	diabetes	NOUN
ijpds-3318	139	145	federation	federation	NOUN
ijpds-3318	139	146	;	;	PUNCT
ijpds-3318	139	147	idh	idh	PROPN
ijpds-3318	139	148	:	:	PUNCT
ijpds-3318	139	149	intra	intra	ADJ
ijpds-3318	139	150	dialytic	dialytic	ADJ
ijpds-3318	139	151	hypotension	hypotension	NOUN
ijpds-3318	139	152	;	;	PUNCT
ijpds-3318	139	153	iec	iec	NOUN
ijpds-3318	139	154	:	:	PUNCT
ijpds-3318	139	155	institutional	institutional	ADJ
ijpds-3318	139	156	ethical	ethical	ADJ
ijpds-3318	139	157	committee	committee	NOUN
ijpds-3318	139	158	;	;	PUNCT
ijpds-3318	139	159	igt	igt	PROPN
ijpds-3318	139	160	:	:	PUNCT
ijpds-3318	139	161	impaired	impair	VERB
ijpds-3318	139	162	glucose	glucose	NOUN
ijpds-3318	139	163	tolerance	tolerance	NOUN
ijpds-3318	139	164	.	.	PUNCT
ijpds-3318	140	1	references	reference	NOUN
ijpds-3318	140	2	1	1	NUM
ijpds-3318	140	3	.	.	PUNCT
ijpds-3318	140	4	nam	nam	PROPN
ijpds-3318	140	5	han	han	PROPN
ijpds-3318	140	6	cho	cho	PROPN
ijpds-3318	140	7	(	(	PUNCT
ijpds-3318	140	8	chair	chair	PROPN
ijpds-3318	140	9	)	)	PUNCT
ijpds-3318	140	10	,	,	PUNCT
ijpds-3318	140	11	david	david	PROPN
ijpds-3318	140	12	whiting	whiting	PROPN
ijpds-3318	140	13	(	(	PUNCT
ijpds-3318	140	14	deputy	deputy	NOUN
ijpds-3318	140	15	chair	chair	NOUN
ijpds-3318	140	16	)	)	PUNCT
ijpds-3318	140	17	.	.	PUNCT
ijpds-3318	141	1	international	international	ADJ
ijpds-3318	141	2	diabetes	diabetes	PROPN
ijpds-3318	141	3	federation	federation	NOUN
ijpds-3318	141	4	.	.	PUNCT
ijpds-3318	142	1	sixth	sixth	ADJ
ijpds-3318	142	2	edition	edition	NOUN
ijpds-3318	142	3	,	,	PUNCT
ijpds-3318	142	4	2013	2013	NUM
ijpds-3318	142	5	.	.	PUNCT
ijpds-3318	143	1	online	online	ADJ
ijpds-3318	143	2	version	version	NOUN
ijpds-3318	143	3	of	of	ADP
ijpds-3318	143	4	idf	idf	PROPN
ijpds-3318	143	5	diabetes	diabetes	PROPN
ijpds-3318	143	6	atlas	atlas	PROPN
ijpds-3318	143	7	:	:	PUNCT
ijpds-3318	143	8	www.idf.org/diabetesatlas	www.idf.org/diabetesatlas	X
ijpds-3318	143	9	.	.	PROPN
ijpds-3318	144	1	2	2	X
ijpds-3318	144	2	.	.	X
ijpds-3318	144	3	chiang	chiang	PROPN
ijpds-3318	144	4	jl	jl	PROPN
ijpds-3318	144	5	,	,	PUNCT
ijpds-3318	144	6	kirkman	kirkman	PROPN
ijpds-3318	144	7	ms	ms	PROPN
ijpds-3318	144	8	,	,	PUNCT
ijpds-3318	144	9	laffel	laffel	X
ijpds-3318	144	10	lmb	lmb	NOUN
ijpds-3318	144	11	et	et	PROPN
ijpds-3318	144	12	al	al	PROPN
ijpds-3318	144	13	.	.	PROPN
ijpds-3318	144	14	type	type	NOUN
ijpds-3318	144	15	1	1	NUM
ijpds-3318	144	16	diabetes	diabetes	NOUN
ijpds-3318	144	17	through	through	ADP
ijpds-3318	144	18	the	the	DET
ijpds-3318	144	19	life	life	NOUN
ijpds-3318	144	20	span	span	NOUN
ijpds-3318	144	21	:	:	PUNCT
ijpds-3318	144	22	a	a	DET
ijpds-3318	144	23	position	position	NOUN
ijpds-3318	144	24	statement	statement	NOUN
ijpds-3318	144	25	of	of	ADP
ijpds-3318	144	26	the	the	DET
ijpds-3318	144	27	american	american	ADJ
ijpds-3318	144	28	diabetes	diabetes	PROPN
ijpds-3318	144	29	association	association	PROPN
ijpds-3318	144	30	.	.	PUNCT
ijpds-3318	145	1	diabetes	diabetes	NOUN
ijpds-3318	145	2	care	care	NOUN
ijpds-3318	145	3	.	.	PUNCT
ijpds-3318	146	1	2014	2014	NUM
ijpds-3318	146	2	;	;	PUNCT
ijpds-3318	146	3	37	37	NUM
ijpds-3318	146	4	:	:	SYM
ijpds-3318	146	5	2034	2034	NUM
ijpds-3318	146	6	54	54	NUM
ijpds-3318	146	7	.	.	PUNCT
ijpds-3318	147	1	3	3	X
ijpds-3318	147	2	.	.	PUNCT
ijpds-3318	147	3	hayashi	hayashi	PROPN
ijpds-3318	147	4	t	t	PROPN
ijpds-3318	147	5	,	,	PUNCT
ijpds-3318	147	6	murayama	murayama	PROPN
ijpds-3318	147	7	h	h	NOUN
ijpds-3318	147	8	,	,	PUNCT
ijpds-3318	147	9	shinfuku	shinfuku	PROPN
ijpds-3318	147	10	y	y	PROPN
ijpds-3318	147	11	,	,	PUNCT
ijpds-3318	147	12	et	et	PROPN
ijpds-3318	147	13	al	al	PROPN
ijpds-3318	147	14	.	.	PROPN
ijpds-3318	147	15	safety	safety	NOUN
ijpds-3318	147	16	and	and	CCONJ
ijpds-3318	147	17	efficacy	efficacy	NOUN
ijpds-3318	147	18	of	of	ADP
ijpds-3318	147	19	vildagliptin	vildagliptin	NOUN
ijpds-3318	147	20	:	:	PUNCT
ijpds-3318	147	21	52	52	NUM
ijpds-3318	147	22	-	-	PUNCT
ijpds-3318	147	23	week	week	NOUN
ijpds-3318	147	24	post	post	NOUN
ijpds-3318	147	25	marketing	marketing	NOUN
ijpds-3318	147	26	surveillance	surveillance	NOUN
ijpds-3318	147	27	of	of	ADP
ijpds-3318	147	28	japanese	japanese	ADJ
ijpds-3318	147	29	patients	patient	NOUN
ijpds-3318	147	30	with	with	ADP
ijpds-3318	147	31	type	type	NOUN
ijpds-3318	147	32	2	2	NUM
ijpds-3318	147	33	diabetes	diabetes	NOUN
ijpds-3318	147	34	in	in	ADP
ijpds-3318	147	35	combination	combination	NOUN
ijpds-3318	147	36	with	with	ADP
ijpds-3318	147	37	other	other	ADJ
ijpds-3318	147	38	oral	oral	ADJ
ijpds-3318	147	39	anti	anti	ADJ
ijpds-3318	147	40	diabetics	diabetic	NOUN
ijpds-3318	147	41	and	and	CCONJ
ijpds-3318	147	42	insulin	insulin	NOUN
ijpds-3318	147	43	.	.	PUNCT
ijpds-3318	148	1	expert	expert	NOUN
ijpds-3318	148	2	opinpharmacother	opinpharmacother	NOUN
ijpds-3318	148	3	.	.	PUNCT
ijpds-3318	149	1	2020	2020	NUM
ijpds-3318	149	2	;	;	PUNCT
ijpds-3318	149	3	21	21	NUM
ijpds-3318	149	4	:	:	SYM
ijpds-3318	149	5	121	121	NUM
ijpds-3318	149	6	30	30	NUM
ijpds-3318	149	7	.	.	PUNCT
ijpds-3318	150	1	4	4	NUM
ijpds-3318	150	2	.	.	X
ijpds-3318	150	3	kalra	kalra	PROPN
ijpds-3318	150	4	s	s	PROPN
ijpds-3318	150	5	,	,	PUNCT
ijpds-3318	150	6	bajaj	bajaj	PROPN
ijpds-3318	150	7	s	s	PROPN
ijpds-3318	150	8	,	,	PUNCT
ijpds-3318	150	9	unnikrishnan	unnikrishnan	PROPN
ijpds-3318	150	10	ag	ag	PROPN
ijpds-3318	150	11	,	,	PUNCT
ijpds-3318	150	12	et	et	PROPN
ijpds-3318	150	13	al	al	PROPN
ijpds-3318	150	14	.	.	PUNCT
ijpds-3318	151	1	therapeutic	therapeutic	ADJ
ijpds-3318	151	2	experience	experience	NOUN
ijpds-3318	151	3	of	of	ADP
ijpds-3318	151	4	saxagliptin	saxagliptin	NOUN
ijpds-3318	151	5	as	as	ADP
ijpds-3318	151	6	first	first	ADJ
ijpds-3318	151	7	add	add	NOUN
ijpds-3318	151	8	-	-	PUNCT
ijpds-3318	151	9	on	on	ADP
ijpds-3318	151	10	after	after	ADP
ijpds-3318	151	11	metformin	metformin	NOUN
ijpds-3318	151	12	in	in	ADP
ijpds-3318	151	13	indian	indian	ADJ
ijpds-3318	151	14	type	type	NOUN
ijpds-3318	151	15	2	2	NUM
ijpds-3318	151	16	diabetes	diabetes	NOUN
ijpds-3318	151	17	patients	patient	NOUN
ijpds-3318	151	18	:	:	PUNCT
ijpds-3318	151	19	a	a	DET
ijpds-3318	151	20	noninterventional	noninterventional	ADJ
ijpds-3318	151	21	,	,	PUNCT
ijpds-3318	151	22	prospective	prospective	ADJ
ijpds-3318	151	23	,	,	PUNCT
ijpds-3318	151	24	observational	observational	ADJ
ijpds-3318	151	25	study	study	NOUN
ijpds-3318	151	26	(	(	PUNCT
ijpds-3318	151	27	ontarget	ontarget	NOUN
ijpds-3318	151	28	-	-	PUNCT
ijpds-3318	151	29	india	india	PROPN
ijpds-3318	151	30	)	)	PUNCT
ijpds-3318	151	31	.	.	PUNCT
ijpds-3318	152	1	indian	indian	PROPN
ijpds-3318	152	2	j	j	PROPN
ijpds-3318	152	3	endocr	endocr	PROPN
ijpds-3318	152	4	metab	metab	PROPN
ijpds-3318	152	5	.	.	PUNCT
ijpds-3318	153	1	2019	2019	NUM
ijpds-3318	153	2	;	;	PUNCT
ijpds-3318	153	3	23	23	NUM
ijpds-3318	153	4	:	:	SYM
ijpds-3318	153	5	312	312	NUM
ijpds-3318	153	6	7	7	NUM
ijpds-3318	153	7	.	.	SYM
ijpds-3318	153	8	5	5	NUM
ijpds-3318	153	9	.	.	PUNCT
ijpds-3318	153	10	zang	zang	PROPN
ijpds-3318	153	11	l	l	PROPN
ijpds-3318	153	12	,	,	PUNCT
ijpds-3318	153	13	han	han	PROPN
ijpds-3318	153	14	y	y	PROPN
ijpds-3318	153	15	,	,	PUNCT
ijpds-3318	153	16	chen	chen	PROPN
ijpds-3318	153	17	l	l	PROPN
ijpds-3318	153	18	,	,	PUNCT
ijpds-3318	153	19	et	et	PROPN
ijpds-3318	153	20	al	al	PROPN
ijpds-3318	153	21	.	.	PROPN
ijpds-3318	153	22	comparison	comparison	NOUN
ijpds-3318	153	23	of	of	ADP
ijpds-3318	153	24	the	the	DET
ijpds-3318	153	25	effectiveness	effectiveness	NOUN
ijpds-3318	153	26	and	and	CCONJ
ijpds-3318	153	27	safety	safety	NOUN
ijpds-3318	153	28	of	of	ADP
ijpds-3318	153	29	vildagliptin	vildagliptin	NOUN
ijpds-3318	153	30	add	add	NOUN
ijpds-3318	153	31	-	-	PUNCT
ijpds-3318	153	32	on	on	NOUN
ijpds-3318	153	33	to	to	ADP
ijpds-3318	153	34	metformin	metformin	NOUN
ijpds-3318	153	35	versus	versus	ADP
ijpds-3318	153	36	other	other	ADJ
ijpds-3318	153	37	oral	oral	ADJ
ijpds-3318	153	38	dual	dual	ADJ
ijpds-3318	153	39	anti	anti	ADJ
ijpds-3318	153	40	diabetes	diabetes	NOUN
ijpds-3318	153	41	agents	agent	NOUN
ijpds-3318	153	42	in	in	ADP
ijpds-3318	153	43	patients	patient	NOUN
ijpds-3318	153	44	with	with	ADP
ijpds-3318	153	45	type	type	NOUN
ijpds-3318	153	46	2	2	NUM
ijpds-3318	153	47	diabetes	diabete	NOUN
ijpds-3318	153	48	:	:	PUNCT
ijpds-3318	153	49	the	the	DET
ijpds-3318	153	50	china	china	PROPN
ijpds-3318	153	51	prospective	prospective	ADJ
ijpds-3318	153	52	diabetes	diabetes	NOUN
ijpds-3318	153	53	study	study	NOUN
ijpds-3318	153	54	.	.	PUNCT
ijpds-3318	154	1	diabetes	diabetes	NOUN
ijpds-3318	154	2	ther	ther	ADV
ijpds-3318	154	3	.	.	PUNCT
ijpds-3318	155	1	2019	2019	NUM
ijpds-3318	155	2	;	;	PUNCT
ijpds-3318	155	3	10	10	NUM
ijpds-3318	155	4	:	:	SYM
ijpds-3318	155	5	1391	1391	NUM
ijpds-3318	155	6	405	405	NUM
ijpds-3318	155	7	.	.	PUNCT
ijpds-3318	156	1	6	6	NUM
ijpds-3318	156	2	.	.	X
ijpds-3318	156	3	gullapalli	gullapalli	PROPN
ijpds-3318	156	4	h	h	PROPN
ijpds-3318	156	5	,	,	PUNCT
ijpds-3318	156	6	desai	desai	PROPN
ijpds-3318	156	7	s.	s.	PROPN
ijpds-3318	156	8	comparison	comparison	NOUN
ijpds-3318	156	9	of	of	ADP
ijpds-3318	156	10	efficacy	efficacy	NOUN
ijpds-3318	156	11	and	and	CCONJ
ijpds-3318	156	12	safety	safety	NOUN
ijpds-3318	156	13	of	of	ADP
ijpds-3318	156	14	metformin	metformin	NOUN
ijpds-3318	156	15	and	and	CCONJ
ijpds-3318	156	16	vildagliptin	vildagliptin	NOUN
ijpds-3318	156	17	versus	versus	ADP
ijpds-3318	156	18	metformin	metformin	NOUN
ijpds-3318	156	19	and	and	CCONJ
ijpds-3318	156	20	glimepiride	glimepiride	NOUN
ijpds-3318	156	21	in	in	ADP
ijpds-3318	156	22	patients	patient	NOUN
ijpds-3318	156	23	of	of	ADP
ijpds-3318	156	24	type	type	NOUN
ijpds-3318	156	25	2	2	NUM
ijpds-3318	156	26	diabetes	diabetes	NOUN
ijpds-3318	156	27	mellitus	mellitus	NOUN
ijpds-3318	156	28	.	.	PUNCT
ijpds-3318	157	1	natl	natl	PROPN
ijpds-3318	157	2	j	j	PROPN
ijpds-3318	157	3	physiol	physiol	PROPN
ijpds-3318	157	4	pharm	pharm	PROPN
ijpds-3318	157	5	pharmacol	pharmacol	PROPN
ijpds-3318	157	6	.	.	PROPN
ijpds-3318	158	1	2018	2018	NUM
ijpds-3318	158	2	;	;	PUNCT
ijpds-3318	158	3	8	8	NUM
ijpds-3318	158	4	:	:	SYM
ijpds-3318	158	5	521	521	NUM
ijpds-3318	158	6	5	5	NUM
ijpds-3318	158	7	.	.	X
ijpds-3318	158	8	7	7	NUM
ijpds-3318	158	9	.	.	X
ijpds-3318	158	10	yavropoulou	yavropoulou	PROPN
ijpds-3318	158	11	mp	mp	PROPN
ijpds-3318	158	12	,	,	PUNCT
ijpds-3318	158	13	pikilidou	pikilidou	NOUN
ijpds-3318	158	14	m	m	PROPN
ijpds-3318	158	15	,	,	PUNCT
ijpds-3318	158	16	kotsa	kotsa	PROPN
ijpds-3318	159	1	k	k	X
ijpds-3318	159	2	,	,	PUNCT
ijpds-3318	159	3	et	et	PROPN
ijpds-3318	159	4	al	al	PROPN
ijpds-3318	159	5	.	.	PROPN
ijpds-3318	159	6	efficacy	efficacy	NOUN
ijpds-3318	159	7	and	and	CCONJ
ijpds-3318	159	8	tolerability	tolerability	NOUN
ijpds-3318	159	9	of	of	ADP
ijpds-3318	159	10	vildagliptin	vildagliptin	NOUN
ijpds-3318	159	11	as	as	ADP
ijpds-3318	159	12	first	first	ADJ
ijpds-3318	159	13	line	line	NOUN
ijpds-3318	159	14	treatment	treatment	NOUN
ijpds-3318	159	15	in	in	ADP
ijpds-3318	159	16	patients	patient	NOUN
ijpds-3318	159	17	with	with	ADP
ijpds-3318	159	18	diabetes	diabetes	NOUN
ijpds-3318	159	19	type	type	NOUN
ijpds-3318	159	20	2	2	NUM
ijpds-3318	159	21	in	in	ADP
ijpds-3318	159	22	an	an	DET
ijpds-3318	159	23	outpatient	outpatient	NOUN
ijpds-3318	159	24	setting	setting	NOUN
ijpds-3318	159	25	.	.	PUNCT
ijpds-3318	160	1	j	j	PROPN
ijpds-3318	160	2	diabetes	diabete	VERB
ijpds-3318	160	3	metab	metab	NOUN
ijpds-3318	160	4	disord	disord	NOUN
ijpds-3318	160	5	.	.	PUNCT
ijpds-3318	161	1	2015	2015	NUM
ijpds-3318	161	2	;	;	PUNCT
ijpds-3318	161	3	14	14	NUM
ijpds-3318	161	4	:	:	SYM
ijpds-3318	161	5	118	118	NUM
ijpds-3318	161	6	.	.	NOUN
ijpds-3318	161	7	8	8	NUM
ijpds-3318	161	8	.	.	PUNCT
ijpds-3318	162	1	nathan	nathan	PROPN
ijpds-3318	162	2	dm	dm	PROPN
ijpds-3318	162	3	.	.	PUNCT
ijpds-3318	163	1	clinical	clinical	ADJ
ijpds-3318	163	2	practice	practice	NOUN
ijpds-3318	163	3	.	.	PUNCT
ijpds-3318	164	1	initial	initial	ADJ
ijpds-3318	164	2	management	management	NOUN
ijpds-3318	164	3	of	of	ADP
ijpds-3318	164	4	glycaemia	glycaemia	NOUN
ijpds-3318	164	5	in	in	ADP
ijpds-3318	164	6	type	type	NOUN
ijpds-3318	164	7	2	2	NUM
ijpds-3318	164	8	diabetes	diabetes	NOUN
ijpds-3318	164	9	mellitus	mellitus	NOUN
ijpds-3318	164	10	.	.	PUNCT
ijpds-3318	165	1	n	n	PRON
ijpds-3318	165	2	engl	engl	PROPN
ijpds-3318	165	3	j	j	PROPN
ijpds-3318	165	4	med	med	PROPN
ijpds-3318	165	5	.	.	PUNCT
ijpds-3318	165	6	2002	2002	NUM
ijpds-3318	165	7	;	;	PUNCT
ijpds-3318	165	8	347	347	NUM
ijpds-3318	165	9	:	:	SYM
ijpds-3318	165	10	1342	1342	NUM
ijpds-3318	165	11	9	9	NUM
ijpds-3318	165	12	.	.	NOUN
ijpds-3318	165	13	9	9	NUM
ijpds-3318	165	14	.	.	X
ijpds-3318	166	1	riddle	riddle	PROPN
ijpds-3318	166	2	mc	mc	PROPN
ijpds-3318	166	3	.	.	PUNCT
ijpds-3318	167	1	a	a	DET
ijpds-3318	167	2	verdict	verdict	NOUN
ijpds-3318	167	3	for	for	ADP
ijpds-3318	167	4	glimepiride	glimepiride	NOUN
ijpds-3318	167	5	:	:	PUNCT
ijpds-3318	167	6	effective	effective	ADJ
ijpds-3318	167	7	and	and	CCONJ
ijpds-3318	167	8	not	not	PART
ijpds-3318	167	9	guilty	guilty	ADJ
ijpds-3318	167	10	of	of	ADP
ijpds-3318	167	11	cardiovascular	cardiovascular	ADJ
ijpds-3318	167	12	harm	harm	NOUN
ijpds-3318	167	13	.	.	PUNCT
ijpds-3318	168	1	diabetes	diabetes	NOUN
ijpds-3318	168	2	care.2019	care.2019	NUM
ijpds-3318	168	3	;	;	PUNCT
ijpds-3318	168	4	42	42	NUM
ijpds-3318	168	5	:	:	SYM
ijpds-3318	168	6	2161	2161	NUM
ijpds-3318	168	7	3	3	NUM
ijpds-3318	168	8	.	.	NOUN
ijpds-3318	168	9	10	10	NUM
ijpds-3318	168	10	.	.	PUNCT
ijpds-3318	169	1	mathieu	mathieu	PROPN
ijpds-3318	169	2	c	c	PROPN
ijpds-3318	169	3	,	,	PUNCT
ijpds-3318	169	4	degrande	degrande	PROPN
ijpds-3318	169	5	e.	e.	PROPN
ijpds-3318	169	6	vildagliptin	vildagliptin	PROPN
ijpds-3318	169	7	:	:	PUNCT
ijpds-3318	169	8	a	a	DET
ijpds-3318	169	9	new	new	ADJ
ijpds-3318	169	10	oral	oral	ADJ
ijpds-3318	169	11	treatment	treatment	NOUN
ijpds-3318	169	12	for	for	ADP
ijpds-3318	169	13	type	type	NOUN
ijpds-3318	169	14	2	2	NUM
ijpds-3318	169	15	diabetes	diabetes	NOUN
ijpds-3318	169	16	mellitus	mellitus	NOUN
ijpds-3318	169	17	.	.	PUNCT
ijpds-3318	170	1	vasc	vasc	PROPN
ijpds-3318	170	2	health	health	PROPN
ijpds-3318	170	3	risk	risk	NOUN
ijpds-3318	170	4	manag	manag	NOUN
ijpds-3318	170	5	.	.	PUNCT
ijpds-3318	170	6	2008	2008	NUM
ijpds-3318	170	7	;	;	PUNCT
ijpds-3318	170	8	4	4	NUM
ijpds-3318	170	9	:	:	SYM
ijpds-3318	170	10	1349	1349	NUM
ijpds-3318	170	11	60	60	NUM
ijpds-3318	170	12	.	.	PUNCT
ijpds-3318	171	1	11	11	NUM
ijpds-3318	171	2	.	.	PUNCT
ijpds-3318	172	1	hayashi	hayashi	PROPN
ijpds-3318	172	2	t	t	PROPN
ijpds-3318	172	3	,	,	PUNCT
ijpds-3318	172	4	murayama	murayama	PROPN
ijpds-3318	172	5	h	h	NOUN
ijpds-3318	172	6	,	,	PUNCT
ijpds-3318	172	7	shinfuku	shinfuku	PROPN
ijpds-3318	172	8	y	y	PROPN
ijpds-3318	172	9	,	,	PUNCT
ijpds-3318	172	10	et	et	PROPN
ijpds-3318	172	11	al	al	PROPN
ijpds-3318	172	12	.	.	PROPN
ijpds-3318	172	13	safety	safety	NOUN
ijpds-3318	172	14	and	and	CCONJ
ijpds-3318	172	15	efficacy	efficacy	NOUN
ijpds-3318	172	16	of	of	ADP
ijpds-3318	172	17	vildagliptin	vildagliptin	NOUN
ijpds-3318	172	18	:	:	PUNCT
ijpds-3318	172	19	52	52	NUM
ijpds-3318	172	20	-	-	PUNCT
ijpds-3318	172	21	week	week	NOUN
ijpds-3318	172	22	post	post	ADJ
ijpds-3318	172	23	-	-	ADJ
ijpds-3318	172	24	marketing	marketing	ADJ
ijpds-3318	172	25	surveillance	surveillance	NOUN
ijpds-3318	172	26	of	of	ADP
ijpds-3318	172	27	japanese	japanese	ADJ
ijpds-3318	172	28	patients	patient	NOUN
ijpds-3318	172	29	with	with	ADP
ijpds-3318	172	30	type	type	NOUN
ijpds-3318	172	31	2	2	NUM
ijpds-3318	172	32	diabetes	diabetes	NOUN
ijpds-3318	172	33	in	in	ADP
ijpds-3318	172	34	combination	combination	NOUN
ijpds-3318	172	35	with	with	ADP
ijpds-3318	172	36	other	other	ADJ
ijpds-3318	172	37	oral	oral	ADJ
ijpds-3318	172	38	antidiabetics	antidiabetic	NOUN
ijpds-3318	172	39	and	and	CCONJ
ijpds-3318	172	40	insulin	insulin	NOUN
ijpds-3318	172	41	.	.	PUNCT
ijpds-3318	173	1	expert	expert	NOUN
ijpds-3318	173	2	opin	opin	NOUN
ijpds-3318	173	3	pharmac	pharmac	NOUN
ijpds-3318	173	4	other	other	ADJ
ijpds-3318	173	5	.	.	PUNCT
ijpds-3318	174	1	2020	2020	NUM
ijpds-3318	174	2	;	;	PUNCT
ijpds-3318	174	3	21	21	NUM
ijpds-3318	174	4	:	:	SYM
ijpds-3318	174	5	121	121	NUM
ijpds-3318	174	6	30	30	NUM
ijpds-3318	174	7	.	.	PUNCT
ijpds-3318	175	1	12	12	NUM
ijpds-3318	175	2	.	.	PUNCT
ijpds-3318	176	1	sarkar	sarkar	PROPN
ijpds-3318	176	2	bs	bs	PROPN
ijpds-3318	176	3	,	,	PUNCT
ijpds-3318	176	4	mukherjee	mukherjee	PROPN
ijpds-3318	176	5	s	s	PROPN
ijpds-3318	176	6	,	,	PUNCT
ijpds-3318	176	7	maji	maji	PROPN
ijpds-3318	176	8	m	m	PROPN
ijpds-3318	176	9	,	,	PUNCT
ijpds-3318	176	10	et	et	PROPN
ijpds-3318	176	11	al	al	PROPN
ijpds-3318	176	12	.	.	PUNCT
ijpds-3318	177	1	a	a	DET
ijpds-3318	177	2	prospective	prospective	ADJ
ijpds-3318	177	3	observational	observational	ADJ
ijpds-3318	177	4	study	study	NOUN
ijpds-3318	177	5	to	to	PART
ijpds-3318	177	6	compare	compare	VERB
ijpds-3318	177	7	the	the	DET
ijpds-3318	177	8	efficacy	efficacy	NOUN
ijpds-3318	177	9	and	and	CCONJ
ijpds-3318	177	10	adverse	adverse	ADJ
ijpds-3318	177	11	effects	effect	NOUN
ijpds-3318	177	12	of	of	ADP
ijpds-3318	177	13	glimepiride	glimepiride	NOUN
ijpds-3318	177	14	and	and	CCONJ
ijpds-3318	177	15	vildagliptin	vildagliptin	NOUN
ijpds-3318	177	16	added	add	VERB
ijpds-3318	177	17	to	to	ADP
ijpds-3318	177	18	metformin	metformin	NOUN
ijpds-3318	177	19	in	in	ADP
ijpds-3318	177	20	type	type	NOUN
ijpds-3318	177	21	2	2	NUM
ijpds-3318	177	22	diabetes	diabetes	NOUN
ijpds-3318	177	23	mellitus	mellitus	NOUN
ijpds-3318	177	24	.	.	PUNCT
ijpds-3318	178	1	j	j	PROPN
ijpds-3318	178	2	clin	clin	PROPN
ijpds-3318	178	3	diagn	diagn	PROPN
ijpds-3318	178	4	res	re	NOUN
ijpds-3318	178	5	.	.	PROPN
ijpds-3318	178	6	2019	2019	NUM
ijpds-3318	178	7	;	;	PUNCT
ijpds-3318	178	8	13	13	NUM
ijpds-3318	178	9	:	:	PUNCT
ijpds-3318	178	10	oc09	oc09	PROPN
ijpds-3318	178	11	oc11	oc11	PROPN
ijpds-3318	178	12	.	.	PUNCT
ijpds-3318	179	1	13	13	NUM
ijpds-3318	179	2	.	.	PUNCT
ijpds-3318	180	1	cohen	cohen	PROPN
ijpds-3318	180	2	cm	cm	PROPN
ijpds-3318	180	3	,	,	PUNCT
ijpds-3318	180	4	davis	davis	PROPN
ijpds-3318	180	5	c	c	AUX
ijpds-3318	180	6	,	,	PUNCT
ijpds-3318	180	7	shalev	shalev	NOUN
ijpds-3318	180	8	v	v	NOUN
ijpds-3318	180	9	,	,	PUNCT
ijpds-3318	180	10	et	et	PROPN
ijpds-3318	180	11	al	al	PROPN
ijpds-3318	180	12	.	.	PROPN
ijpds-3318	180	13	effectiveness	effectiveness	NOUN
ijpds-3318	180	14	of	of	ADP
ijpds-3318	180	15	vildagliptin	vildagliptin	NOUN
ijpds-3318	180	16	as	as	ADP
ijpds-3318	180	17	add	add	NOUN
ijpds-3318	180	18	-	-	PUNCT
ijpds-3318	180	19	on	on	ADP
ijpds-3318	180	20	to	to	PART
ijpds-3318	180	21	metformin	metformin	VERB
ijpds-3318	180	22	monotherapy	monotherapy	NOUN
ijpds-3318	180	23	among	among	ADP
ijpds-3318	180	24	uncontrolled	uncontrolled	ADJ
ijpds-3318	180	25	type	type	NOUN
ijpds-3318	180	26	2	2	NUM
ijpds-3318	180	27	diabetes	diabetes	NOUN
ijpds-3318	180	28	mellitus	mellitus	NOUN
ijpds-3318	180	29	patients	patient	NOUN
ijpds-3318	180	30	in	in	ADP
ijpds-3318	180	31	a	a	DET
ijpds-3318	180	32	real	real	ADJ
ijpds-3318	180	33	-	-	PUNCT
ijpds-3318	180	34	world	world	NOUN
ijpds-3318	180	35	setting	setting	NOUN
ijpds-3318	180	36	.	.	PUNCT
ijpds-3318	181	1	j	j	PROPN
ijpds-3318	181	2	diabetes	diabetes	NOUN
ijpds-3318	181	3	.	.	PUNCT
ijpds-3318	182	1	2018	2018	NUM
ijpds-3318	182	2	;	;	PUNCT
ijpds-3318	182	3	10	10	NUM
ijpds-3318	182	4	:	:	SYM
ijpds-3318	182	5	68	68	NUM
ijpds-3318	182	6	72	72	NUM
ijpds-3318	182	7	.	.	PUNCT
ijpds-3318	183	1	14	14	NUM
ijpds-3318	183	2	.	.	PUNCT
ijpds-3318	184	1	li	li	PROPN
ijpds-3318	184	2	-	-	PUNCT
ijpds-3318	184	3	nong	nong	PROPN
ijpds-3318	184	4	ji	ji	PROPN
ijpds-3318	184	5	,	,	PUNCT
ijpds-3318	184	6	chang	chang	PROPN
ijpds-3318	184	7	-	-	PUNCT
ijpds-3318	184	8	yu	yu	PROPN
ijpds-3318	184	9	pan	pan	PROPN
ijpds-3318	184	10	,	,	PUNCT
ijpds-3318	184	11	ju	ju	PROPN
ijpds-3318	184	12	-	-	PUNCT
ijpds-3318	184	13	ming	ming	PROPN
ijpds-3318	184	14	lu	lu	PROPN
ijpds-3318	184	15	,	,	PUNCT
ijpds-3318	184	16	et	et	PROPN
ijpds-3318	184	17	al	al	PROPN
ijpds-3318	184	18	.	.	PROPN
ijpds-3318	184	19	efficacy	efficacy	NOUN
ijpds-3318	184	20	and	and	CCONJ
ijpds-3318	184	21	safety	safety	NOUN
ijpds-3318	184	22	of	of	ADP
ijpds-3318	184	23	combination	combination	NOUN
ijpds-3318	184	24	therapy	therapy	NOUN
ijpds-3318	184	25	with	with	ADP
ijpds-3318	184	26	vildagliptin	vildagliptin	NOUN
ijpds-3318	184	27	and	and	CCONJ
ijpds-3318	184	28	metformin	metformin	NOUN
ijpds-3318	184	29	versus	versus	ADP
ijpds-3318	184	30	metformin	metformin	PROPN
ijpds-3318	184	31	up	up	ADP
ijpds-3318	184	32	-	-	PUNCT
ijpds-3318	184	33	titration	titration	NOUN
ijpds-3318	184	34	in	in	ADP
ijpds-3318	184	35	chinese	chinese	ADJ
ijpds-3318	184	36	patients	patient	NOUN
ijpds-3318	184	37	with	with	ADP
ijpds-3318	184	38	type	type	NOUN
ijpds-3318	184	39	2	2	NUM
ijpds-3318	184	40	diabetes	diabetes	NOUN
ijpds-3318	184	41	mellitus	mellitus	NOUN
ijpds-3318	184	42	:	:	PUNCT
ijpds-3318	184	43	study	study	VERB
ijpds-3318	184	44	design	design	NOUN
ijpds-3318	184	45	and	and	CCONJ
ijpds-3318	184	46	rationale	rationale	NOUN
ijpds-3318	184	47	of	of	ADP
ijpds-3318	184	48	the	the	DET
ijpds-3318	184	49	vision	vision	NOUN
ijpds-3318	184	50	study	study	NOUN
ijpds-3318	184	51	.	.	PUNCT
ijpds-3318	185	1	cardiovascular	cardiovascular	ADJ
ijpds-3318	185	2	diabetology	diabetology	NOUN
ijpds-3318	185	3	.	.	PUNCT
ijpds-3318	186	1	2013	2013	NUM
ijpds-3318	186	2	;	;	PUNCT
ijpds-3318	186	3	12	12	NUM
ijpds-3318	186	4	:	:	SYM
ijpds-3318	186	5	118	118	NUM
ijpds-3318	186	6	.	.	PUNCT
ijpds-3318	187	1	kareenmulla	kareenmulla	PROPN
ijpds-3318	187	2	et	et	PROPN
ijpds-3318	187	3	al	al	PROPN
ijpds-3318	187	4	efficacy	efficacy	PROPN
ijpds-3318	187	5	,	,	PUNCT
ijpds-3318	187	6	safety	safety	NOUN
ijpds-3318	187	7	of	of	ADP
ijpds-3318	187	8	vildagliptin	vildagliptin	NOUN
ijpds-3318	187	9	-	-	PUNCT
ijpds-3318	187	10	metformin	metformin	NOUN
ijpds-3318	187	11	versus	versus	ADP
ijpds-3318	187	12	glimepiride	glimepiride	NOUN
ijpds-3318	187	13	-	-	PUNCT
ijpds-3318	187	14	metformin	metformin	NOUN
ijpds-3318	187	15	vol	vol	NOUN
ijpds-3318	187	16	1	1	NUM
ijpds-3318	188	1	|	|	NOUN
ijpds-3318	188	2	issue	issue	NOUN
ijpds-3318	188	3	2	2	NUM
ijpds-3318	189	1	|	|	ADV
ijpds-3318	189	2	jul	jul	PROPN
ijpds-3318	189	3	sep	sep	PROPN
ijpds-3318	189	4	2022	2022	NUM
ijpds-3318	189	5	indian	indian	PROPN
ijpds-3318	189	6	j	j	PROPN
ijpds-3318	189	7	pharm	pharm	PROPN
ijpds-3318	189	8	drug	drug	PROPN
ijpds-3318	189	9	studies	study	NOUN
ijpds-3318	189	10	|	|	ADV
ijpds-3318	189	11	68	68	NUM
ijpds-3318	189	12	15	15	NUM
ijpds-3318	189	13	.	.	PUNCT
ijpds-3318	190	1	hye	hye	PROPN
ijpds-3318	190	2	-	-	PUNCT
ijpds-3318	190	3	soon	soon	ADV
ijpds-3318	190	4	kim	kim	PROPN
ijpds-3318	190	5	,	,	PUNCT
ijpds-3318	190	6	doo	doo	NOUN
ijpds-3318	190	7	-	-	PUNCT
ijpds-3318	190	8	man	man	NOUN
ijpds-3318	190	9	kim	kim	PROPN
ijpds-3318	190	10	,	,	PUNCT
ijpds-3318	190	11	bong	bong	PROPN
ijpds-3318	190	12	-	-	PUNCT
ijpds-3318	190	13	soo	soo	PROPN
ijpds-3318	190	14	cha	cha	PROPN
ijpds-3318	190	15	,	,	PUNCT
ijpds-3318	190	16	et	et	PROPN
ijpds-3318	190	17	al	al	PROPN
ijpds-3318	190	18	.	.	PROPN
ijpds-3318	190	19	efficacy	efficacy	NOUN
ijpds-3318	190	20	of	of	ADP
ijpds-3318	190	21	glimepiride	glimepiride	NOUN
ijpds-3318	190	22	-	-	PUNCT
ijpds-3318	190	23	metformin	metformin	NOUN
ijpds-3318	190	24	fixed	fix	VERB
ijpds-3318	190	25	dose	dose	NOUN
ijpds-3318	190	26	combination	combination	NOUN
ijpds-3318	190	27	vs	vs	ADP
ijpds-3318	190	28	metformin	metformin	NOUN
ijpds-3318	190	29	uptitration	uptitration	NOUN
ijpds-3318	190	30	in	in	ADP
ijpds-3318	190	31	type	type	NOUN
ijpds-3318	190	32	2	2	NUM
ijpds-3318	190	33	diabetic	diabetic	ADJ
ijpds-3318	190	34	patients	patient	NOUN
ijpds-3318	190	35	inadequately	inadequately	ADV
ijpds-3318	190	36	controlled	control	VERB
ijpds-3318	190	37	on	on	ADP
ijpds-3318	190	38	low	low	ADJ
ijpds-3318	190	39	dose	dose	NOUN
ijpds-3318	190	40	metformin	metformin	NOUN
ijpds-3318	190	41	monotherapy	monotherapy	NOUN
ijpds-3318	190	42	:	:	PUNCT
ijpds-3318	190	43	a	a	DET
ijpds-3318	190	44	randomized	randomized	ADJ
ijpds-3318	190	45	,	,	PUNCT
ijpds-3318	190	46	open	open	ADJ
ijpds-3318	190	47	label	label	NOUN
ijpds-3318	190	48	,	,	PUNCT
ijpds-3318	190	49	parallel	parallel	ADJ
ijpds-3318	190	50	group	group	NOUN
ijpds-3318	190	51	,	,	PUNCT
ijpds-3318	190	52	multicenter	multicenter	ADJ
ijpds-3318	190	53	study	study	NOUN
ijpds-3318	190	54	in	in	ADP
ijpds-3318	190	55	korea	korea	PROPN
ijpds-3318	190	56	.	.	PUNCT
ijpds-3318	191	1	j.	j.	PROPN
ijpds-3318	191	2	diabetes	diabetes	PROPN
ijpds-3318	191	3	investigation	investigation	NOUN
ijpds-3318	191	4	.	.	PUNCT
ijpds-3318	192	1	2014	2014	NUM
ijpds-3318	192	2	;	;	PUNCT
ijpds-3318	192	3	5(6	5(6	NUM
ijpds-3318	192	4	):	):	PUNCT
ijpds-3318	192	5	701	701	NUM
ijpds-3318	192	6	708	708	NUM
ijpds-3318	192	7	.	.	PUNCT
ijpds-3318	193	1	16	16	NUM
ijpds-3318	193	2	.	.	PUNCT
ijpds-3318	194	1	manuel	manuel	PROPN
ijpds-3318	194	2	gonzale	gonzale	PROPN
ijpds-3318	194	3	,	,	PUNCT
ijpds-3318	194	4	guerrero	guerrero	PROPN
ijpds-3318	194	5	romero	romero	PROPN
ijpds-3318	194	6	,	,	PUNCT
ijpds-3318	194	7	rafael	rafael	PROPN
ijpds-3318	194	8	violanteortiz	violanteortiz	PROPN
ijpds-3318	194	9	,	,	PUNCT
ijpds-3318	194	10	et	et	PROPN
ijpds-3318	194	11	al	al	PROPN
ijpds-3318	194	12	.	.	PROPN
ijpds-3318	194	13	,	,	PUNCT
ijpds-3318	194	14	efficacy	efficacy	NOUN
ijpds-3318	194	15	of	of	ADP
ijpds-3318	194	16	glimepiridemetformin	glimepiridemetformin	NOUN
ijpds-3318	194	17	combination	combination	NOUN
ijpds-3318	194	18	versus	versus	ADP
ijpds-3318	194	19	glibenclamidemetformin	glibenclamidemetformin	NOUN
ijpds-3318	194	20	in	in	ADP
ijpds-3318	194	21	patients	patient	NOUN
ijpds-3318	194	22	with	with	ADP
ijpds-3318	194	23	uncontrolled	uncontrolled	ADJ
ijpds-3318	194	24	type	type	NOUN
ijpds-3318	194	25	2	2	NUM
ijpds-3318	194	26	diabetes	diabetes	NOUN
ijpds-3318	194	27	mellitus	mellitus	NOUN
ijpds-3318	194	28	.	.	PUNCT
ijpds-3318	195	1	j	j	PROPN
ijpds-3318	195	2	of	of	ADP
ijpds-3318	195	3	diabetes	diabetes	NOUN
ijpds-3318	195	4	and	and	CCONJ
ijpds-3318	195	5	its	its	PRON
ijpds-3318	195	6	complications	complication	NOUN
ijpds-3318	195	7	.	.	PUNCT
ijpds-3318	196	1	2009	2009	NUM
ijpds-3318	196	2	;	;	PUNCT
ijpds-3318	196	3	23(6	23(6	NUM
ijpds-3318	196	4	):	):	PUNCT
ijpds-3318	196	5	376379	376379	NUM
ijpds-3318	196	6	.	.	PUNCT
ijpds-3318	197	1	how	how	SCONJ
ijpds-3318	197	2	to	to	PART
ijpds-3318	197	3	cite	cite	VERB
ijpds-3318	197	4	this	this	DET
ijpds-3318	197	5	article	article	NOUN
ijpds-3318	197	6	:	:	PUNCT
ijpds-3318	197	7	bingi	bingi	PROPN
ijpds-3318	197	8	p	p	X
ijpds-3318	197	9	,	,	PUNCT
ijpds-3318	197	10	kareemulla	kareemulla	PROPN
ijpds-3318	197	11	s	s	NOUN
ijpds-3318	197	12	,	,	PUNCT
ijpds-3318	197	13	himabindu	himabindu	PROPN
ijpds-3318	197	14	b	b	PROPN
ijpds-3318	197	15	,	,	PUNCT
ijpds-3318	197	16	khan	khan	PROPN
ijpds-3318	197	17	ds	ds	PROPN
ijpds-3318	197	18	,	,	PUNCT
ijpds-3318	197	19	ramu	ramu	PROPN
ijpds-3318	197	20	d	d	PROPN
ijpds-3318	197	21	,	,	PUNCT
ijpds-3318	197	22	mahammed	mahammed	PROPN
ijpds-3318	197	23	rafi	rafi	PROPN
ijpds-3318	197	24	s.	s.	PROPN
ijpds-3318	197	25	a	a	DET
ijpds-3318	197	26	comparative	comparative	ADJ
ijpds-3318	197	27	study	study	NOUN
ijpds-3318	197	28	on	on	ADP
ijpds-3318	197	29	efficacy	efficacy	NOUN
ijpds-3318	197	30	and	and	CCONJ
ijpds-3318	197	31	safety	safety	NOUN
ijpds-3318	197	32	of	of	ADP
ijpds-3318	197	33	vildagliptin	vildagliptin	NOUN
ijpds-3318	197	34	-	-	PUNCT
ijpds-3318	197	35	metformin	metformin	NOUN
ijpds-3318	197	36	versus	versus	ADP
ijpds-3318	197	37	glimepiride	glimepiride	NOUN
ijpds-3318	197	38	-	-	PUNCT
ijpds-3318	197	39	metformin	metformin	NOUN
ijpds-3318	197	40	in	in	ADP
ijpds-3318	197	41	type	type	NOUN
ijpds-3318	197	42	2	2	NUM
ijpds-3318	197	43	diabetes	diabetes	NOUN
ijpds-3318	197	44	mellitus	mellitus	NOUN
ijpds-3318	197	45	patients	patient	NOUN
ijpds-3318	197	46	.	.	PUNCT
ijpds-3318	198	1	indian	indian	PROPN
ijpds-3318	198	2	j	j	PROPN
ijpds-3318	198	3	pharm	pharm	PROPN
ijpds-3318	198	4	drug	drug	PROPN
ijpds-3318	198	5	studies	study	NOUN
ijpds-3318	198	6	.	.	PUNCT
ijpds-3318	199	1	2022	2022	NUM
ijpds-3318	199	2	:	:	PUNCT
ijpds-3318	199	3	1(2	1(2	NUM
ijpds-3318	199	4	)	)	PUNCT
ijpds-3318	199	5	63	63	NUM
ijpds-3318	199	6	-	-	SYM
ijpds-3318	199	7	68	68	NUM
ijpds-3318	199	8	.	.	PUNCT
ijpds-3318	200	1	funding	funding	NOUN
ijpds-3318	200	2	:	:	PUNCT
ijpds-3318	200	3	none	none	NOUN
ijpds-3318	200	4	conflict	conflict	NOUN
ijpds-3318	200	5	of	of	ADP
ijpds-3318	200	6	interest	interest	NOUN
ijpds-3318	200	7	:	:	PUNCT
ijpds-3318	200	8	none	none	NOUN
ijpds-3318	200	9	stated	state	VERB